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Note 1
age health care expenses that are also eligible for
coverage under Medicaid is excepted from ERISA
preemption Melior v Wasatch Crest Mut Ins
Co, 2009 201 P.3d 1004, 622 Utah Adv Rep 20,
2009 UT 5 Insurance c=> 1117(3), States c=* 18 41
Group health insurance pohcy under employee
benefit plans failed to comply witn statute forbidding employee benefit plan from limiting oi excluding coverage or payment for any health care for an
individual who would otherwise be covered or entitled to benefits or services under terms of plan
notwithstanding that plan specified that "services"
covered by Medicaid were not excluded, where
plan also precluded coverage for any expenses
coveied by a government program Melior v
Wasatch Crest Mut Ins Co, 2009, 201 P 3d 1004,
622 Utah Adv Rep 20, 2009 UT 5 Insurance &*
§ 26-19-19.

2484, Insurance c=> 2525(1), Laboi and Employment <&=> 567, Labor and Employment e=> 569(2;
Terms of the group health insui ance pohcj under employee welfare benefit plan did not operate
to terminate insured's coverage when insured became eligible foi Medicaid coverage, notwithstanding ambiguity in policy that precluded coverage for
any expenses covered by government program, but
did not exclude "services" covered by Medicaid,
policy evidenced attempt to comply with nominal
requirements of law while at same time circumventing actual requirement of providing coverage
regardless of whether beneficiary was also covered
by Medicaid Melior v Wasatch Crest Mui Ins
Co, 2009, |201 P 3d 1004, 622 Utah Adv Rep 20,
Insurance c=> 959vi ^ T abor and
2009 UT
Employment <s=> 569(2)
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UTAH FALSE CLAIMS ACT
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Title
Definitions
Kickbacks or bribes prohibited
False statements or false representations relating to qualification of
health institution or facility prohibited—Felony
False claims for medical benefits prohibited

§ 26-20-1.

Section
26-20-9
26-20-9 fi|
26-20-12,
26-20-13,
26-20-14
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Civil penalties
Violation of other laws
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Investigations—Civil investigative demands
Limitation of actions—Civil acts ante
dating this section—Civil burden of
proof—Estoppel—Joint civil liability—Venue

Title

This chapter is known as the "Utah False Claims Act
Laws 1981, c 126, § 19, Laws 2007, c 48, § 1, eff April 30, 20(1)7
Historical and Statuto: Notes
"This chaptei shall be known and may be cited
Laws 2007, c 48, rewrote this section, which
as the 'False Clanns Act":
formerly provided
Research References
Encyclopedias
100 Am Jur Proof of Facts 3d 1, Proof of a
Claim Arising from Off-Label Use of Prescription Medications
§ 26-20-2. Definitions
As used m tnis chapter.
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§ 26-20-4

(1) "Benefit" means the receipt of money goods, or any other thing of pecuniary value
(2) "Claim" means any request or demand for money or property
(a) made to any
d) employee, officer, or agent of the state,
(n) contractor with the state, or
(in) grantee or other recipient, whether or not under contract with the state, and
(b) if
(l) any portion of the money or property requested or demanded was issued from or
provided by the state, or
(n) the state will reimburse the contractor, grantee, or other recipient for any portion
of the money or property
(3) "False statement" or "false representation" means a wholly or partially untrue statement or representation which is
(a) knowingly made, and
(b) a material fact with respect to the claim
(4) "Knowing" and "knowingly"
(a) for purposes of criminal prosecutions for violations of this chapter, is one of the
culpable mental states described in Subsection 26-20-9(1), and
(b) for purposes of civil prosecutions for violations of this chapter, is the required
culpable mental state as defined in Subsection 26-20-9.5(1)
(5) "Medical benefit" means a benefit paid or payable to a recipient or a provider under a
program administered by the state under
(a) Titles V and XIX of the federal Social Security Act,1
(b) Title X of the federal Public Health Services Act,2
(c) the federal Child Nutrition Act of 1966 as amended by P.L 94-105, and
(d) any programs for medical assistance of the state
(6) "Person" means an individual, corporation, unincorporated association, professional
corporation, partnership, or other form of business association
Laws 1981, c 126, § 19, Laws 1986, c 46, § 1, Laws 2007, c 48, § 2, eff April 30, 2007
142USCA § 701etseq and42USCA.§ 1396etseq
242USOA § 300etseq
Historical and Statutory Notes
Laws 2007, c 48, rewrote this section, which his conduct is substantially certain to cause the
formerly provided
intended result
"As used in ttos chapter
"(4> '*J edlca] b e n e f m e a n s » b e n e f i * P a , d o r
r
payable to a recipient or a provider under a pro"U) 'Benefit' means the receipt of money, goods, gram administered by the state undei Titles V and
oi any other thing of pecuniary value
XIX of the federal Social Security Act, Title X of
«fo\
~~ <f«w
,awfiPO«+«+1^' QMd
the federal
Public Health
Services Act,the
federal
0+«^*«t' or
(2) <*?oW
False «,+
statement
false representation
j
NufcntiQn
1966 ^
p L
means a statement or representation which is ^ m ^
^
^
^
^
m
s
of
J
&
knowingly and willfully made if the person making , v *.
^
the statement or representation has knowledge of
_N mP e r s , m e a n s n
, , ,
U/(&)
die falsityJ thereof
™
* ^dividual, corporation,
unincorporated association, professional corporals) 'Knowing' and 'knowingly* mean tnat a pei- tion, partnership, or other form of busmess associson is aware of the nature of his conduct and that ation "
§ 26-20-4.

Kickbacks or bribes prohibited

(1) For purposes of this section, kickback or bribe
(a) includes rebates, compensation, or any other form of remuneration which is
(l) direct or indirect,
(u) overt or covert, or
(ui) m cash or in kind, and
103
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(b) does not include a rebate paid to the state under 42 U S C Sec 1396r-8 or any state
supplemental rebates
(2) A person maj not solicit, offer, pay, or receive a kickback or bribe in return for or to
induce
(a) the purchasing leasing or ordering of any goods or services for which payment is or
ma\ be made in whole or m part pursuant to a medical benefit program, or
(b) the referral of an individual to another person for the furnishing of any goods 01
services for which payment is or may be made m whole or m part pursuant to a medical
benefit program
Laws 1981 c 120, § 19, Laws 1986, c 46, § 3, Laws 2007, c 48J § 3, eff April 30,2007
Historical and Statutory Notes
Laws 2007, c 48 repealed and reenacted this of goods or services for which payment is o* may
section, wnich formerly provided
be made in whole or m part pursuant to z medical
_
benefit program, or pay or receive a rebate of ? fee
A person may not solicit, offer pay, or receive a o r c h a r g k for referring an individual to another
kickbad or bribe m connection with the furnishing person fpi the furnishing of goods or services "
§ 26-20-5. F a l s e s t a t e m e n t s or false representations relating to qualification
of h e a l t h institution or facility p r o h i b i t e d - J F e l o n y
(lj A person may not knowingly, intentionally, or recklessly make, induce, or seek to
induce the making of a false statement or false representation of a material fact with respect
to the conditions or operation of an institution or facility m order that the institution or
facility may qualify, upon initial certification or upon recertification, as a hospital, skilled
nursing facility, intermediate care facility, or home health agency
(2) A person who violates this section is guilty of a second degree felony
Laws 1981, c 126, k 19, Laws 2007, c 48, § 4, eff April 30, 20
Historical and Statutory Notes
Laws 2007, c 48, in subsec (1) substituted "may
not knowingly, intentionally, or recklessly" foi
"shall not. Knowingly and willfully"
§ 26-20-7.

F a l s e claims for medical benefits Prohibited

(1) A person may not make or present or cause to be made or presented to an employee or
officer of the state a claim for a medical benefit
(a) whicn is wholly or partially false, fictitious, or fraudulent,
(b) for services wr3uch were not rendered or for items or materials which were not
delivered,
(c) which misrepresents the type, quality, or quantity of items or services rendered,
(d) representing charges at a higher rate than those charged by the provider to the
general pubhc
(e) for items or services which the person or the provider knew were not medically
necessary m accordance with professional^ recognised standards,
(f) which has previously been paid,
(gi for services also covered by one or more private sources when the person or pro^ idei
knew of the private sources without disclosing thojse sources on the claim, or
0.) where a provider
I
(1) unoundles a product, procedure or group of procedures usually and customanh
provided or performed as a single billable product or procedure into artificial components
ov separate procedures and
(ii) bills for each component of the product, procedure or group of procedures
(A) as if they had beer provided or perfoifmed independently and at separate times,
and
104
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Note 1

(B) the aggregate billing for the components exceeds the amount otherwise billable
for the usual and customary single product or procedure
(2) In addition to the prohibitions m Subsection (1), a person maj not
(a) fail to credit the state for payments received from other sources,
(b) i ecover or attempt to reco\ er payment in violation of the provider agreement from
(i) a recipient under a medical benefit program, or
(nj the recipient's family,
(c) falsify or alter with intent to deceive, any report or document required bj state or
federal law, rule, oi Medicaid provider agreement,
(d) retain any unauthorized payment as a result of acts described h} this section or
(e) aid or abet the commission of any act prohibited by tins section
Laws 1981 c 126, § 19, Laws 1986, c 46, § 5 Laws 1987 c 92, § 35 Laws 2007, c 48, * 5 eff April
30 2007
Historical and Statutory Notes
"(g) file a claim foi a medical benefit foi serLaws 2007 c 48, lewrote this section, which
vices also covered by one or more private sources
formerh provided
"(1) No person may make or present oi cause to when the person or providei knew of the private
be made oi presented to an employee oi officer of sources without disclosing those sources on the
the state a claim for a medical benefit, knowing the claim,
claim to be false, fictitious, oi fraudulent
"(h) recover or attempt to recover payment
"(2) In addition, no pel son shall knowingly
from a recipient unaer a medical benefit program,
"(a) file a claim for a medical benefit foi services or the recipient s familj in violation of the provider
which vere not rendered oi foi items or materials agreement,
vhich were not delivered
"(l) file a claim for a medical benefit where a
"(b) file a claim for a medical benefit which provider divides an accepted multiple medical promisrepresents the type, quality, or quantity of cedure into artificial components or single proceitems oi services rendered,
dures requesting full medical benefits for perform"(c) file a claim foi a medical benefit represent- ing those component procedures as if the} had
ing cnarges at a highei rate than those charged by each been performed independently and at sepathe pi ovidei to the general public,
rate times,
"(d) file a claim foi a medical benefit for items
"0) falsify or alter with intent to deceive, any
oi services winch the person or the provider knew repoH or document required by state or federal
were not medically necessary in accordance with law, rule, oi medicaid providei agreement,
professional^ recognized standards
"(k) retain any unauthorized payment as a re"(e) file a claim for a medical benefit which has
sult of acts described by this section, or
jneviouslj been paid,
"(I) aid or abet the commission of any acr pro"(f) fail to credit the state for payments received
hibited by this section"
nom other sources,
Umted States Supreme Court
ties using government funds, see Allison
Engine Co Inc A I S ex rei Sanders
2008 128 SCt 2123, 170 LEd2d 1030

In general,
False claims act intent to cause government payment of false claim prr\ ate enti-

Notes of Decisions
disputed, substantial fedei al question was presented federal preemption did not applj, and no cleai
rule existed justifying removal of state Medicaid
reimbursement actions Utah v Eh Lilh and Co
1 Jurisdiction
2007 509 F Supp 2d 1016 Removal Of Cases c=»
Exeicise of fedeial jurisdiction in State of 19(1) Remo\ al Of Cases o 25(1)
Utahs Medicaid reimbursement action against
Ko actually disputed, substantial fedeial quesfr*ug manufacturei which manufacturei had ie- tion was presented in State of Utahs Medicaid
moved nom state court on federal-question i eimbursement action against drug manufacturer,
pound* would disturb congressional!v appioved so as to warrant removal on that ground fedeia1
balance of federal and state judicial responsibili- issues were not essential to a dedication of state s
ties requu'ing grant of states lemand motion
claims, grounded on its False Claims Act and
even though exercise of federal jurisdiction would common law manufacture!'s raising of federal
not atnact hoide of oneni&l filing's, no actualh questior *• JS inadequate to confei federal lunsdic105
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tion mere presence of federal standards such as
"medically accepted indications" did not confei jurisdiction absent federal remedj and Congress
had specifically required states to seek reimbur^e§ 26-20-9.

ment from liable thiio parties without providing
such remedy Utah \ Eb Lilly ano Co , 2007, 509
F Sipp 2d 1016 Removal Of Cases c=* 19(1), Re
movjal Of Cases c^ 25(1;

Criminal penalties

(l)(a) Except as provided m Subsection (l)(b) the culpable mental state required for a
criminal violation of this chapter is knowingly, intentionally, or recklessly as defined in
Section 76-2-103
(b) The culpable mental state required for la criminal violation of this chapter for
kickbacks and bribes under Section 26-20-4 is knowingly and intentionally as defined in
Section 76-2-103
(2) The punishment for a criminal violation of jany provision of this chapter, except as
pi ovided under Section 26-20-5 is determined by the cumulative value of the funds or other
benefits received or claimed m the commission of all violations of a similar nature, and not by
each separate violation
(3) Punishment for criminal violation of this chapter, except as provided under Section
26-20-5, is a felony of the second degree, felony of the third degree class A misdemeanor, or
class B misdemeanor based on the dollar amoanti as nreannbed by Subsection 76-6-412(1)
for theft of property and services
Laws 1986, c 46, § 6, Laws 2007, c 48, § 6, eff April 30,|2007
Historical and Statutory Notes
Laws 2007, c 48 rewrote this section, which rectei\ed or claimed in violation of this chapter
formerly pi ovided
exieeds Si,000,
T(b) as a felony of the third degree if the cumu"(1) The punishment for violation of any provision of this chapter, except as provided under lative value of the funds oi other benefits received
Section 26-20-5, is determined by the cumulative or claimed m violation of this chapter exceeds $250
value of the funds or other benefits received or but does not exceed $1,000,
j'(c) as a class A misdemeanor if the cumulative
claimed m the commission of all violations of a
value of the funds or other benefits received or
similar nature, and not bj each separate violation
claimed in violation of this chapter exceeds $100
"(2) Punishment for violation of this chapter, but does not exceed $250, or
(
except as provided under Section 26-20-5, is as
(d) as a class B misdemeanor if the cumulative
follows
value of the funds or other benefits received or
"(aj as a felonj of the second degree if the claimed in violation of this chantei does not exceed
cumulative value of the funds or other benefits $100 "
United States Supreme Court
ties using government funds, see Allison
Engine Co., Inc v U S ex rel Sanders,
2008, 128 SCt 2J.23, 170 LEd2d 1030

False claims.
False claims act intent to cause government payment of false claim, private enti§ 26-20-9.5.

Civil penalties

Q) The culpable mental state required for a cifnl violation of this chapter is "knowing'" or
"knowingly' which*
(a) means that person, with respect to mfornjauon
d) has actual knowledge of the information,
'n) acts m deliberate ignorance of the trutlp or falsity of the information, or
(in) acts m l eckless disregard of the truth Ipr falsity of the information, and
(b) does not require a specific intent to defraudi
C; Any person who violates tins chapter shall m all cases, m addition to other penalties
pi ovided by lav, be required to
(a) make full and complete restitution to the state of all damages that the state sustains
because oi the person s violation of this chapter],
106
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§ 26-20-12

(b) pa} to the state its costs of enforcement of this chaptei in that case including but not
limited to the cost of investigators, attorneys, and othei public employees as determined b>
the state, and
(c) pay to the state a civil penalty equal to
U) three times the amount of damages that the state sustains because of the pei son's
violation of this chapter, and
(n) not less than $5 000 or more than SI0,000 for each claim filed or act done m
violation of this chapter
(3) Any civil penalties assessed under Subsection (2) shall be awarded bj the court as part
of its judgment m both criminal and civil actions
(4) A criminal action need not be brought against a person m order for that person to be
civilly liable under this section
Laws 1986, c 46, § 7, Laws 1987, c 92, § 36, Laws 2007 c 48 § 7 efi April 30 2007
Historical and Statutory Notes
Laws 2007, c 48, rewrote this section, which
"(c) may he lequired, in the discretion of the
formerly provided
court to pay to the state a civil penalty not to
"(1) Any person who violates this chapter shall e x c e e d three times the amount of value improperly
in addition to other penalties provided by lav, be c l a i m e d o r received as a medical benefit or
((
subject to the following civil penalties
(d) may be required, m the discretion of the
"(a) in all cases, shall be required to make full c o u r t ' to paj to the state a civil penalty of up to
and complete restitution to the state of all medical $>2>000 fo1 e a c h d a m nled ° J act done in violation
of tills c h a t e l
benefits impropei ly obtained,
P
"(h) m all cases, shall be required to pay the
"W Any civil penalties assessed undei Subsecstate its costs of enforcement of this chapter m t l o f M sha11 b e awarded bj the court as part of its
that case, including but not limited to the cost of judgment in both criminal and civil actions
investigators attorneys, and other pubhc employ"(3) A criminal action need not be brought
ees, as determined by the Bureau of Medicaid against a person in ordei foi that person t-o be
Fraud,
civilly liable under this section "
United States Supreme Court
False claims,
ties using government funds, see Allison
False claims act, intent to cause governEngine Co, Inc v U S ex rel Sanders,
ment payment of false claim, private enti2008, 128 S Ct 212S 170 LEd2d 1030
§ 26-20-12.

Violation of o t h e r laws

(1) The provisions of this chapter are
(a) not exclusive, and the remedies provided for in this chapter are in addition to any
other remedies provided for under
d) any other applicable law, or
(li) common law, and
(b) to be liberally construed and applied to
(i) effectuate the chapter's remedial and deterrent purposes and
(n) serve the public interest
(2) If any provision of this chapter or the application of this chaptei to am person or
circumstance is held unconstitutional
(a) the remaining provisions of tins chaptei shall not be affected and
(b) the application of this chapter to other persons or circumstances shall not be affected
Laws 1986, c 46 § 9, Laws 2007, c 48 * 8 eff Apnl 30 2007
Historical and Statutory Notes
Laws 2007 c 48 repealed and reenacted this
section, which formerly provided

"This chaptei shall not be construed to p^onibit
or limit an action against a person foi violation of
an> other law '
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Medicaid fraud enforcement

(1) This chapter shall be enforced m accordance with this section
(2' The department io l esponsible for
(a)Ci; im estiganng and prosecuting suspected civil violations of this chapter, or
{ii) referring suspected civil violations of this chapter to the attorney general for
investigation and prosecution and
(b) piompth lef erring suspected criminal violations cff this chapter to the attorney
general foi criminal investigation and prosecution
(3) The attorney geneialhas
(a) concurrent jurisdiction with the department for ln+estigatine and prosecuting suspected civil violations of this chapter, and
(b) exclusive jurisdiction to lm estigate and prosecute all suspected criminal violations of
this chaptei
(4) The department and the attorney general share concurrent civil enforcement authority
under tins chapter and mav enter into an interagency agreement regarding the investigation
and prosecution of ^ lolauons of this chapter in accordance with this section, the requirements
of Title XIX of the federal Social Security Act3, and applicable federal regulations
(5) Any violation oi this chapter which comes to the attention of any state government
officei or agency shall be leportecl to the attorney general or the department All state
government officers and agencies shall cooperate with apd assist m any prosecution for
violation of thib chapter
Lavs 2000 c 310, * 2 eft Ma\ 1, 2000 Laws 2007, c 4S § 9, eff jApril 30, 2007
1 41 U S> C A * 13% et sea
Historical and Statutory Nbtes
"(a) investigating criminal violations of this
Laws 2007, c 4S rewrote this section, which
chaptei thai are reported to the attorney general
formerly provided
b\ the department or others
"(1) This chaptei shall be enforced in accor"(b) promptly referring probable civil violations
dance with tins section
of this chaptei that are not related to a criminal
investigation or prosecution to the department for
"(2) The department shall be responsible for
civil investigation and prosecution, and
"(a) investigating and piosecutmg all civil viola"(c) prosecuting criminal violations of this chaptions of this chapter and
tei
"(4) The department and the attorney general
"(b) promptly referring suspected criminal violations of this chaptei to the atton^ general for ma^ enter into an interagency agreement regarding the investigation and prosecution of violations
criminal investigation and prosecution
of this chaptei m accordance with this section, the
"(3) The attorney general shall be responsible l equii ements of Title XIX of the federal Social
Security Alct and applicable federal regulations"
foi
Notes of Decisions
First Amendment retaliation claim Becker v
Ilroll 2004, 340 F Supped 1230, affirmed m part,
lexei'sed m part and remanded 494 F3d 904, on
lemand 2009 WL 819373 Constitutional Law ®=>
1171, States o 79
2 Immunitv
1 First amendment
Utah s Governmental Immunitv Act ban ed libel
Nemologisi wnv v>a*> cnmmalh investigated and claim bi ought by neurologist who v>as cnmmalh
pi osecuted fr Utah «* Medicaid Fraud Conta ol Unit investigated and prosecuted by Utah's Medicaid
<MFCU> foi 'upcodmg' ie the practice of m> Fraud Gdntrol Unit (MFCU) foi "upcodmg,' I e,
pioperh billing Medicaid foi a more expensne the practice of improper^ billing Medicaid for a
semce than vas actualh provided to the patient
more expensive service than was actually provided
failed to pi oduce sufficient e\ idence that officials to the patient against MFCU officials, based solely
veie substantially motivated as a response to hei upon publication of annual report on MFCU's webexercise of constitutionalh protected conduct, oi site vhere neurologist failed to produce evidence
were e\en ava^e of such conduct as would suppoit sufficient to support a finding of fraud oi malice in
First amendment 1
Immunity 2
Malicious prosecution
Subpoena 4
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Beckei \ Kioll 2004 pi osecution of neurologist for "upcoding' I e the
tue publication of report
Medicaia for a mo^e
040 FSupp2d 1230 affirmed in pait leversed m practice of improperly billing
ngrt and remanded 494 F 3d 904, on remand 2009 expensive service than wras actually provided to the
patient, would be reviewed undei due process stanV/L S1Q373 Libel And Slandei c=> 51(5)
Genuine issue of material fact existed as to dara of the Fourteenth Amendment rather than
v hethei alleged m ongful conduct of state officials leasonableness standard of the Fourth Amendoceuned while they were acting in administrative ment, where neurologist was never incarcerated
and investigative capacities, precluding summary Becker v Kroll 2004, 340 F Supp 2d 1230 afjudgment for officials on basis of absolute lmmum- firmed in part reversed in part and remanded 494
F 3d 904 on remand 2009 WL 819373 Constitun m erul rights action against them undei
$§1933 Beckei v Kioll 2004, 340 FSupp2d tional Law c=> 4527(2), Searches And Seizures c=
1<?30 affirmed in part, reversed m part and re- 23 States c= 79
manded 494 F 3d 904 on remand 2009 WL 819373
State trial court's independent finding of probaFedeial Civil Piocedure c=> 2491 5
ble cause was not fatal to neurologist's §§ 1983
malicious prosecution claim against officials of
3 Malicious prosecution
Utah's Medicaid Fraud Control Unit (MFCU),
Neurologist who was nevei arrested or incal cer- based on investigation and prosecution of neuroloated in connection with the filing of criminal gist foi "upcodmg," l e, the practice of improperly
charges of alleged Medicaid fraud was not seized billing Medicaid foi a more expensive service than
within meaning of Fourth Amendment, as required was actually provided to the patient Becker v
ror constitutional tort of malicious prosecution un- Kroll, 2004, 340 F Supp 2d 1230, affirmed in pan,
der §§ 1983 Becker -\ Kroll, 2007, 494 F 3d 904, reversed in part and remanded 494 F 3d 904 on
on remand 2009 WL 819373 Arrest e* 68(4)
remand 2009 WL 819373 Civil Rights o 1088(5)
Civil Eights e= 1088(5)
Genuine issue of material fact existed as to 4 Subpoena
\\ hethei officials of Utah's Medicaid Fraud Conuol
State officials' copying of neurologist's medical
Unit (MFCU) knowingly targeted neurologist for records through use of a subpoena in connection
prosecution without sufficient basis to believe there with investigation and prosecution of her for "upwas probable cause she committed a crime, pre- coding,' l e, the practice of improperly billing for a
cluding summary judgment for officials on neurolo- more expensive service than was actually provided
gist's §§ 1983 malicious prosecution claim, based to the patient, did not violate neurologist's Fourth
on investigation and prosecution of her foi "upcod- Amendment rights although officials' use of subuig" I e, the practice of improperly billing Medic- poena did not comply with state statutes, where
aid for a more expensive service than was actually use of subpoena did not invoke same protections as
provided to the patient Becker v Kroll, 2004, 340 use of a warrant, given that neurologist read subF Supp 2d 1230, affirmed m part, reversed in part poena and understood that she could either proand remanded 494 F 3d 904 on remand 2009 WL duce her records immediately or appear m person
819373 Federal Civil Procedure &=> 2491 5
a few days latei Becker* \ Kroll, 2004, 340
Neurologist's §§ 1983 malicious prosecution F Supp 2d 1230, affirmed in part, reversed in part
claim against officials of Utah's Medicaid Fraud and remanded 494 F 3d 904, on remand 2009 WL
Control Unit (MFCU), based on investigation and 819373 Searches And Seizures e=» 75
§ 26-20-14. Investigations—Civil investigative d e m a n d s
(1) The attorney general may take investigative action under Subsection (2) if the attorney
general has reason to believe that
(a) a person has information or custody or control of documentary material relevant to
the subject matter of an investigation of an alleged violation of this chapter,
(b) a person is committing, has committed, or is about to commit a violation of this
chapter, oi
(c) it is m the public interest to conduct an investigation to ascertain whether or not a
person is committing, has committed, or is about to commit a violation of this chapter
(2) In taking investigative action, the attorney general may
(a) require the person to file on a prescribed form a statement m writing under oath or
affirmation describing
(O the facts and circumstances concerning the alleged violation of tins chapter, and
(n) othei information considered necessary by the attorney general,
(b) examine under oath a person in connection with the alleged violation of tins chapter,
and
(c) in accordance with Subsections (7) through (18) execute m writing, and serve on the
person, a civil investigative demand requiring the person to produce the documental
matenal and permit inspection and copying of the material
109
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(3; The attorney general may not release or disclose information that is obtained under
Subsection (2)(a) or (b), or any documentary material or other record derived from the
information obtained under Subsection (2)(a) or (b)J except:
(a) by court order for good cause shown;
(b) with the consent of the person who provided the information;
(c) to an employee of the attorney general or the department;
(d) to an agency of this state, the United States, or another state;
(e) to a special assistant attorney general representing the state in a civil action;
(f) to a political subdivision of this state; or
(g) to a person authorized by the attorney general to receive the information.
(4) The attorney general may use documentary material derived from information obtained
under Subsection (2)(a) or (b), or copies of that material, as the attorney general determines
necessary in the enforcement of this chapter, including presentation before a court.
(5)(a) If a person fails to file a statement as required by Subsection (2)(a) or fails to submit
to an examination as required by Subsection (2)(b), the attorney general may file in district
court a complaint for an order to compel the person to within a period stated by court order:
(i) file the statement required by Subsection (2)(a); or
(ii) submit to the examination required by Subsection (2)(b).
(b) Failure to comply with an order entered under Subsection (5)(a) is punishable as
contempt.
(6) A civil investigative demand must:
(a) state the rule or statute under which th|e alleged violation of this chapter is being
investigated;
(b) describe the:
(i) general subject matter of the investigation; and
(ii) class or classes of documentary material to be produced with reasonable specificity
to fairly indicate the documentary material demanded;
(c) designate a date within which the documentary material is to be produced; and
(d) identify an authorized employee of the attorney general to whom the documentary
material is to be made available for inspection and copying.
(7) A civil investigative demand may require disclosure of any documentary material that is
discoverable under the Utah Rules of Civil Procedure.
(8) Sendee of a civil investigative demand may be made by:
(a) delivering an executed copy of the demand to the person to be served or to a partner,
an officer, or an agent authorized by appointment or by law to receive service of process on
behalf of that person;
(b) delivering an executed copy of the demand to the principal place of business in this
state of the person to be served; or
(c) mailing by registered or certified mail an executed copy of the demand addressed to
the person to be served:
(i) at the person's principal place of business in this state; or
(ii) if the person has no place of business in this state, to the person's principal office
or place of business.
(9) Documentary material demanded in a civil investigative demand shall be produced for
inspection and copying during normal business hours at the office of the attorney general or
as agreed by the person served and the attorney general.
(10) The attorney general may not produce for inspection or copying or otherwise disclose
the contents of documentary material obtainep pursuant to a civil investigative demand
except:
(a) by court order for good cause shown;
(b) with the consent of the person who produced the information;
(cj to an employee of the attorney general or the department;
(d) to an agency of this state, the United States, or another state;
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(e) to a special assistant attorney general representing the state in a civil action:
(f) to a political subdivision of this state; or
(g) to a person authorized by the attorney general to receive the information.
(ll)(a) With respect to documentary material obtained pursuant to a civil investigative
demand, the attorney general shall prescribe reasonable terms and conditions allowing such
documentary material to be available for inspection and copying by the person who produced
the materia] or by an authorized representative of that person.
(b) The attorney general may use such documentary material or copies of it as the
attorney general determines necessary in the enforcement of this chapter, including
presentation before a court.
(12) A person may file a complaint, stating good cause, to extend the return date for the
demand or to modify or set aside the demand. A complaint under this Subsection (12) shall
befiledin district court and must be filed before the earlier of:
(a) the return date specified in the demand; or
(b) the 20th day after the date the demand is served.
(13) Except as provided by court order, a person who has been served with a civil
investigative demand shall comply with the terms of the demand.
(I4)(a) A person who has committed a violation of this chapter in relation to the Medicaid
program in this state, or to any other medical benefit program administered by the state has
submitted to the jurisdiction of this state.
(b) Personal service of a civil investigative demand under this section may be made on
the person described in Subsection (14)(a) outside of this state.
(15) This section does not limit the authority of the attorney general to conduct investigations or to access a person's documentary materials or other information under another state
or federal law, the Utah Rules of Civil Procedure, or the Federal Rules of Civil Procedure.
(16) The attorney general may file a complaint in district court for an order to enforce the
civil investigative demand if:
(a) a person fails to comply with a civil investigative demand; or
(b) copying and reproduction of the documentary material demanded:
(i) cannot be satisfactorily accomplished; and
(ii) the person refuses to surrender the documentary material.
(17) If a complaint is filed under Subsection (16), the court may determine the matter
presented and may enter an order to enforce the civil investigative demand.
(18) Failure to comply with a fmal order entered under Subsection (17) is punishable by
contempt.
Laws 2007, c. 48, § 10, eff. April 30, 2007.
§ 26-20-15. Limitation of actions—Civil acts antedating this section—Civil
burden of proof—Estoppel—Joint civil liability—Venue
(1) An action under this chapter may not be brought after the later of:
(a) six years after the date on which the violation was committed; or
(b) three years after the date an official of the state charged with responsibility to act in
the circumstances discovers the violation, but in no event more than ten years after the
date on which the violation was committed.
(2) A civil action brought under this chapter'may be brought for acts occurring prior to the
effective date of this section if the limitations period set forth in Subsection (1) has not lapsed.
(3) In any civil action brought under this chapter the state shall be required to prove by a
preponderance of evidence, all essential elements of the cause of action including damages.
(4) Notwithstanding any other provision of law, a final judgment rendered in favor of the
state in any criminal proceeding under this chapter, whether upon a verdict after trial or upon
a plea of guilty or nolo contendere, shall estop the defendant from denying the essential
elements of the offense in any civil action under this chapter which involves the same
transaction.
Ill
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(5) Civil liability under this chapter shall be joint and several for a violation committed by
two or more persons
(6) Any action brought b} the state under this chapter shall be brought m district court m
Salt Lake County or m an} county where the defendant resides or does business
Laws 2007, c 48 § 11 eff Apnl 30, 2007

CHAPTER 21
HEALTH CARE FACILITY LICENSING
AND INSPECTION ACT
Section

Section

2G-21-2
2C-21-8

26121-20

Definitions
Health Facility Committee—Members—Terms—Organization—Meetings
26-21-5
Duties of committee
26-21-9 5 Criminal background check and Licensing Information System check
26-21-16 Operating facility in violation of chaptei a misdemeanor

261-21-23
26^21-24
26- -21-25

Requirement for hospitals to provide
statements of itemized charges to
patients
Licensing of non-Medicaid nursing
care facility beds
Piohibition against bed banking by
nursing care facilities for Medicaid
reimbursement
Patient identity protection

Cross References
Integrated health systems, contract negotiation
Municipal land use development, defining resistandards, see § 13-5b-103
dential facility for persons with a disability, see
Medical records requests for copies, see § 10-9a-103
§ 26-6b-3 4
Law Review and Journal Commentaries
Assisted living m Utah A bnef overview foi
consumers Mary Jane Ciccarello, Joanne Wetzler,
19 Utah B J 24 (Feb 2006)

§ 26-21-1. Title
Cross Reiejrences
Disabilities, residences for certain persons, see
Residences for persons with a disability, see
§ 17-27a-519
10-9a-520
Human services licensing, exclusions, see
Standardized health benefit plan cards , see
§ 62A-2-110
J 31A-22-636
§ 26-21-2.

Definitions

As used in this chapter
(1) "Abortion clinic'' means a facility, othei trian a general acute or specialty hospital, that
performs abortions and provides abortion services during the second trimester of pregnancy
(2) "Activities of daily living* means essential activities including
(a) dressing,
(b) eating,
(c) grooming,
(d) bathing,
(e) toileting,
(f) ambulation
(g) transferring, and
(h) self-administration of medication
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W. Daniel "Dee" Miles, III (Pro Hac Vice pending)
Clinton C. Carter (Pro Hac Vice pending)
Special Assistant Attorneys General
Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.
272 Commerce Street, P.O. Box 4160
Montgomery, AL 36103-4160
Telephone: (334) 269-2343
Fax: (334)954-7555
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Joseph W. Steele (Bar No. 9697)
Kenneth D. Lougee (Bar No. 10682)
Special Assistant Attorney General
Steele & Biggs, LLC
5664 South Green Street, Suite 300
Salt Lake City, Utah 84123
Telephone: (801) 266-0999
Fax: (801)266-1338
David R. Stallard (Bar No. 7993)
Assistant Attorney General
Utah Medicaid Fraud Control Unit
5272 College Drive, Suite 200
Salt Lake City, Utah 84123-2772
Telephone: (801)281-1269
Fax: (801)281-1250
Attorneys for Plaintiff'

IN THE THIRD JUDICIAL DISTRICT COURT OF SALT LAKE COUNTY
STATE OF UTAH

THE STATE OF UTAH ,
AMENDED COMPLAINT
Plaintiff,

AND JTTRV DF.MAND

vs.

APOTEX CORPORATION;
BAXTER INTERNATIONAL, INC.;
BOEHRINGERINGELHEIM
CORPORATION;
MALLTNCKRODT INC.;
CSL BEHRING;
FOREST LABORATORIES, INC.,
MORTON GROVE PHARMACEUTICALS,

Civil No. 080907678
J,udge Tyrone E. Medley
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INC.;
MUTUAL PHARMACEUTICAL
COMPANY, INC.;
NOVARTIS
PHARMACEUTICALS CORPORATION;
OTSUKA AMERICA, INC.;
PFIZER, INC.;
QUALITEST PHARMACEUTICALS, INC.;
SCHERING-PLOUGH CORPORATION;
SCHWARZ PHARMA USA HOLDINGS,
INC;
TARO PHARMACEUTICALS USA, INC.;
UPSHER-SMITH, INC.; and
WYETH, INC.;
Defendants.

Plaintiff, the State of Utah (hereinafter "Plaintiff' or "the State"), by and through its
Attorney General Mark L. Shurtleff, hereby complains of the above-named Defendants and
alleges, on information and belief, the following:
INTRODUCTION
1.

The Defendants have engaged in false, misleading, wanton, unfair, and deceptive acts and
practices in the pricing and marketing of their prescription drug products. The
Defendants' fraudulent pricing and marketing of their prescription drugs have caused the
State's Medicaid program ("Utah Medicaid") to pay grossly excessive prices for the
Defendants' prescription drugs. Utah Medicaid is administered by the Division of Health
Care Financing within the single state agency, the Utah Department of Health.
2
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Fair and honest drug pricing is a matter of great importance to the State and its citizens.
Expenditures by Utah Medicaid for prescription drug reimbursement have increased
dramatically in the past several years as a result, in part, of Defendants' fraudulent pricing
scheme, Each year Utah Medicaid spends tens of millions of dollars on prescription
drugs. In fiscal year 2005 alone, Utah Medicaid spent $2(1)7.6 million on prescription
drugs. Significant increases in prescription drug costs in:recent years have contributed to
a health care funding crisis within the State that requires [action
|
to ensure fair dealing
between the Defendants and the State.
The State is accountable to its citizens and taxpayers for how it spends limited State
resources, and it is obligated to pursue any party whose unlawful conduct has led to the
excessive expenditure of State funds. Consequently, the State, by and through its Attorney
General, brings this action to recover amounts overpaid for prescription drugs by Utah
Medicaid, including both pharmacy-dispensed and physician-administered drugs, as a
result of the fraudulent and wanton conduct of Defendants.
This lawsuit seeks legal redress for the fraudulent and wanton marketing and pricing
conduct of Defendants, who have profited from their wrongful acts and practices at the
expense of the State.

3
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JURISDICTION AND VENUE
5.

Jurisdiction over the subject matter of this cause of action is based upon the Utah False
Claims Act, Title 26, Chapter 20 of the Utah Health Code, which provides remedies to
redress Defendants' actions under Utah Code Annotated § 26-20-1 et seq.

6.

Personal jurisdiction over these Defendants is proper under the Utah Long Arm Statute as
codified in §§ 78-27-22 and 78-27-24 of the Utah Code Annotated.

7.

Venue is proper in the Third Judicial District and Salt Lake County pursuant to Utah Code
Annotated § 78-13-7 in that the false or fraudulent Utah Medicaid claims caused to be
filed by Defendants' unlawful acts were filed in Salt Lake County with the State of Utah,
its departments, agencies, instrumentalities and contractors.

8.

This case alleges causes of action which arise exclusively under Utah law and not the laws
of the United States. To the extent that federal laws are implicated, the State disavows
such intent. Specifically, the State makes no claim for reimbursement of Medicare Part B
co-payments for udual eligible5' individuals.
PARTIES

9.

Plaintiff is the State of Utah. The Utah Attorney General is authorized to initiate and
maintain this action pursuant to Utah Code Annotated § 67-5-1 (18).

10.

The Defendants listed in paragraphs 11 through 39 are engaged in the business of
manufacturing, distributing, marketing and/or selling prescription drugs that are
reimbursed by Utah Medicaid. A comprehensive analysis is currently in process to
4
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identify each Defendant's prescription drugs reimbursed bV Utah Medicaid for which a
claim is made in this litigation; however, a few representative examples are listed in the
attached Exhibit A.
Defendant Apotex
11.

Defendant Apotex Corporation. ("Apotex") is a Delaware!«corporation with its principal
place of business located at 1776 Broadway Suite 1800, New York, NY 10019. Apotex
Corporation is a wholly-owned United States subsidiary of Apotex, Inc., a Canadian
corporation with its principal place of business located at) 150 Signet Drive, Weston,
Toronto, Ontario, Canada M9L 1T9.
The Baxter Defendants

12.

Defendant Baxter International, Inc. ("Baxter International") is a Delaware corporation
with its principal place of business located at One Baxter Parkway, Deerfield, EL 600154633.

13.

Defendant Baxter Healthcare Corporation ("Baxter Healthcare"), a wholly-owned
subsidiary of Baxter International, Inc, is a Delaware corporation with its principal place
of business located at One Baxter Parkway, Deerfield, 1% 60015.
The Boehringer Defendant^

14.

Defendant Boehringer Ingelheim Corporation ("Boehringer") is a corporation organized
under the laws of Nevada with its principal place of business located at 900 Ridgebury
Road, Ridgefield, CT 06877, and is the parent company of Roxane, BIPI, and Ben Venue.
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15.

Defendant Roxane Laboratories, Inc. ("Roxane"), a subsidiary of Boehringer Ingelheim
Corporation, is a Delaware corporation with its principal place of business located at 1809
Wilson Road, Columbus, OH 43228-9579.

16.

Defendant Boehringer Ingelheim Pharmaceuticals, Inc. ("BDPF'), a subsidiary of
Boehringer Ingelheim Corporation, is a Delaware corporation with its principal place of
business located at 900 Ridgebury Road, Ridgefield, CT 06877.

17.

Defendant Ben Venue Laboratories, Inc. ("Ben Venue"), a subsidiary of Boehringer
Ingelheim Corporation, is a Delaware corporation with its principal place of business
located at 300 Northfield Road, Bedford, OH 44146.

18.

Boehringer, Roxane, BIPI and Ben Venue (collectively "the Boehringer Defendants") are
diversified healthcare companies that individually, and/or in combination with one
another, engage in the business of manufacturing, distributing, marketing, and/or selling
prescription drugs that are reimbursed by state Medicaid agencies nationwide.
Defendant Mallinckrodt Inc.

19.

Defendam Mallinckrodt Inc. is a Delaware corporation. Its headquarters are located at 675
McDonnell Boulevard, Hazelwood MO 63042. Mallinckrodt Inc. is the U.S. subsidiary of
Covidien Ltd., a Bermuda corporation with its principal place of business located at 131
Front Street, Hamilton HM 12, Bermuda,

6
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Defendant CSL Behring
20.

Defendant CSL Behring ("CSL"), formerly known as ZLB| Behring, is a Pennsylvania
corporation with its principal place of business located at 1020 First Avenue, P.O. Box
61501, King of Prussia, PA 19406. CSL Bearing is a wholly-owned subsidiary of CSL
Limited, an Australian corporation with its principal plac^ of business located at 45 Poplar
Road, Parkville Victoria 3052, Australia.
Defendant Forest

21.

Defendant Forest Laboratories, Inc. ("Forest") is a DelaWare cornoration with its principal
place of business located at 909 Third Avenue, New York, NY 10022-4731.
Defendant Morton Grove

22.

Defendant Morton Grove Pharmaceuticals, hie. ("Mortoii") is an Illinois corporation with
its principal place of business located at 6451 W Main Sftreet, Morton Grove, IL 60053.
Defendant Mutual

23.

Defendant Mutual Pharmaceutical Company, hie. ("Mutual") is a Pennsylvania
corporation with its principal place of business located it 100 Orthodox Street,
Philadelphia, PA 19124.
• Novartis Defendant

24.

Defendant Novartis Pharmaceuticals Corporation ("Nojartis") i s a Delaware corporation
with its principal place of business located at One Healjh Plaza, East Hanover, NJ 079361080.
7
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Defendant Otsuka
25.

Defendant Otsuka America, Inc ("Otsuka") is the US holding company of Otsuka
Pharmaceutical Co., Ltd. a corporation with its nrincioal nlace of business located at One
Embarcadero Center, Suite 2020, San Francisco, CA. 94111.
The Pfizer Defendants

26.

Defendant Pfizer, Inc. ("Pfizer") is a Delaware corporation with its principal place of
business located at 235 East 42nd Street, New York, NY 10017. With the merger of Pfizer
and Pharmacia Corporation in 2003, Pfizer became the largest drug company in the world
today.

27.

Defendant Pharmacia Corporation ("Pharmacia") is a Delaware corporation with its
principal place of business located at 235 East 42nd Street, New York, NY 10017-5755. ,

28.

Defendant Pharmacia & Upjohn Company Corporation ("P & U"), a subsidiary of
Pharmacia Coiporation, is a Delaware corporation with its principal place of business
located at 235 E. 42nd Street, New York, NY 10017-5703.

29.

Defendant G.D. Searle, L.L.C. ("Searle"), a subsidiary of Pharmacia Corporation, is a
Delaware limited liability company with its principal place of business located at 4901
Searle Parkway, Skokie, IL 60077-2919.

30.

Defendant Agouron Pharmaceuticals, Inc. ("Agouron") is a California coiporation with its
principal place of business located at 10777 Science Center Drive, San Diego, CA 92121,

8
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31.

Pfizer, Pharmacia, P & U, Searle and Agouron (collectively the "Pfizer Defendants") are
diversified healthcare companies that individually, and/or [n combination with one
another, engage in the business of manufacturing, distributing, marketing, and/or selling
prescription drugs that are reimbursed by state Medicaid agencies nationwide.
Defendant Qualitest

32.

Defendant Qualitest Pharmaceuticals, Inc. ("Qualitest") isj an Alabama corporation with its
principal place of business located at 130 Vintage Drive 2JIE, Huntsville, AL 35811.
Defendant Schwarz

33.

Defendant Schwarz Pharma USA Holdings, Inc. ("Schwa|rz") is a Delaware corporation
with its principal place of business located at 103 Foulk Kd Suite 202, Wilmington, DE
19803. Schwarz is a wholly-owned U.S. subsidiary of Schwarz Pharma AG, a German
coiporation with its principal place of business located at| Alfred-Nobel-StraBe, 10
Monheim, Germany.
Defendant Taro

34.

Defendant Taro Pharmaceuticals USA, Inc. ("Taro"), a >jtew York corporation with its
principal place of business located at 3 Skyline Drive, Hawthorne, NY 10532.
Defendant Upsher-Smith

35.

Defendant Upsher-Smith, Inc. ("Upsker-Smith") is a Minnesota corporation with its
principal place of business located at 13700 1st Ave, N, Minneapolis, MN 55441.

9

The Schering Defendants
36.

Defendant Schering-Plough Corporation ("Schering-Plough") is a New Jersey corporation
with its principal place of business located at 2000 Galloping Hill Road, Kenilworth, NJ
07033.

37.

Defendant Wamck Pharmaceuticals Corporation ("Warrick"), a wholly-owned subsidiary
of Schering-Plough, is a Delaware corporation with its principal place of business located
at 12125 Moya Blvd., Reno, NV 89506-2600.
The Wveth Defendants

38.

Defendant Wyeth, Inc. ("Wyeth"), formerly American Home Products Corp., is a
Delaware corporation with its principal place of business located at Five Giralda Farms,
Madison, NJ 07940.

39.

Defendant Wyeth Pharmaceuticals, Inc. ("Wyeth Pharm"), a division of Wyeth, is a
Delaware corporation with its principal place of business located at 500 Areola Road,
Collegeville, PA 19426.
NATURE OF THE CASE

40.

This is a civil action for damages and civil penalties pursuant to the Utah False Claims
Act, Utah Code Annotated § 26-20-1 et seq., and Utah common law. No federal claims
are asserted.
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FACTUAL BACKGROUND
The Utah Medicaid Program
41.

Utah Medicaid is a state-administered program with federal matching funds that pays for
medical care, including prescription drug benefits, for Utah's low-income and disabled
citizens. Utah Medicaid currently covers about 300,000 individuals. Prescription drug
benefits represent about 14% of Utah Medicaid's annual qost of approximately SI.5
billion. The prescription drug benefit cost has increased dramatically in recent years from
$47.5 million in 1996 to $207.6 million in 2005, an increase of 437% in nine years or a
compounded rate of 17.8% per year.

42.

Utah Medicaid reimburses medical providers, including pharmacies and physicians,
pursuant to statutoiy and administrative guidelines and formulae for drugs prescribed for,
and dispensed or administered to, Utah Medicaid recipients.

43.

Reimbursement amounts for prescription drugs under Utah Medicaid are based on pricing
information supplied by Defendants to industry reporting services. This information
includes the following price indices: (I) Average Wholesale Price ("AWP"). which is
commonly understood as the average price charged by wholesalers to retailers, such as
hospitals, doctors and pharmacies, for prescription drugs, (ii) Wholesale Acquisition Cost
("WAC"), which is commonly understood as the average price paid by wholesalers to the
manufacturers for prescription drugs, and (iii) on occasion (but prior to 2003), Direct
Price, which is commonly understood as the price chars-ed by drug manufacturers to non11
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wholesaler customers for prescription drugs. At all times relevant to this action,
Defendants were aware of Utah Medicaid's drug reimbursement guidelines, formulae and
procedures for prescription drugs.
The Defendants' Reporting of Inflated Pricing Information
44.

Defendants knowingly, willfully, wantonly, and/or intentionally provided, or caused to be
provided, false and inflated AWP, WAC, and/or Direct Price information for their
respective drugs to various nationally known drug industry reporting services, including
First DataBank (a/k/a Blue Book), Medical Economics, Inc. (a/k/a Red Book), and
Medispan. These reporting services provide the pricing information to various third party
payers, such as Utah Medicaid, who have contracted to receive the pricing data as a basis
to determine reimbursement amounts to the providers who dispense or administer the
drugs to Utah Medicaid patients. Given the tens of thousands of separate National Drug
Codes ("NDCs") and the hundreds of thousands of prescription drug claims electronically
filed each month with Utah Medicaid, the State has no other feasible alternative to relying
on these drug industry reporting services. The State quite literally relies on the honesty
and fair dealing of the phannaceutical manufacturers in reporting their pricing information
to these drug industry reporting services, Pharmaceutical manufacturers are keenly aware
of this reliance and some, including the Defendants, have chosen to exploit it to their
benefit and the detriment of taxpayer-funded Medicaid.

12
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45,

Utah Medicaid purchased and utilized the Defendants1 published AWP, WAC, and/or
Direct Price information from First DataBank (Blue Book], and Medical Economics, Inc.
(Red Book). The information from Blue Book was and is |used by Utah Medicaid with
respect to reimbursement for pharmacy-dispensed drugs. At all relevant times to this
action, Utah Medicaid relied upon the AWP, WAC, and/ot Direct Price provided by
Defendants to the industry reporting services in determining the amount Utah Medicaid
reimburses providers.

46.

Defendants knew that the false and deceptive inflation of (AWP, WAC, and/or Direct Price
for their drugs would cause Utah Medicaid to pay excessive amounts for these drugs.
Defendants' inflated AWPs, WACs, and Direct Prices greatly exceeded the actual prices at
which they sold their drugs to retailers (physicians, hospitals, and pharmacies) and
wholesalers. Defendants' reported AWPs, WACs, and/or.Direct Prices were false and
misleading and bore no relation to any price, much less arwholesale or actual sales price.
A few representative examples are listed in the attached pxhibit A.

47.

Defendants knowingly, willfully, wantonly, and/or intentionally concealed the true AWP,
WAC, and/or Direct Price information for their respective drugs from Utah Medicaid.
Each Defendant knows its own AWP, WAC, and Direct [Price which it reports to the
industry reporting services for use by third party payers, including Utah Medicaid and
other state Medicaid programs. Each Defendant also knbws whether the prices it reports
to the reporting sendees accurately and truthfully represent the actual prices as reflected
13
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by market experience and conditions. Unless governmental or industry surveys, lawsuits,
or criminal or regulatory investigations publicly reveal the true AW?, WAC, or Direct
Price for a particular drug at issue, Utah Medicaid, like other state Medicaid programs, is
not privy to the actual market prices which can then be compared to the reported prices.
Defendants have concealed true market pricing information from the State for the purpose
of avoiding detection of the fraudulent scheme described herein.
Defendants used undisclosed discounts, rebates, charge-backs and other inducements
which had the effect of lowering the actual wholesale or sales prices charged to their
customers as compared to the reported prices. In addition, Defendants employed secret
agreements to conceal the lowest prices charged for their pharmaceutical products. As a
result of these concealed inducements and agreements, Defendants have prevented third
parties, including Utah Medicaid, from determining the true prices it charges its
customers.
Defendants' Marketing of the "Spread"
Defendants refer to the difference between the reported AWP and WAC, on the one hand,
and the actual price of a drug, on the other, as the "spread" or, alternatively, "return to
practice" or "return on investment." Defendants knowingly and intentionally created a
"spread" on their drugs and used the "spread" to increase their sales and market share of
their drugs, thereby increasing their profits. Defendants induced physicians and
pharmacies to purchase their drugs, rather than a competitor's drugs, by persuading them
14
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that the larger "spread" on Defendants' drugs would allow me providers to receive more
money, and thereby make more of a profit, through higher reimbursement at the expense
of Utah Medicaid.
50.

Defendants manipulated and controlled the size of the "spread" on their respective drugs
by both increasing their reported AWPs, WACS, and Direct Prices and decreasing their
actual prices to wholesalers and providers over time.

51.

In addition to manipulating the reported AWP, WAC, and/or Direct Price. Defendants
used free goods, educational grants and other incentives tcb induce providers to purchase
their drugs, all of which lowered the actual prices of the Defendants' drags, resulting in
increased profits for providers, as well as increased market share and profits for the
Defendants, at the expense of Utah Medicaid.

52.

The unfair, fraudulent, wanton, and deceptive practices engaged in by the Defendants in
creating and reporting, or causing to be reported, false and inflated AWP, WAC, and/or
Direct Price information for their drugs, or otherwise concealing actual pricing
information, and marketing the "spread" on their drugs as an inducement to providers to
utilize Defendants' drugs, has resulted in the State paying tens of millions of dollars in
excess Medicaid payments, while at the same time enricping Defendants with excessive,
unjust and illegal profits primarily from the resulting increased sales of then drugs.

53.

Drug manufacturers are aware of the AWPs reported by their competitors and of the
actual sales prices of their competitors' products. Drug Manufacturers manipulate their
15
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own AWPs in order to gain or maintain a competitive advantage in the market for their
products.
Some of the conduct described herein goes back over 10 years prior to the filing of the
original complaint in this action. As explained above, however, the nature and extent of
the fraudulent scheme were not known to the State because information concerning the
true prices which should have been reported to the reporting services was concealed and
not publicly available, It has only been through recent regulatory investigations, criminal
actions, and civil actions that the impact of the fraudulent scheme on the State has been
indicated or revealed. Even today, the true market prices for many of the drugs in question
for the entire time period at issue are not known by the State.
Additionally, it would be impractical, if not impossible, to list in this Complaint, for the
entire time period that the inflated pricing scheme has been in effect, the true market price
as compared to the reported price for each NDC in question. It is not unusual for a drug
manufacturer to reportfluctuatingprices for a particular drug on multiple occasions within
a particular year, month, week, or even day. To display pricing reports for all of the
Defendants and all of the NDCs in question over a ten-year-plus period would be a
massive undertaking. Limitations of time and space do not permit that information, even
if it were aivailable, to be set forth in this pleading; however, some representative
examples are listed in the attached Exhibit A.
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56.

For purposes of specificity of pleading, particularly with rispect to the fraud allegations,
suffice it to say that Defendants are and have been on notice of the claims asserted herein
as a result of the many investigations and actions undertaken around the country on this
same subject. Indeed, each Defendant should know without further allegation from the
State exactly how its reported prices compare to its true prices and whether it has engaged
in an inflated pricing scheme regarding prescription drugs.
FIRST CLAIM FOR RELIEF
(Restitution, Costs and Civil Penalties under the Utah False Claims Act)

57.

Plaintiff incorporates paragraphs 1 through 56 as if fully ?et forth herein, and further
alleges as follows:

58.

Defendants violated the Utah False Claims Act as codifidd in the Utah Health Code at
Title 26, Chapter 20 of the Utah Code Annotated. Defendants issued false and inflated
AWP, WAC, and/or Direct Price information for publication by the industry reporting
sendees, in violation of Utah Code Annotated §§ 26-20-3 and 26-20-7. Because of
Defendants' fraudulent conduct and misrepresentations, Utah Medicaid relied on the false
information in setting prescription drug reimbursement rates. Defendants "knowingly"
acted in deliberate ignorance or reckless disregard of the truth, and in so doing, caused the
State to pay false claims due to the grossly excessive reimbursements for Defendants'
prescription drugs.

59.

Under Utah Code Annotated § 26-20-9.5, Defendant is liable for the following damages:
17
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a.

Full and complete restitution to the state of all damages that the State sustained;

b.

The costs of enforcement, including but not limited to the cost of investigators and
attorneys;

6U.

c.

A civil penalty equal to three times the restitution amount; and

d.

A civil penalty of $5,000 to $105000 for each false claim filed.

These costs and penalties are in addition to and not a substitute for other damages caused
by Defendants' actions.
SECOND CLAIM FOR RELIEF
(Common Law Fraudulent Misrepresentation)

61.

Plaintiff incorporates paragraphs 1 through 60 as if fully set forth herein, and further
alleges as follows:

62.

Defendants committed fraud against the State and its single state agency administering
Utah Medicaid, the Utah Department of Health. Defendants reported or caused to be
reported AWP, WAC, and/or Direct Price for their respective products on a periodic and
continuing basis for publication and dissemination to third party paj'ers, including Utah
Medicaid and other state Medicaid programs. Defendants knew that the AWP, WAC,
and/or Direct Price information that they provided and caused to be reported was false and
material to the determination of Utah Medicaid reimbursement rates.

63.

Defendants misrepresented the pricing information with the intent of inducing Utah
Medicaid to rely on the false information in setting prescription drug reimbursement rates.

18

A0032

64.

Utah Medicaid reasonably relied on the false pricing data in setting prescription drug
reimbursement rates and making payment based on said rites. Defendants'
misrepresentations are continuing, as they regularly and periodically continue to issue
false and inflated AWP, WAC, and/or Direct Price informsation for publication by the
industry reporting services.

65.

As a result of Defendants' fraudulent conduct, the State his been damaged by paying
grossly excessive amounts for Defendants' prescription drugs.

66.

By engaging in the acts and practices described above, the Defendants have engaged and
continue to engage in repeated fraudulent acts and practices in violation of Utah common
law.

67.

Defendants' conduct was and is knowing, intentional, grolss, oppressive, malicious,
wanton, and/or committed with the intention to cause injury. These actions subject
Defendants to an award of punitive damages sufficient to punish the Defendants and make
an example of them.
JURY DEMAND
The State respectfully requests a trial by jury pursuant to [Rule 38, Utah R. Civ. Proc.
PRAYER FOR RELIEF
Wherefore, Plaintiff, the State of Utah, prays for relief ad follows:

1.

For the costs of enforcement pursuant to § 26-20-9.5(2)(p), Utah Code Ann.;

2.

For an award of full and complete restitution to the State in such amount as is
proved at trial;
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3.

For punitive damages for the wanton and reckless conduct as outlmed herein and
as an example for the benefit of all other drug manufacturers that wrongly
misrepresent the prices of their products to the detriment of Utah Medicaid;

4.

For civil penalties pursuant to § 26-20-9.5(2)(c), Utah Code Ann., equal to:
a.

Three times the restitution amount; and

b.

$5,000 to $10,000 for each false claim filed with Utah Medicaid.

5.

For an award of costs and prejudgment interest; and

6.

For such other and further relief as may be justified and which Plaintiff may be entitled to
by law including, but not limited to, all court costs, witness fees and deposition fees.
Respectfully SUBMITTED and DATED this p

day of June, 2008.

MARKL.SHURTLEFF
Attorney General of Utah
RAYMOND A. HINTZE
Chief Deputy Attorney General
ROBERT STEED
Assistant Attorney General
Director, Medicaid Fraud Control Unit
DAVID R. STALLARD
Assistant Attorney General
Medicaid Fraud Control Unit
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KENNETH D. LOUGEE
W. DANIEL "DEE" MILES, III
•CLINTON C. CARTER
JOSEPH W. STEELE
Special Assistant Attorneys General
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CERTIFICATE OF SERVICE

I hereby certify that on the 10
day of June, 2008,1 served the attached
documents (Amended Complaint and Jury Demand, and Notice of Amendment) by mail
on the following:
Mr. Matthew Solum
msolum@ldrkland.com
KJRKLAND & ELLIS

Citigroup Center
153 East 53rd Street
New York, NY 10022
Attorneys for Oualitest Pharmaceuticals, Inc.
Mr. George M. Haley
Mr. David Parkinson
george.haley@hro.com; david.parkinson@hro.com
HOLME ROBERTS & OWEN

299 South Main Street, Suite 1800
Salt Lake City, UT 84111
Attorneys for Pfizer, Inc.
Mr. David G. Greene
dgreene@lockelord.com
LOCKE LORD BISSELL & LIDDELL LLP

885 Third Avenue, 28th Floor
New York, NY 10022
Attorneys for Apotex Corporation
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EXHIIBIT A
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EXHIBIT A
Through the following list, the State of Utah intends to capture not only the drug names
listed, but also all variations of the drug names which incorporate prefixes, suffixes, modifiers,
supplements, application nomenclatures and/or drug delivery methods, to the extent not already
specified

APOTEX DEFENDANTS
ACYCLOVIR
ALENDRONATE
;AMLODIPINE
;BALSALAZID
I BENAZEPRIL
iBETAXOLOL
BUPROPION
BUTORPHANOL
CAPTOPRIL
jCARBAMAZEPINE
ICARBIDOPA
jCARVEDILOL
ICEFAZOLIN
CEFEPIME
'CEFOXITIN
iCEFTRIAXQN
iCEFURQXIME
CETIRIZINE
CHLORHEXIDINE
CICLOPIRQX
CILOSTAZOL
CIMETIDINE
CIPROFLOXA
CITALOPRAM
CLARITHRQM
CLONAZEPAM
CLOPIDPGREL
CROMOLYN
CYCLOSPQRINE
DESMQPRESS
DICLOFENAC
DILTIAZEM
DIVALPROEX
DOXAZOSIN
ENALAPRIL
EPLERENQNE
ETODQLAC
FLUCONAZOLE
FLUNISOLIDE
FLUOXETINE
FLUPHENAZINE
FLUTICASON
FLUVOXAMINE
GABAPENTIN
GEMFIBROZIL
GLIPIZIDE
HALOPERIDOL

A0038

EXHIBIT A

pPRATROPIUM
KETOCONAZOLE
KETOTIFEN
LACTULOSE
LEFL1NOMID
LISINOPRIL
LITHIUM CA
LORATADINE
LOVASTATIN
MEGESTROL
MELOXICAM
METFORMIN
MIDAZOLAM
MIDODRINE
MIRTAZAPINE
MORPHINE
NIZATIDINE
OFLOXACIN
OMEPRAZOLE
ONDANSETRON
pXAPROZIN
OXCARBAZEPINE
OXYBUTYNIN
PAROXETINE
PENTOXIFYLLINE
PRAVASTATIN
QUINAPRIL
RANITIDINE
SELEGILINE
SERTRALINE
SOTALOL
TERAZOSIN
TICLOPIDIN
TIMOLOL
TIZANIDINE
TOBRAMYCIN
TORSEMIDE
TRAMADOL
TRAZODONE
TRIAMETERENE
TRIANTERENE
ZINISAMIDE
ZOLPIDEM F
ZONISAMIDE
BAXTER DEFENDANTS
IACETICACID
IALDOCLOR
IALDOMET
ALDORIL
AMERINET
AMIKACIN
AMINOACETI

EXHIBIT A
AMINOPHYLL
AMPICILLIN
AQUA-MEPHY
ARALAST
ATIVAN
ATROPINE
IAZITHROMYC
BEBULIN
BENEMID
BLOCADREN
BUMINATE
CANCIDAS
CEFAZOLIN
CEFOXITIN
CEFTR1AXON
CEFUROXIME
CERNEVIT
CH1BROXIN
CHLORPROMA
CLINDAMYCI
CLINORIL
COGENTIN
COL-BENEMI
CORTONE
COSMEGEN
COSOPT
COZAAR
CRIXIVAN
CUPRIMINE
CYANOCOBAL
CYCLOPHOSP
DARANIDE
DECADRON
DECASPRAY
DEMSER
DEXAMETHAS
DEXTROSE
DIAZEPAM
DIGOXIN
piPHENHYDR
DIUPRES
DIURIL
DOLOBID
DOXYCYCLIN
DURAMORPH
EDECRIN
ELAVIL
ELSPAR
EMEND
EPINEPHRIN
ERYTHROMYC
[FAMOTIDINE

|
1
1
1
1
1
1
1

1
1
1
1
1
1
1
1

1

1

1
1

1
1
1

1
1
1
1
1
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EXHIBIT A
IFEIBAVHI
FENTANYLC
FLEXERIL
FLOROPRYL
FOSAMAX
FUROSEMIDE
GAMMAGARD
GENTAMICIN
GLYCOPYRRO
HEMOFIL
HEPARIN
HEP-LOCK
HEPTAVAX-B
HUMORSOL
HYDELTRA
HYDROCORTI
HYDRODIURI
HYDROMORPH
HYDROPRESHYDROXYZIN
HYZAAR
INDOCIN
INFUMORPH
INTRALIPID
INVANZ
INVERS1NE
ISENTRESS
JANUMET
JANUVIA
KETOROLAC
LACRISERT
LACTATED
LIDOCAINE
LORAZEPAM
LOSEC
MAXALT
MEFOXIN
MEPERIDINE
MEPHYTON
METHYLDOPA
METOCLOPRA
METRONIDAZ
MEVACOR
MIDAMOR
MIDAZOLAM
MILRIONONE
MINTEZOL
M-M-RIIV
MODURETIC
IMONISTATD
IMORPHINE
MUSTARGEN

|

|

|

|

i

|
1

|

1
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EXHIBIT A

MYOCHRYSIN
NALLPEN
NEODECADRO
NEOSTIGMIN
NOROX1N
NUTREN
ONDANSETRO
OXYTOCIN 1
PENICILLIN
PEPCID
PERIACTIN
PHENERGAN
PHENOBARBI
PHENYTOIN
PLENDIL
PNEUMOVAX
POTASSIUM
PR LOSEC
PR MAXIN
PR NIVIL
PR NZIDE

1
1
1
1
1
1

1
1
1
1
1
1
1
1
1

PROCHLORPE
PROMETHAZI
PROPECIA
PROSCAR
RECOMBINAT
RECOMBIVAX
REGLAN 5MG
REPLETE
RINGER'S L
ROBINUL
SINEMET
SINGULAIR
SODIUM CHL
STERILE WATER
STROMECTOL
SULFAMETHO
SYPRINE
THIAMINE
TIMOLIDE
TIMOPTIC
TONOCARD
TRANSDERM
TRAVASOL
TRAVASORB
TRIAVIL
TRUSOPT
URECHOLINE
VANCOCIN
VANCOMYCIN
VAQTA
VASERETIC

1

1
1

1
1
~1
1
~~1
|
1
1
~~1
j
1
1
1
~1
1
~1
[
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EXHIBIT A

[VASOTEC
VIOXX
VIVACTIL
WATER
ZOCOR
ZOSTAVAX
BOEHRJNGER DEFENDANTS
ACARBOSE
ACETAMINOPHEN
ACETAZOLAM
ACETYLCYST
ACYCLOVIR
ADRIAMYCIN
AGGRENOX
ALBUTEROL
ALPRAZOLAM
ALUMINUM
ALUPENT
AMIKACIN S
AMINOPHYLL
AMITRIPTYL
APTIVUS
ATROVENT
AZATHIOPRI
BALSALAZID
BUMETANIDE
BUTORPHANO
CAFCIT
CALC CARB
CALCIUM GLUCONATE
CALCITRIOL
CALCIUM CARBONATE
CATAPRES
CERUBIDINE
CHLORAL HY
CHLORPHENI
CHLORPROMA
CILOSTAZOL
CIMETIDINE
CIPROFLOXA
CISPLATIN
CITALOPRAM
CLADRIBINE
|CLARITHROM
jCLINDAMYCI
ICLOTRIMAZO
ICOCAINEHC
CODEINE 15
CODEINE PH
CODEINE SU
COMBIPRES

COMBIVENT

|

|

|

|

I
|

|
|
|

|

|
|
|
I

I

J

EXHIBIT A

CROMOLN
CROMOLYN
CYCLOPHOSP
CYCLOSPORI
CYTARABINE
DEXAMETHASONE
DIHYDROTACHSTEROL
DIAZEPAM
DICLOFENAC
DIFLUNISAL
DIGOXIN
DIHYDROERGOTAMINE
DIPHENHYDR
DIPHENOXYL
DOCUSATE
DOLOPHINE
DOXORUBIC1
DOXYCYCUN
DULCOLAX
DURACLON
ENALAPRILA
FAMOTIDINE
FELCAINIDE
FERROUS SU
jFLECAINIDE
IFLOMAX
IFLUCONAZOL
jFLUPHENAZI
jFLUTICASON
FOLIC ACID
FUROSEMIDE
GLUCAGEN
GUAIFENESI
HALOPERIDO
1HYDROCHLOR
jHYDROMORPH
IHYDROXYURE
jIMIPRAMINE
jlNDOMETHAC
llODINATED
jlPRATROPIU
IISOETHARIN
| KAOLIN-PEC
IKETAMINE H
KETOROLAC
LABETALOL
LACTULOSE
LACTULOSE
[LEUCOVORIN
ILEVOCARNIT
LEVORPHANO
LEVOTHYROX

EXHIBIT A

(LITHIUM CARBONATE
LITHIUM CITRATE
LOPERAMIDE
LORAZEPAM
MARINOL
MEFLOQUINE
MEGESTROL
MELOXICAM
MEPERID50
MEPERIDINE
MERCAPTOPU
MESNAINJE
METAPROTER
METHADONE
METHOTREX
METHYLDOPA
METHYLPRED
METOCLOP
METOCLOPRA
METOPROLOL
MEXILETINE
MEXITIL
MICARDIS
MIDAZOLAM
MILK OF MA
MIRAPEX
MIRTAZAPIN
MITOMYCIN
MOBIC
MORPHINE SULFATE
MORPHINE
NAPROXSUSPEN
NAPROXEN
NEFAZODONE
NEOMYCIN
OCTREOTIDE
ONDANSETRO
ORAMORPH
OXCARBAZEP
OXYCODONE
PACLITAXEL
PAMIDRONAT
PAPAVERINE
PERSANTINE
PHENOBARBI
PHENTOLAMI
PILOCARPIN
!PIROXICAM
POLYMYXIN
POTASSIUM CHLORIDE
PREDNISONE
PROCHLORPE

|

1

|

|

EXHIBIT A

PROPANTHEL
PROPOXYPHE
PROPRAN
PROPRANOLO
PSEUDOTAB
PSEUDOEPHE
QUINIDINE
RANITIDINE
RESPBID
RIFAMPIN
ROPINIROLE
ROXAN
ROXANOL
ROXICET
ROXICODONE
ROXILOX
ROXIPRIN
!SALIVA SUB
jSERENTIL
[SERTRALINE
SODIUM POLY SULFONATE
[SODIUM CHLORIDE
[SODIUM POLYSTYRENE SULFONATE
SPIRIVA
[STERILE AC
[SULFAMETHOXAZOLE
[TAMOXIFEN
THEOPHYLLI
THIORIDAZI
THIOTHIXEN
TORECAN
TORSEMIDE
TRIAZOLAM
VINBLASTIN
VIRAMUNE
ZALEPLON
ZIDOVUDINE
ZOLPIDEM T
CSL BEHRING DEFENDANTS
ACTHAR H P
ALBUMINAR
AQUASOL A
ARM-A-VIAL
BIOCLATE
CARIMUNE
DIALUME
GAMMAR
HELIXATE
HUMATE-P
M V I PEP
MONOCLATE
MONONINE

EXHIBIT A

IRHOPHYLAC
STIMATE
VIVAGLOBIN
ZEMAIRA
FOREST DEFENDANTS
AEROBID
AEROCHAMBE
AMBENYL
APAP/HYDRO
ARMOUR THY
BANCAP
BENZONATAT
BETACHRON
BUCET
BUTALBITAL
BYSTOLIC
CAMPRAL
CARBAMAZEP
CEBOCAP
CELEXA
CITALOPRAM
COMBUNOX
DILTIAZEM
ELIXOPHYLL
ENDAL
ESGIC
FEOSTAT
FLUMADINE
HYDROCODON
INDOCHRON
INDOMETHAC
ISOSORBIDE
KAYCIEL
LEVOTHROID
LEXAPRO
LORCET
MONUROL
NAMENDA
NITROGARD
PARAL
PEDAMETH
PROPRANOLO
PYOCIDIN
RIMANTADIN
SUS-PHRINE
TESSALON P
THEOCHRON
THEOPHYLLI
THYROLAR
TIAZAC
TRIAD
UAD OTIC EAR SU

]

,
1

1

EXHIBIT A
IVERTAB
I ZONE-A
WIALLINCKRODT DEFENDANTS"
ACETAMINOPHEN
AMPHETAMINE
ANAFRANIL
ANAGRELIDE
ANEXSIA
I ATENOLOL
jAZATHIOPRI
IBENZONATAT
BUTALBITAL
jCOCAINE HYDROCHLORIDE
CODEINE PH
IDEXTROAMPH
IDIPHENOXYL
jFLUOXETINE
IHYDQCODONE
HYDRQMORPH
1MIPRAM1NE
MAGNACET
MELQXICAM
MEPERIDINE
METFORMIN
METHADONE
METHADOSE
METHYLIN E
METHYLPHEN
MORPHINE
M-OXY
NALTREXONE
OXYCODONE
PAMELOR50
PEMADD
PEMOLINE
PENTAZOCIN
PROMETHAZI
PROPADE

PROPOXYPHE
RESTORIL
[RIBAVIRIN
jSIMVASTATI
ITEMAZEPAM
ITOFRANIL
[TRAMADOL
TUSSIZONE
WARFARIN
MORTON GROVE DEFENDANTS
ACETAMINOPHEN
ACETIC ACID
ACIDULATED
AMANTADINE

EXHIBIT A
IBROMAXEFED
BROMODIPHE
CARBAMAZEP
CARBAXEFED
CARBINOXAM
CHLORAL HYRATE
CIMEDTIDIN
CIMETIDINE
CLEMASTINE
CLIN DAM YCI
CLOBETASOL
C-PHED
CYCLOSPORI
DEC-CHLORPHEN
DECOHISTIN
DEXAMETHAS
DIPHEN
DOCUSATES
DOXEPIN HC
ERYTHROMYCIN
FERROUS SULF
FLUOXETINE
FUROSEMIDE
GENERLAC
GUAIFENESI
HYDROCODONE
HYDROXYZINE
HYOSCYAMINE
LACTULOSE
LIDOCAINE
LINDANE
LITHIUM CARBONATE
MEGESTROL
METAPROTERENOL
METOCLOPRAMIDE
MORPHINE
MULTI-VITAM
MYPHETANE
MYTUSSIN
NYSTATIN
OXYBUTYNIN
PAREGORIC
PHENCLOR
PHENOBARBI
PHENYTOIN
POTASSIUM
PREDNISOLONE
(PROMETHAZINE
PYRILAFEN
SELENIUM S
TANNIHIST
TETRA TANN

i

|
1

EXHIBIT A
THEOPHYLLINE
TR1AMCINOL
TRIPLE TAN
TRIPLE VITA
TRIPROLIDINE
VALPROIC A
MUTUAL PHARMACEUTICAL DEFENDANTS
ACETAMINOPHEN
IACETAZOLAM
jALBUTEROL
IALLOPURINOL
AMANTADINE
AMITRIPTYL
AMPHETAMIN
ASPIRIN
jATENOLOL
JBENZTROPIN
BETHANECHO
BISOPROLOL
CARBAMAZEP
CARISOPRODOL
CHLORDIAZE
CHLORTHALID
[CHLORZOXAZONE
ICLONIDINE
JCYCLOBENZAPRINE
DIPHENHYDRAMINE
IDOXEPIN
DOXYCYCLIN
ERGOLOID
FELODIPINE
FLUOXETINE
FOLIC ACID
GABAPENTIN
GUAIFENESIN
HYDRALAZINE
HYDROCODONE
HYDROXYZINE
HYOSCYAMINE
IBUPROFEN
IMIPRAMINE
INDOMETHAC
KETOCONAZOLE
LABETALOL
LORAZEPAM
LOVASTATIN
MECLIZINE
MELOXICAM
METFORMIN

|
1

1
1
1

1
1
1

1
1
1
1
1
1
1
1

1
1

1

1

1
1
1
1
1

METOPROLOL
METRONIDAZOLE
[MINOXIDIL

1
I
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IMULTIHIST
NYSTATIN
ORDRiNE
PANCRELIPASE
PIROXICAM
PREDNISONE
PRIMIDONE
PROPAFENON
PROPOXYPHENE
QUINIDINE
SALSALATE
SPIRONOLAC
SULFASALAZ
SULFISOXAZ
SULINDAC
THEOPHYLLINE
THIORIDAZINE
TOLAZAMIDE
TOLMETIN
TRAMADOL
TRAZODONE
TRIMETHOBENZAMIDE
VERAPAMIL
ZOLPIDEM
ZONISAMIDE
NOVARTIS DEFENDANTS
ACTIGALL
ANAFRANIL
ANTURANE
APRESOLINE
AREDIA
ASBRON G
ASCRIPTIN
ATROPISOL
AZMACORT
BELLERGAL
BETIMOL
BRETHAIRE
BRETHANCER
BRETHINE
BUTAZOLIDI
CAFERGOT
CATAFLAM
CERUBIDINE
ICIBACALCIN
CIBAUTH-S
(CLEMASTINE
(CLOZARIL
^COMBIPATCH
!COMTAN
CONSTANT-T
CYTADREN
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EXHIBIT A

CYTARABINE
D.H.E45
DENAVIR
DESENEX AF
DESFERAL
DEXACIDIN
D1APID NAS
DIOVAN
DOXORUBICI
DULCOLAX
DYNACIRC
EFIDAC
EFLONE
ELIDEL
ENABLEX
ESERINE SU
ESIDR1X
ESIMIL
ESTRADERM
EXELON
EXFORGE FC
EXJADE
EX-LAX MIL
FAMVIR
FEMARA
FIORICET
FIORINAL
FIORTAL
FLUOR-OP
FOCALIN
FORADIL AE
GENTACIDIN
GENTEAL
GLEEVEC
GLUCOSE
HABITROL
HOMATROPIN
HYDERGINE
HYPOTEARS
INFLAMASE
ISMELIN
KLORVESS
LAMISIL
LAMPRENE
LESCOL
LIORESAL
LITHOBID
LIVOSTIN
LOPRESSOR
LOTENSIN
LOTREL
LUDIOMIL

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

1
1
1

1
1
|
1
~1
~~|
1
1
1
1
J
1
1
1
1
|
~~1
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EXHIBIT A
IMAALOX
MELLARIL
MESANTOIN
METAPREL
METHERGINE
METOPIRONE
METOPROLOL
MIACALCIN
MIGRANAL
MYFORTIC
NEO-CALGLU
NEORALSOL
NICOTINE
NUPERCAINA
OCUPRESS
OSCO NTS 1
PAMELOR
PAREPECTOL
PARLODEL
PERDIEM FIBER
PILOCAR
PROLEUKIN
RECLAST
REGITINE
RESCULA
RESTORIL
RIMACTANE
IRITAUN
SANDIMMUNE
SANDOGLOBULIN
SANDOSTATIN
SANSERT
SER-AP-ES
SERPASIL
SLO-BID10
SLO-PHYLLI
SLOWFE
SLOW-K
STALEVO
STARLIX60
SULF-10
SYNTOCINON
TASIGNA HG
TAVIST
TEARISOL
TEGRETOL
ITEKTURNA H
JTEN-K
TETRACAINE
TEXTURNA
THIORIDAZINE
TOBI

|

|

I

I

A0053

EXHIBIT A
TOFRANIL
TOMYCINE
TRANSDERM
TRIAMINIC
TRIAMTEREN
TRILEPTAL
VASOC1D1N
VASOCINE
VASOCON
VASOSULF
VISKEN
VISUDYNE
VIVELLE
VOLTAREN
ZADITOR
ZELNORM
ZOMETA
I PFIZER DEFENDANTS
ACCUPRIL
IACCURETIC
ACETAMINOPHEN
ACTH
ACTIVELLA
ADRENALIN
ADRIAMYCIN
ADRUC1L
ALDACTAZID
lALDACTONE
ALPRAZOLAM
AMBIEN
AMINOPHYLL
AMITRIPTYL
AMLODIPINE
AMOXICILLINE
AMPHOCIN
AMPICILLINE
AN SAID
ANTIMINTH
ANTIVERT
ANUSOL
APLISOL
APLITEST
AROMASIN
ARTHROTEC
ASPIRIN
ATARAX
AXERT
AXOTAL
AZITHROMYC
AZULFIDINE
BACITRACIN
BANTHINE

EXHIBIT A
1 BENADRYL
BENYLIN
BEXTRA
BLEOMYCIN
BREVICON
BRONDECON
CABERGOLIN
CADUET
CALAN
CAMPTOSAR
CARDURA
CAVERJECT
CEFOBID PI
CELEBREX
CELONTIN
CENTRAX
CEREBYX
ChANTIX
CHERACOL
CHILDREN'S
CHLOROMYCE
CHLORPROMA
CHOLEDYL
CHOLYBAR
CLEOCIN
CLEOCIN
CLINDAMYCI
CLONIDINE
COGNEX
COLESTID
COLESTIPOL
COLY-MYCIN
CORTAID
CORTEF
ICORTISONE
COVERA
CYCLOBENZA
CYTOSAR
CYTOTEC
DAYPRO
! DELTASONE
IDEMULEN
iDEPO PROVE
DEPO-ESTRA
:DEPO-MEDRO
;DEPO-PROVE
DEPO-SUBQ
DEPO-TESTA
DETROL
DIABINESE
DIAZEPAM
DIDREX
T

A0055

EXHIBIT A
DIFLUCAN
DILANTIN
DIPENTUM
DIPHENOXYL
DIULO
DORYX
DOSTINEX
DOXIDAN
DOXYCYCLIN
DRAMAMINE
EASPRIN
ELASE
EMCYT
EMETE-CON
EMETROL
E-MYCIN
EPLERENONE
ERAXIS
ERGOSTAT
ERYC
ERYTHROMYC
ESTRING
ESTROSTEP
ESTROVIS
EUTHROID
EXUBERA
FELDENE
FEMHRT
FEMINONE
FEMPATCH
FERROUS SU
FLAGYL
FLAVORED C
FLUCONAZOL
FLUOGEN
FLURBIPROF
FRAGMIN
FUROSEMIDE
GABAPENTIN
GELUSIL
GENOTROPIN
GEOCILLIN
GEODON
GLIPIZIDE
GLUCOTROL
GLYBURIDE
GLYNASE
GLYSET 50M
HALCION
HALOPERIDO
HALOTESTIN
HEPARIN SO

A0056

EXHIBIT A

HU MATIN
HYDROCHLOR
IBUPROFEN
INDOMETHAC
INSPRA
KAO LECTRO
KAOCHLOR
KAON
KAOPECTATE
KERLONE
KETALAR
K-LEASE
LACTULOSE
LEOSTRIN 2
LEOSTRIN F
LEVORA-28
LEVSIN PRO
LINCOCIN
LIP1TOR
LOESTRIN
LOMOTIL
LONITEN
LOPID
LUNELLE
LYRICA
MANDELAMIN
MAO LATE
jMAXAQUIN
MECLOMEN"
MEDROL

MEDROXYPRO
JMETAMUCIL~~
JMETHYLDOPAT
'METHYLPRED
MICRONASE
IMICRONIZED
1M1LONTIN
iMINIPRESS
MINIZIDE 1
MIRAPEX
MISOPROSTO
MODANE
MOTRIN
"
MYCOBUTIN
NARDIL
NATABEC RX~"
NAVANE
NEO-CORTEF
NEOSAR
NEURONTIN
NICOTROL
NITRODISC"

EXHIBIT A
NITROL
NITROSTAT
NORETHIN
NORINYL
NORLESTRIN
NORLUTATE
NORPACE
NOR-Q-D
NORVASC
OGEN
OMNICEF
OPHTHOCORT
OR NASE
OXAPROZIN
PANMYCIN
PARSIDOL
PEDIACARE
PENICILLIN
PERMAPEN
PFIZERPEN
PHENOBARBI
PIROXICAM
PITOCIN
PITRESSIN
POLYMYXIN
PONSTEL
PRO-BANTHI
PROCAN SR
PROCAINAMIDE
PROCARDIA
PROLOID
PROSTIN
PROVERA
PYRIDIUM
QUINAPRIL
QUINIDINE
QUININE SU
RELPAX
RENESE
RESCR1PTOR
REVATIO
REZULIN
R-GENE10
SERTRALINE
SINEQUAN
S1NUBID
SLOW-MAG
SODIUM CHL
SOLU-CORTE
SOLU-MEDRO
SPIRONOLAC
STREPTOMYC

1
1
1
1
1

1
1
1
~~1
~~1
~"1
1
1
1
1
1
~1
1
1
1
1
1
1
1
1
~1
|
I
~1
1
1
"~1
1
1
1
\
~1
~|

A0058

EXHIBIT A
ISULFASALAZ
SULFASALZI
SURFAK
SUSTAIRE
SUTENT
SYNAREL
SYTOBEX
TABRON
TAO
TEDRAL
TERRA-CORT
TERRAMYCIN
TETRACYCLI
THEELIN
THEO
TIKOSYN CA
TOLINASE
TRIAZOLAM
TRI-NORINY
TRIVORA
TROVAN
TYMPAGESIC
UNASYN
UTICORT
VAGIFEM
VANTIN
VERAPAMIL
VFEND
VIAGRA
VIBRAMYCIN
VIBRA-TABS
VINCASAR
VIRA-A
VIRACEPT
VISTARIL
XALATAN SS
XANAX
ZARONTIN
ZINECARD
ZINECARDS
jZITHROMAX
;ZMAX
ZOLOFT
ZYRTEC
ZYVOX
QUALITEST DEFENDANTS
A/B OTIC
ACETAMINOPHEN
ACETAZOLAM
ACETIC ACID
ACIDIC VAG
ALBUTEROL

1
'
|

|

1

|
i

1
|

EXHIBIT A

ALLOPURINO
AMANTADINE
AM1LOR1DE
AMITRIPTYL
AMOXAPINE
AMOXICILLI
AMPICILLIN
ANTACID
ANTIBIOTIC
APAP
ASPIRIN-LO
ATENOLOL
ATROPINE S
BACLOFEN
BENZONATAT
BENZOYL PE
BENZTROPIN
BETAMETHAS
BETHANECHO
BISACODYL
BROMANYL
BROMATAPP
BROMOPHED
BROMPHENIR
BROMUPHED
BUFFERED A
BUTALBITAL
CALCIUM AN
CARBAMAZEP
CARBIDOPA/
CARDEC
CARISOPROD
CEFACLOR
CEPHALEXIN
CEPHRADINE
CERVICAL A
CHERATUSSI
CHLORAL HY

CHLORAMPHE
CHLORDIAZE
CHLOROTHIA
CHLORPHENI
CHLORPROMA
CHLORPROPA
CIMETIDINE
CLEMASTINE
CLINDAMYCI
CLONAZEPAM
CLONIDINE
CLORAZEPAT
CLOTRIMAZO
CLOXACILLI

I
1
1
1
1
1
1
1
1
"1
1
1
"1
j
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

1
1

1
1
1
1
1
1

A0060

EXHIB'- A
CODAMINE
CODITUSS D
COLCHICINE
CORTISONE
CYCLOBENZA
CYPROHEPTA
DECONESTIN
DECONGEST
DESIPRAMIN
DESOXIMETA
DETUSSIN
DEXAIR
DEXAMETHAS
DEXCHLORPH
DIAZEPAM
DICLOXACIL
DICYCLOMIN
DIGOXIN
DILTIAZEM
DIMENHYDRI
DIPHENHYDR
DIPHENOXYL
DIPYRIDAMO
DISOPYRAMI
DISULFIRAM
DOC-Q-LACE
DOXEPINHC
DOXYCYCLIN
DREXOPHED
DRITUSSDM
DRITUSS
EAR-GESIC
ENTERIC CO
fERGOLOIDM
l ERYTHROMYC
ESTROPIPAT
FENOPROFEN
IFERROUSSU
FLOURIDEC
FLUOCINOLO
IFLUOCINONI
IFLUORIDED
FLUPHENAZI
FLURAZEPAM
FLURBIPROF
iFOAMING ANTACID
FOLIC ACID
FUROSEMIDE
GENTAFAIR
GENTAMICIN
GLIPIZIDE
GLYBURIDE

——___-—__-———_-—

1

—

.

—|

—f—— H

|

|
_

_

1

j

j

|

A0061

GRANUL-DER
GUAIFEN PS
GUAIFENESI
GUAIFEN-PS
GUAIVENT
GUANFACINE
HALOPERIDO
HC TUSSIVE
HDROCODONE
HEMORRHOIDAL
HYDORCODONE
HYDRALAZINE
HYDROCHLOR
HYDROCODONE
HYDROCORTISONE
HYDROMORPH
HYDROXYZIN
HYOSCYAMIN
IBUPROFEN
IMIPRAMINE
INDOMETHAC
INSULIN SY
IOPHEN
ISOSORBIDE
K EFFERVES
K+ POTASSIUM
K-EFFERVES
KETOPROFEN
LACTULOSE
LEUCOVORIN
LEVOTHYROX
LIDOCAINE
LINDANE
LITHIUM CA
LOPERAMIDE
LORAZEPAM
LOXAPINE S
MAPROTIUN
MATERNITY
MECLIZINE
MECLOFENAM
MEDROXYPRO
MEGESTROL
MEPERIDINE
MEPERITAB
MEPROBAMAT
METAPROTER
METHAZOLAM
METHOCARBA
METHOTREXA
METHYLDOPA
METHYLPHENIDATE

EXHIBIT A
iMETHYLPRED
jMETOCLOPRA
METRONIDAZ
M1NOCYCUN
MINOXIDIL
MULTI VIT
MULTI-BRET
MYLACARE
NAPHAZOUN
NAPROXEN
NATURAL VE
NEO-DEX
NEOPTIC
NIACIN TD
NIFEDIPINE
NITROFURAN
NITROGLYCE
NOLPHENAMI
NYSTATIN
OCTICAINE
OCUTRICIN
ORGAN-I
OR-PHEN-AD
OR-PRIN
OTICAINE
OTIGESICO
OXAZEPAM
pXYBUTYNIN
OXYCODONE
PANASE
PAPAVERINE
PAREGORIC
PEMOLINE
PENICILLIN
PERPHENAZINE
PHENAZOPYRIDINE
PHENOBARBI
PHENTERMINE
PHENYLHISTINE
PILOCARPIN
PINDOLOL
PINK BISMUTH
iPIROXICAM
ipOLYCS
iPOLY-D
IPOLY-DM
; POTASSIUM
PRAZOSIN H
PREDNISOLONE
PREDNISONE
PRENATAL
PRIMIDONE

|

\

I
T

I

•

\
|

EXHIBIT A

PROBENECID
PROCAINAMIDE
PROCTOSERT
PROMETHAZINE
PROPAFENON
PROPOXYPHENE
PROPRANOLO
PSEUDOEPHE
QNOL325
Q-BID
Q-DRYL
Q-FED
Q-MIBID
Q-NOL
Q-PAP
Q-PROFEN
iQ-TUSSIN
•QUINDAL
QUINIDINE
QUININE
iQUINTEX
R-TANNAMIN
SALSALATE
SELENIUM S
SENNA LAX
SILVER SUL
SODIUM FLUORIDE
SODIUM SULF
SORBITOL
SOTALOL
SPIRONOLAC
SUCRALFATE
SULFACETAM
SULFAMETHO
SULFASALAZ
SULFATRIM
SULFAZINE
SULFISOXAZ
SULINDAC
SULPRED
SUR-Q LAX
TEMAZEPAM
TETRACYCLI
THEOPHYLLINE
THERMAZENE
THEROBEC
THIORIDAZINE
THIOTHIXEN
THYROID
TOBRAMYCIN
iTOLBUTAMID
ITOLMETIN S

A0064

EXHIBIT A

TRAZODONE
TRIACTIN
TRIAMCINOL
TRIAMTEREN
TRIAZOLAM
TRICOSAL
TRIHEXYPHE
TRIMETHOPRIM
TRIPLE ANTIBIOTIC OINTMENT
TRIPLE SUL
TRI-VITAMIN
TRIXAICIN
UR NARY ANTISEPTIC
URSODIOL
VALPROIC A
VEGETABLE LAX
VERAPAMIL
VICA-FORTE
Vl-Q TUSS
YOHIMBINE
Z+PRENATAL
ZOCORT HC
ZOLENEHC
ZOTANE HC
SGHER1NGI3EFENDANTS
ADALAT
AEROBID
AFRIN
ALBUTEROL
AMOXICILLIN
ASMANEX
AUGMENTED BETAMETHASONE
AVELOX IV
AVELOXTAB
BETAMETHAS
BILTRICIDE
CEDAX
CELESTONE
CHLOR-TRIM
CIMETIDINE
CIPRO
ICLARINEX
iCLARITIN
ICLOTRIMAZO
iDERMOLATE
;DIPROLENE
iDIPROSONE
!
DRIXORAL
ELOCON
EMKO
ESTINYL
ETRAFON
.

:

_...,_

.,._

..„—,_

_ _ _ . _ -

!

|

j

1
|

!

1

;

|
!

i

j

|
j
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A0065

EXHIBIT A
EULEXIN
FEMCARE
FORADIL
FULVICIN P
GARAMYCIN
GLYBURIDE
GRISEOFULV
GYNE-LOTRI
IMDUR
INSPIREASE
INSPIREASE
INTRON
ISOSORBIDE
K-DUR
LABETALOL
LEVITRA
LOTRIMIN
LOTRISONE
METICORTEN
METIMYD
MEXILETINE
MIRADON
MOL-IRON
MOMETASONE
NAQUA
NASONEX
NASONEX NA
NITRO-DUR
NONOXYNOL
NORMODYNE
NORMOZIDE
NOXAFIL PO
OPTIMINE
ORETON MET
OTOBIOTIC
OXAPROZIN
PAXIPAM
PEG-INTRON
PERMITIL
PERPHENAZI
POLARAMINE
POTASSIUM
PROVENTIL
REBETOL
REBETRON 1
RELA
RIBAVIRIN
SEBIZON
SODIUM SUL
SOLGANAL
SUCRALFATE
TEMODAR

\
1
j
1
1
1
~1
1

1
|
1
1
|
1
\
1
1
~1
1
1
1
1
1
1
1
1
~1
1
1
|
~~|
1
~1
1
|
|
1
1
1

A0066

EXHIBIT A
THEO-DUR
THEOPHYLLI
TINACTIN
TRILAFON
TRINAUN
UNI-DUR
VALISONE
VANCENASE
VANCERIL
SCHWARTZ DEFENDANTS
CALCIFEROL
CODICLEAR
CODIMAL
CO-GESiC
COLYTE
CORTIFOAM
DEPONIT
DILATRATE
EDEX
EPIFOAM
FEDAHIST
GLYCOLAX
GUAIMAX-D
HYDROCODONE
HYOSCYAMINE
ISOSORBIDE
KUTAPRESSI
KUTRASE
KU-ZYME
LACTRASE
LEVATOL
LEVBID
LEVSIN
LEVS1NEX
MILKINOL
MOEXIPRIL
MONOKET
NASCOBAL
NEUPRO
NIFEDIPINE
NIFEREX
NIRAVAM TA
NITROCINE
NULEV
(OMEPRAZOLE
PARCOPA
PEDIAPAP
PEG 3350
PROCTOCREA
PROCTOFOAM
PSEUDOEPHEDRIN
REGLAN

|

!

|

A0067

EXHIBIT A
ROBAXIN
THEOCLEAR
TRILYTE
UNIRETIC
UNIVASC
jURSO
I VERAPAMIL
VERELAN
TARO DEFENDANTS
ACETAZOLAMIDE
ACETIC ACID
ALCLOMETASONE
AMCINONIDE
JAM QDARONE
AMMONIUM
ANTIPYRINE
BETAMETHASONE
CARBASUSP
CARBAMAZEP
CICLOPIROX
CIPROFLOXACIN
CLINDAMYCIN
CLOBETASOL
CLOMIPRAMINE
CLOREZAPATE
CLOTRIM
CLOTRIMAZOLE
DESONIDE
DESOXIMETASONE
piFLORASON
ECONAZOLE
ELIXSURE
ENALAPRIL
ETODOLAC
ETOLODAC
FLUCONAZOLE
FLUOCINOLONE
FLUOCINONIDE
FLUOROURAC
FLUTICASON
GENTAMICIN
HALOBETASOL
HYDROCORTISONE
KETOCONAZOLE
LIDOCAINE
LORATADINE
MICONAZOLE
MOMETASONE
MUPIROCIN
NYSTATIN
ORALONE
[OVIDE

I
1
"1
1
1

1
1
"1

1
1
1
1
1
1
1

1
1
1
1
1
1

1
1
1

1
1

1

A0068

EXHIBIT A

ENYTOIN
RXEARDRO
RX-OTIC
TERCONAZOLE
TOPICORT
TRIAMCINOL
TRIPLE ANTIBIOTIC
UCORT
WARFARIN
yPSHERiSWlTH DEFENDANTS
ACETAMINOPHEN
ALTINAC
ASPIRIN
BISACODYL
CLENIA
DIVALPROEX
DIVIGEL
DOCUSATE
FERATAB
FERROUS SULF
FEVERALL
FOLGARD
FOLIC ACID
FORTICAL
GEMCOR
KLOR-CON
MIDODRINE
OMS
PACERONE
PENTOXIL
POTASSIUM
PREVALITE
RMS-SUPPOS
SALSITAB
SORBITOL
SSKI
IVANDAZOLE
ZINC SULFATE
WYETH DEFENDANTS
A.P.L.
ACEBUTOLOL
IACEL-IMUNE
lACETAMINOPHEN
IACHROMYCIN
i ACYCLOVIR
j ADVIL
;ALAVERT
ALBUTEROL
ALESSE
ALLOPURINO
ALPRAZOLAM
ALUDROX

|

1

!

|
i

|

EXHIBIT A

AM I CAR
AMIKACIN S
AMILORIDE
AMINOPHYLL
AMITRIPTYL
I AMOXICILLIN
jAMPHOJEL
IAMPICILUN
AN AC IN
ANA-GUARD
ANA-KIT
ANTABUSE
jANTIVENIN
jARISTOCORT
IARTANE
ARTHRITIS
ASENDIN
ATENOLOL
ATIVAN
ATROMID
ATROPINE
AURALGAN
AXID
AYGESTIN
BASAL J EL
BENEFIX
BENZTROPIN
BICILLIN
BISOPROLOL
BUTORPHANO
JCALTRATE-6
jCAPTOPRIL
jCARAFATE
ICARBAMAZEP
JCARDIZEM
[CEFACLOR
ICEFAZOLIN
jCENTRUMJR
CEPHALEXIN
CEPHRADINE
CERUBIDINE
[CHILDREN'S ADVIL
iCHLORDIAZEPOXIDE
[CHLORPHENIR
ICHLORPROMAZ
[CHLORPROPAM
CHLORTHALID
CIMETIDINE
CLINDAMYCIN
CLONIDINE
CLORAZEPATE
CLOXACILLIN

EXHIBIT A

CODEINE PH
CORDARONE
COUMADIN
CVC HEPARI
CYANOCOBAL
CYCLOCORT
CYCLOPHOSPH
CYCRIN
DECLOMYCIN
DEPONIT
DEXAMETHAS
DEXTROSE
DIAMOX
DIAZEPAM
piCLOXACIL
DICYCLOMIN
DIGOXIN
piLTIAZEM
DIMETANE
DIMETAPP
DIPHENHYDR
DIPHENOXYL
DIPHTHERIA
DIPYRIDAMOLE
DOCUSATE
DOLENE
DONNAGEL-P
DONNAZYME
DOXEPIN HC
DOXYCYCLIN
DTPC&A
DTPDMC&C
DURACT
DURAMORPH
EFFEXOR
ENTOZYME
EPINEPHRIN
EQUAGESIC
EQUANIL
ERYTHROMYC
ESTRADIOL
ESTROGENIC
ETODOLAC
FACTREL
FAMOTIDINE
IFENOPROFEN
FENTANYL
iFERRO-SEQU
iFERROUS
FIBERCON
FILIBON
FLUIMMUNE

1

A0071

EXHIBIT A
FLURAZEPAM
FOLVITE
FUROSEMIDE
GEMFIBROZI
GENTAMICIN
GRISACTIN
GRISEOFULVIN
GUAIFENESIN
GUANFACINE
HALOPERIDO
HCTZ/RESER
HEPARIN
HEP-LOCK
HIB-IMUNE
HYDRALAZIN
HYDROCHLOR
HYDROCODONE
HYDROCORTIZONE
HYDROMORPH
HYDROXYZIN
IBUPROFEN
IMIPRAMINE
INDERAL
INDERIDE
INDOMETHAC
INFLUENZA
INFUMORPH
ISMO
ISORDIL
ISOSORBIDE
KERODEX
KETOPROFEN
LEDERCILLIN
LEUCOVORIN
LEVO-T
LEVOTHYROX
LIDOCAINE
LQ/OVRAL
LODINE
LQRAZEPAM
LOXITANE
LYBREL
MATERNA
MAXZIDE
MECLIZINE
IMECLOFENAMATE
IMEDROXYPRO
jMEPERGAN
;MEPERIDINE
METHAZOLAMIDE
METHENAMIN
IMETHOCARBA

A0072

EXHIBIT A

| METHOTREXA
jMETHYCLOTH
METHYLDOPA
1 METOCLOPRA
METRONIDAZ
MICRO-K
MIDAZOLAM
MINOCIN
MINOCYCLIN
MITROLAN
MORPHINE
MYAMBUTOL
MYSOLINE
NAPRELAN
NAPROXEN
NESIMEGA
NEPTAZANE
NEUMEGA
NILSTAT
NITROGLYCE
NORDETTE-2
NORPLANT
NOVANTRONE
OCUCOAT
OMNIPEN
OPIUM
ORIMUNEDI
ORUDIS
ORUVAIL
OVRAL-21
OVRETTE
OXAZEPAM
PANTOPRAZO
PAPAVERINE
IPATHOCIL
PENTOBARBI
PENTOXIFYL
PEN-VEEK
PHENAPHEN
PHENERGAN
JPHENOBARBI
PHENYTOIN
!PHOSPH. IO
IPHOSPHOLIN
PIPRACIL
PIROXICAM
PNU-IMUNE
PONDIMIN
POSTURE
POTASSIUM
PRAZOSIN H
PREDNISONE

A0073

EXHIBIT A

PREMARIN
PREMPHASE
PREMPRO
PRENATAL PLUS
PRIMATENE
PRISTIQ EX
PROBENECID
PROCHLORPER
PROMETHAZINE
PROPOXYPHENE
PROPRANOLOL
PROPYLTHIOURACIL
PROSTEP
PROTONIX
PYRAZINAMIDE
QUINIDEX
QUINIDINE
RAPAMUNE
REGLAN
RHEUMATREX
RIOPAN
ROBAXIN
ROBAXISAL
ROBICILLIN
ROBIMYCIN
ROBINUL
ROBITET
ROBITUSSIN
SECTRAL
SELEGILINE
SEMICID
SERAX
SODIUM CHL
SONATA
SPARINE
SPIRONOLAC
STORZ-DEXA
STUART PRE
STUARTNATA
SULFAMETHO
SULFASALAZINE
SULINDAC
SUPRAX
SURMONTIL
SYNALGOS
TEMAZEPAM
TENEX
TETANUS PI
THEOPHYLLINE
THIAMINE H
THIORIDAZINE
THYROID

EXHIBIT A

TOBRAMYCIN
TODAY SPONGE
TOLAZAMIDE
TOLBUTAMIDE
TRAZODONE
TRI-IMMUNO
ITRIPHASIL
TUBERCULIN
TUBEX INJ
;TYGACIL IN
IUNIPEN

IVANCOLED
VANCOMYCIN
VERAPAMIL
VIOKASE
WYAMYCIN
WYCILLIN
WYDASE
WYGESIC
WYMOX
IWYTENSIN
Z-BEC
iZEBETA
iZIAC
IZOSYN

1

A0075

ADDENDUM C

A0076

Rule 8

RUIJES OF CIVIL PROCEDURE

Niote 60
932 P2d o22 309 Uuah Kc\ Rep 5 Criminal
Lav, o 1136
Plainuffs failure to oDiect to irrigation COTI
pan's s assertion of Limitation of Landovnei
Liabilm Act as aefense m motion for luagmem
on pleadings on grounds that compam failea to
laise defense ID answer -waived compam s de
fective mode of placing Act in issue U C A
1953 57-14-6 Rules Cn Proc Rules S^b c e)
12(b) (b)(6) (hj Goldmg \ Ashto Cent Irr
Co P90 793 P 2d 897 Appeal And Erroi C=>
196
Defendant m negligence action waived issue
of mitigation of damages fy failing to raise the
issue as an affirmative defense in his answer to
complaint or present eudence or argument on
mitigation at trial P^ules Ci\ Proc Rules 8(c)
J 2(h) 15(b) Gill \ Timm 1986 "20 P 2d
1352 Appeal And Error o=> 173(2)
Defense of election of remedies is an affirma
tive one and must be raised h\ wa\ of answei
notion or demana so as to put issue before

trial counj and is not to be raiseo for first time
on appeal the aefense ma's be waived or a
litigant m ^ be estopped to assert such aefense
Rules of Uivil Proceduie rules 8(b c) 12(a-c)
Rcr\al Resources Inc > Gib^altei Financial
Corp 197Q o03 P 2d 793 Appeal And Error
o 173(2) Election Of Remedies C=> 1 Election
Of Remedies c=> 1 o
In considering motion to dismiss complaint
Doth distr cl court and Supreme Court on review are Jo s u n ^ its allegations m light most
favoiable to plaintiff and grant dismissal onh if
plaintiff could not lr an} event establish a right
to recover Barrus -^ Wilkinson 1965 16 "Utah
2d 20* 398 P 2d 207 Appeal And Error c=»
919 Pleading c=> 3^(3) Pleading o=> 354 Pre
trial Procedure c=> 622
A point pa's not be raised for the first time on
appeal Rules of Civil Proceaure rules 8(cj,
12(h) Tvgesen ,\ iviagna Water Co 1962 13
Utah 2d 3|97 375 P 2d *56 Appeal And Error
c=> 169

R U L E 9. PLEADING SPECIAL MATTERS
(a)(1) Capacity. It is not necessarv to aver thfe capacin of a parfr to sue or
be sued or the authority of a part} to sue or be sued m a representative capacity
or the legal existence of an organized association of persons that is made a
party A part} may raise an issue as to the legal existence of an} party or the
capacity of any part}' to sue or be sued or the authority of a party to sue or be
sued m a representative capacity by specific negative averment, which shall
include facts withm the pleader's knowledge If raised as an issue, the party
relying on such capacity, authority, or legal existence, shall establish the same
on the trial
(a)(2) Designation of unknown defendant When a party does not know the
name of an adverse party, he may state that fact m the pleadings and
thereupon such adverse party may be designated m any pleading or proceeding
b} am name, provided, that when the true nkmc of such adverse party' is
ascertained, the pleading or proceeding must be amended accordingly
(a)(3) Actions to quiet title, desenpnon of interest of unknown parties In an
action to quiet title wherein anv of the parties are designated in the caption as
unknown ' the pleadings ma^ describe such unknown persons as ' all other
persons unknown claiming any right, tide, estate or interest m, or hen upon
the real property described m the pieacLng adverse to the complainant's
ownership, or clouding his title thereto
(b) Fraud, mistake, condition of the mind. In all averments of frauc or
mistake, the circumstances constituting fraud or mistake shall be stated \\ith
particulars
Malice, intent, knowledge and other condition of mind of a
person ma^ be averred generally
(c) Conditions precedent In pleading the performance oi occurrence of
conditions precedent, it is sufficient to a^er generalK that all conditions
precedent ha\e been performed oi ha\e occurrp.h A rU-iial of perfoimance oi
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occurrence shall be made specifically and with particularity, and when so made
the party pleading the performance 01 occurrence shall on the tnal establish
the facts show mg such performance or occurrence
(d) Official document or aci In pleading an official document or act it is
sufficient to aver that the document was issued or the act done in compliance
with law
(e) Judgment. In pleading 2 judgment or decision of a domestic or foreign
court, judicial or quasi judicial tribunal or of a board or officer it is sufficient
to aver the judgment or decision without setting forth matter showing jurisdiction to lendei it A denial of jurisdiction shall be made specifically and with
particularity and when so made the parts pleading the judgment or decision
shall establish on the trial all controverted jurisdictional facts
(f) Time and place. For the purpose of testing the sufficiency of a pleading,
averments of time and place are material and shall be considered like all other
averments of material matter
(g) Special damage. When items of special damage are claimed, they shall
be specifically stated
(h) Statute of limitations. In pleading the statute of limitations it is not
necessary to state the facts showing the defense but it may be alleged generally
that the cause of action is barred by the provisions of the statute relied on
referring to or describing such statute specifically and definitely by section
number, subsection designation, if any, or otherwise designating the provision
relied upon sufficiently clearly to identify it If such allegation is controverted,
the party pleading the statute must establish, on the trial, the facts showing that
the cause of action is so barred
(1) Private statutes; ordinances. In pleading a private statute of this state, or
an ordinance of any political subdivision thereof, or a right derived from such
statute or ordinance, it is sufficient to refer to such statute or ordinance b} its
title and the day of its passage or by its section number or other designation m
any official publication of the statutes or ordinances The court shall thereupon take judicial notice thereof
(j) Libel and slander.
(jXl) Pieaaing defamaton moitei It is not necessary m an action foi libel or
slander to set forth any intrinsic facts showing the application to the plaintiff of
the defamatorv matter out of which the action arose, but it is sufficient to state
generally that the same was published or spoken concerning the plaintiff If
such allegation is controverted, the party alleging such defamaton matter must
establish, on the trial, that it was so published or spoken
(j)(2) Pleading defense In his answer to an action for libel or slandei, the
defendant may allege both the truth of the matter charged as defamaton? and
any mitigating circumstances to 1 educe the amount of damages, and, whether
he proves the justification or not, ftc ma)' give m evidence the mitigating
circumstances
93
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(k) Renev* judgment A complaint alleging failure to pay a judgment shall
describe the judgment with particular^} or ajtach a copy of the judgment to the
complaint
(/) Allocation of fault.
(Z)(l) A party seeking to allocate fault [to a non-part} under Title 78B,
Chapter 5, Part 8 shall file
(I )(l)(A) a description of the factual and legal basis on which fault can be
allocated, and
(/)(1)(B) information known or reasonably available to the party identifying
the non-party, including name, address, telephone number and employer If
the identity of the non-party is unknown, the part} shall so state
(/ )(2) The information specified m subseccjtion (/ )(1) must be included m the
party's responsive pleading if then known on must
:
be included m a supplemental notice filed within a reasonable time afier the party discovers the factual
and legal basis on which fault can be allocated but no later than the deadline
specified m the discovery plan under Rule 26(f) The court, upon motion and
for good cause shown, may permit a party to file the information specified m
subsection (/ )(i) after the expiration of any period permitted b} this rule, but m
no event later than 90 days before trial
(/ )(3) A party ma} not seek to allocate fauj.lt to another except by compliance
with this rule
[Amended effective November 1, 2003, May 2,20105, November 1 2008]
Cross References
Joinder of defendants allocation of fault to non-parrv description of factual and legal basis on
which fault can be allocated and information identifying non-party, sec § 78B-5-821
Library References
Damages C=>142
Limitation of Actions O l ^ b to 192
Pleading ^ 4 6 18 59
Vvestlavv Ke\ Number Starches 302k4b
302U8 302L59 U5kM2, 24JL376 to
241L192

|J S Damages §§ 225 to 228
J S Limitations of Actions §§ 269 to 285
287 to 290
J S Pleading §§ 70 to 73 96 136 to 138
lo2 lo5

Research References
Forms
Am Jur PI & Pr Foims Laboj and Laboi
Relations § 3 Procedural Rules Reieiences
Umted Stales Supreme Court
Standing,
Challenging constitutionality ol legislation see Diamond \ Cha/les U S 111
198o 106 SCt lo97 47o U S 54 Q0
L Ed 2d 48
Federal antitrust action necessity of
proving injun see Cargill Inc v Mon-

fort ot Colorado Inc U S Colo 198o
107 SCt 464 4"9 US 104 93
L Ed 2d 427
Inmn in fact, qui tarn suit bi ought b\
individual under False Claims Act, state
not subicct to Labi lit} m federal court
Eleventh Amendment immunity see
Vermont Asrenc\ of Nat Resources \
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IN THE DISTRICT COURT 0? THE THIRD JUDICIAL DISTRICT
IN AND FOR SALT LAKE COUNTY, STATE (pF UTAH

STATE OF UTAH,

MEMORAJNDUM DECISION

Plaintiff,

CASE N|O. 080907678

vs ,
APOTEX CORPORATION; BAXTER

:

HEALTHCARE CORPORATION; 30EHRINGER
INGELHSIM CORPORATION; KALLINCKRODT:
INC.; CSL 3EHRING; FOREST
LABORATORIES, INC.; MORTON GROVE
:
PHARMACEUTICALS, INC.; MUTUAL
PHARMACEUTICAL COMPANY, INC.;
:
NOVARTIS PHARMACEUTICALS
CORPORATION; OTSUKA AMERICA, INC.; :
PFIZER, INC.; QUALITEST
PHARMACEUTICALS, INC.; SCHSRING:
PLOUGH CORPORATION; SCHWARZ PHARMA
USA HOLDINGS, INC.; TARO
:
PHARMACEUTICALS USA, INC.; UPSEERSMITH, INC.; andWTETH, INC.,
:
Defendants.

:

This matter came before the Court

x r i n q on December

2005, in connection with defendant Pfizer, Inc
Dismiss the Amended Complaint.
remain

oineci

The Court notes
m

>&-r ' q

^iiC

Mr.H

•¥'-'•

- TV
iLiCL ; r^,y
U I JL

p"
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At the conclusion of the hearing, trie Court: cook the matter

under advisement to firtr.er consider the parties' written submissions,
the relevant legal authority and counsel's oral argument.

Being now

fully informed, the Court rules as stated herein.
LEGAL ANALYSIS
At the outset, the Court notes tnat Pfizer's Motion to Dismiss is
brought pursuant to both Rule 9(b) and Rule 12 (5) (6) of the Utah Rules
of Civil Procedure and seeks dismissal of the State of Utah's (tne
"State") Amended Complaint.

The Amended Complaint alleges that the

defendant pnarmaceucicai companies committed fraud m connection with the
pricing of prescription drugs. Specifically, tne defendants are alleged
to nave knowingly and falsely inflated pricing information, which the
State tnen relied on m
Medicaid program.
n

determining

reimbursement

rates under its

The State's first claim for relief alleges that

[d] efendants issued false and inflated AKP, KAC and/or Direct Price

information2 for oublicaticn bv the mdistrv reocrtmo services . . " m
violation of tne Utah Fslse Claims Act

Utan Code Ann.

§ 25-22-1

et.

3

Defendants films supplemental memoranda include Defendant Boehrmger Ingelheim
Corporation ("BIC"). defendants Mallinckrodt, Inc and Taro Pharmaceuticals USA. Lie
(/'Generic Defendants*"] and defendant Morton Grcn e Pharmaceuticals. Inc ("Morton Gro\ e").
:

In discussing the pricing information* the parties ha"\ e used a number of acronyms
Since these acronyms are commonh understood and used b\ the panes, the Court will not define
then herein

STATE V. APCTSX COR?.
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premised or. fraudulen

c^rr^nr

c

-isrepresentamcn.
In its tone:., Pfizer first argues thai: wh^ le m e State'
oased clairr and its False Claims Act claim reauire corrYDLiar.ee v,-tm Rule
9 (n)

-c^e ..as za-it

leaa mese c_aim£ wii!: parcicuLancv.

Pfizer complains mat m e Amended CompLair.t doe|s not oelmeate earn
individual defendants' alleged misconduct, does not elaborate as to whim
defendant reverted \\nicn false and inflated prices and does not identify
v*maft defendant: provided such allegedly inflated pricing information to

me

"iDQvszry reporting services."

Amended

Complaint

Pfizer

also points out that the

fails to identify when and

to

\Cion

misstatements *ere made.
Pfizer has cited a number of cases v;him idert ~. i zv t n e v-or" * - v-ciT-i^.-r- — ^
for pleading fram wich particularity

These $ ;.:sc2>

plaintiff ~ust plead ^::r. specificity tne reLevafc

-::u^cate

s ~r r e n a m e

sum as tne ti^e, place and contents, of false :

ai

- V

:e terser, marina m e misrecr

woros, tne party must t*
how" of m e alleged fra
Furthermore, *he:

s w_ v t S

^t^^CX— Ci _ ~ .

W..S>

^ZLK

,

54i

wc
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requirements

are
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(indicating

''especially important
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that Rule
m

cases

9(b) particularity
involving

multiple

defendants").
zer mas a Iso cited a number of cases which apply tnis heightened
pleading stancara m tne specnic context or utigaticn involving claims
cf pharmaceuticals overstating prescription drug prices. It appears that
these cases are typically brought oy states and private insurers who
reimburse and patients wr.o have made coinsurance payments, all based on
published AK?'s, wmch are alleged to be false and inflated. These cases
are particularly instructive because they identify how shortcomings

m

pleading witn particularity can oe re-pled to provide greater specificity
cf allegations m

order to meet Rule 9(b) recuirements.

Nctanlv, the State nas tacitlv acknowledoed its failure to dead
witn particularity.

Tr.e State's reasoning for not dcmg so is that the

'"K

: & ~ c c_c_ 7 ib

*.

v-s'l

& ;

• c ^ p c ^
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3

The Court is similarly unoersuacea DV tne Stat$' s aroument that
Court car. simply relax the Rule 9 (b)

maarcs .

rst, Pfizer has cited

Tenth Circuit case law specifically declining :o r elax tne requirements
of Rule 9'r>) and instead indicating that u]d]ef fendants are under no
obligation :c research missing information for each specific claim.
Rather, plaintiff must plead [its] claim Vvith suf ficient oarticularitv
:hat lie defendants are on notice of which specifi^ claims are alleqedly
false." U.S. ex rel. Sikkenca v. Reoence Blueshield of Utah, 2001 U.S
Lexis 25717 ;D. Utah Nov. 27, 2001).
Further, the Court is not convinced that the State is unable to
obtain essential information regarding the defendants' pricing methods,
such that relaxing the Rule 9(b) standard is warranted.

Indeed, Exhibit

A to the State's Amended Complaint, w.tich contains a list with
,ct:sc..LCu-\c

cAii

es" of the soectf ic

»

.

• s.

rv

-Ui

Oil

c »-

;_ci5

r>--e;%^- '

a few

ms

I ~ ere:

a •_• ^ ~ a — i

v

w.

- a.

ccs:
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individual defendant for which they provided an allegedly fraudulent or
false price.

Zhe nroadly-worded, blanker: allegations of fra^d m

the

Amended Complaint against the defendants as a collective will not suffice
-r.der Rile 9 (h)

However, rather tnan dismissing the State's Amended Complaint, the
Court grants tee State leave to amend m

order to

(1) identify the

specific drug at issue; (2) identify the specific defendant involved

m

that drug's sale, manufacture or for which they provide prices for; (3)
the allegedly false publication of that specific drug's pricing, to whom
that publication was made and when; and (4) whether the State actually
used or relied on the allegedly false pricing information which was
reported m

setting reimbursement rates.

To the extent possible, the

State should also identify the actual price that snould have reen
puclisited and identity of the party p^rcnasmg tne drug.
Further, with respect to allegations that the defendants engaged m
a practice wnich nas Deer, termed as a "marketing of tne spread" between
AVC? and KAC, tne State rn^st also identify n, the specific defendant
engaging m

this practice- (2) specifics of now providers 'were induced

to purchase the specific drug
grants and other incentives

i e. prevision of free goods, educational
and

2,

the actual zs.rcha.se

price of tne

drug to the pharmacy and/or pnysician.
Kicn respect to tne State's claim under tne False Claims Act, a
fundamental element is tne s~uo~issicn of a clai~ fcr a medical nenefit

t>l ^ ~

7
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the State' s Amended CoTjlair.: does nor allege wiu.v s p e c i m e n i.y tnat any
of the defendants
s u b m t claims.

submtted

claims to the State <p:r directed

others to

Furtner, it remains unclear vtiat b ^nefit the defendants

derived directly from the State, ratner tnan from :he tarcr.ase of tneir
urucs nv tnysicians and or.armacies . Ti
:ese snortc W
witn

l

enament snoula aocress

~.Z> .

respect

to 3IC,

the

State

should

fodus

on

this

company's

separate corporate existence and identify only those drugs for which 3IC,
and not its corporate subsidiaries, is legally responsible.
m a t three of BIC's subsidiaries are mentioned m
and may be responsible

for certain of the

It appears

the Amended

"representative"

Complaint
drugs, but

presently not namea as oeienoants ana r*a*ve net oeen
\Mtn respect

to the Generic

Defendants, i:

anoears

servea.

that

federal

=aiiatic is r e c u re reimbursements with benchmarks
r--i

1

-.ftr'.

let,

Corrolamc is focused on "riu-clished Av\?s and does

or vz

n e t s vi"

ot
.0 urucs.

the state s amei

=ncu-a icentiiv
• S2.-V

v — c:..
.^•jrse:

dr*
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TPe renaming issje presented py tr.e defendants' Motion is *netne:
:ne 2007 arrencnents 10 tr.e Utar. False Claims ACT: apply retroactively
rr.e State presently relies on :r.e 2007 version of tne Act m
-r>y"

its reo^est

T-s

Tr.e sarnies agree tr.at amendments are prospective unless expressly
race retrcactive py one legislature
20-15^2

of

retroactive

one

Act

evidences

Tr.e State's position is tnat § 26an

intent

chat

one

amendments

Pe

Section 26-20-15(2) provides that u[al civil action orougnt

under tnis chapter may pe prougnt

for acts

occurring prior

to

the

effective date of this section if one limitations period set fcrtn in
Section (1) nas not lapsed "
Tr.e defendants counter that tr.is retroactivity pro\_sion is located
r.e amenae <JL
net a o o ^

s ^a

ooes

L « U :

to

t;.u-.:c*v

:s * n i c n v e r s amenoea ;
eacn

1 C

O C — £S~

*r.ere one _ e g i s - . a t w . r e e x p r e s s l y maae
or

t r . e s e Ac

-U

c ~ c e r "^ i n e d

.en cormoare o t n e ]

id"

_iam_ity
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PAGE

the amendment extending the statute of limitation^ period was intended
to be retroactive.
To

summarize,

Dismiss,

Court

msteaa
will

or

pendants'

granting

allow ti

State

to

i Le

Motions

a Second

to

Amended

Complaint consistent with the Court's guidelines, ^ : outlined above. The
State must file its Second Amended Complaint wi .hin 4 5 days of this
Memorandum Decision or the Court will enter a di^missal of its Amended
Complaint en the grounds that the State failed to olead its claims with
sufficient particularity.
Because

the Court will permit

the

State

to amend

its Amended

Complaint, it aoes not reach tr.e issue of wnetner the State's claims
:d and violation of the raise Claims Act ar^ also susceptible to
CIST..

ssal under Rule 12 (b- {6) .
This Memorandum Decision will stand as the Carder of the Court.
Dated this

day of February, 2 009.

d !! /^/sS
[YEONE E. MEDLEY
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MAILING CERTIFICATE

I hereby certify chat I mailed a :rue and ccrrec: copy of the
foregoing Memorandum Decision, to the following, this

/O

day of

February, 2 005:

K. Daniel u Dee" Miles, III
Clinton C. Carter
Special Assistant Attorneys General
Attorneys for Plaintiff
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Joseph W. Steele
Kenneth D. Lougee
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Special Assistant Attorneys General
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Brian P. Miller
Derek J. Williams
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Mailing Certificate - Continued

Merle M. DeLancev, Jr.
Jason D. Wallach
Attorneys for Defendant Baxter Healthcare
1825 Eye Street, NW
Washington, DC 20 0 06
Phillip S. Ferguson
Geoffrey C. Kaslam
Attorneys for Defendant Baxter Healthcare
15 W. South Temple, Suite BOO
Salt Lake City, Utah 84101
M e l a m e Vartabedian
Attorney for Defendant Boehnnger Ingeiheiin
170 S. M a m Street, Suite 400
Salt Lake City, Utah 54101
James ?. illison
Attorney tor Defendants Mallmckrodt and Tare Pharmaceutical:
700 Thirteenth Street, N.ft., Suite 120:
rWashington, D.C. 2 n0n0C
Richard A. Vazquez
Attorney for Defendants Mallmckrodt and Tare Phpir:ri5ceiticals
10 Exchange Place, Eleventh Floor
P.O. Bex 45:0 0
Salt Lake Citv. Utah £414 5

r.obert -J. Andreasen
Attornevs fcr Defendant Morton Prcve Pharmaceuticals
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Mailing Certificate - Continued

John P. Harrington
Cecilia M. Romero
J. Simon Cantarero
Attorneys for Defendant Mutual Pharmaceutical
60 E. South Temple, Suite 2000
Salt LaKe City, Utah 84111
jsryon J . ^enevento
Attorney fcr Defendant Novartis Pharmaceuticals
15 W. Soutn Temple, Suite 1200
Salt Lake City, Utah 54101
Jane W. Parver
Saul P. Morgenstern
Mark Godler
Sam Lonegan
Attorneys fcr Defendant Novartis Pharmaceuticals
42 5 Park Avenue
New York, New York 10 022
Matthew Campbell
Attorney for Defendant Ctsuka A.merica
17 0 0 K Street, N.W.
Washington, D.C.
2:0 05-3517
Georoe M. Halev
David Parkins on
Attorneys for Defendant Pfizer
299 S. M a m Street Suite 1BCD

Erica Smith-Klocek
Jonn C. Dodds
Ka t nryn ? o t a11vo
rneys z;
Market

: w. i

~

*

^

>

153 East
New Ycrk,

^

-

«.i.
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Mailing Certificate - Continued

Scott A.. DuBois
Tammy 3. Gecrcelas
Artorneys for Defendant: Qualitest Pharmaceuticald
15 W. South Temple, Suite 1200
Salt Lake City, Utah B4I01-1004
Thomas R. Karrenherg
Heather M. Sneddon
Attorneys for Defendants Schering-Plough
Warrick Pharmaceuticals, and Schwarz Pharma US.^
5 0 W. Broadway, Suite 7 00
Salt Lake City, Utah 64101
Camille N. Johnson
Attorney for Defendant Wyeth
10 Exchange Place, Eleventh Floor
P.O. Box 450O0
Salt Lake City, Utah 84145
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Mailing Certificate - Continued

Merle M. DeLancey, Jr.
Jason D. Wallach
Attorneys for Defendant Baxter Healthcare
1825 Eye Street, NW
Washington, DC 20006
Phillip S. Ferguson
Geoffrey C. Haslam
Attorneys for Defendant Baxter Healthcare
15 W. South Temple, Suite 800
Salt Lake City, Utah 84101
Melanie Vartabedian
Attorney for Defendant Boehringer Ingelheim
170 S. Main Street, Suite 400
Salt Lake City, Utah 84101
James P. Ellison
Attorney for Defendants Mallinckrodt and Taro Pharmaceuticals
700 Thirteenth Street, N.W., Suite 1200
Washington, D.Q. 20005
Richard A. Vazquez
Attorney for Defendants Mallinckrodt and Taro Pharmaceuticals
10 Exchange Place, Eleventh Floor
P.O. Box 4 500 0
Salt Lake City, Utah 84145
Matthew A. Steward
Robert D. Andreasen
Attorneys for Defendant Morton Grove Pharmaceuticals
201 S. Main Street, Thirteenth Floor
Salt Lake City, Utah 84111-2216
Frederick R. Ball
David I. Curkovic
Attorneys for Defendant Morton Grove Pharmaceuticals
190 S. LaSalle Street, Suite 3700
Chicago, Illinois 60603
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Mailing* Certificate - Continued

John P. Harrington
Cecilia M. Romero
J. Simon Cantarero
Attorneys for Defendant Mutual Pharmaceutical
60 E. South Temple, Suite 2000
Salt Lake City, Utah 84111
Bryon J. Benevento
Attorney for Defendant Novartis Pharmaceuticals
15 W. South Temple, Suite 1200
Salt Lake City, Utah 84101
Jane W. Parver
Saul P. Morgenstern
Mark Godler
Sam Lonegan .
Attorneys for Defendant Novartis Pharmaceuticals
425 Park Avenue
New York, New York 10022
Matthew Campbell
Attorney for Defendant Otsuka America
1700 K Street, N.W.
Washington, D.C. 20006-3817
George M. Haley
David Parkinson
Attorneys for Defendant Pfizer
299 S. Main Street, Suite 1800
Salt Lake City, Utah 84111
Erica Smith-Klocek
John C. Dodds
Kathryn Potalivo
Attorneys for Defendant Pfizer
1701 Market Street
Philadelphia, Pennsylvania 19103
Matthew Solum
Attorney for Defendant Qualitest Pharmaceuticals
153 East 53rd Street
New York, New York 10 022
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Mailing Certificate - Continued

Scott A. DuBois
Tammy B. Georgelas
Attorneys for Defendant Qualitest Pharmaceuticals
15 W. South Temple, Suite 1200
Salt Lake City, Utah 84101-1004
Thomas R. Karrenberg
Heather M. Sneddon
Attorneys for Defendants Schering-Plough
Warrick Pharmaceuticals, and Schwarz Pharma USA
50 W. Broadway, Suite 700
Salt Lake City, Utah 84101
Camille N. Johnson
Attorney for Defendant Wyeth
10 Exchange Place, Eleventh Floor
P.O. Box 45000
Salt Lake City, Utah 84145
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IN THE DISTRICT COURT OF THE THIRD JUDICIAL DISTRICT
IN AND FOR SALT LAKE COUNTY, STATE (t>F UTAH

MEMORANDUM DECISION

STATE OF UTAH,
Plaintiff,
vs.

J

CASE ND. 080907678

:

APOTEX CORPORATION; BAXTER
:
INTERNATIONAL, INC.; BOEHRINGER
INGELHEIM CORPORATION; MALLINCKRODT:
INC.; CSL BEHRING; FOREST
LABORATORIES, INC.; MORTON GROVE
:
PHARMACEUTICALS, INC.; MUTUAL
PHARMACEUTICAL COMPANY, INC.;
:
NOVARTIS PHARMACEUTICALS
CORPORATION; OTSUKA AMERICA, INC.; :
PFIZER, INC.; QUALITEST
PHARMACEUTICALS, INC.; SCHERING:
PLOUGH CORPORATION; SCHWARZ PHARMA
USA HOLDINGS, INC.; TARO
:
PHARMACEUTICALS USA, INC.; UPSHERSMITH, INC.; and WYETH, INC.,
:
Defendants.

:

This matter came before the Court for a hearing on December 11,
2009, in connection with the defendant pharmaceutical companies' second
round of Motions to Dismiss the State's Second Amended Complaint.

The

Court notes that defendant Pfizer, Inc.'s Motion to Dismiss has been
joined in by the majority of the defendants (the "Pfizer defendants").
Defendant Morton Grove Pharmaceuticals Inc. (^Morton") has filed separate
Motions to Dismiss.

A group of defendants which [include defendants

A0098
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Mallmckrodt, Inc., Taro Pharmaceuticals USA, Inc. and Upsher-Smith
Laboratories,

Inc.

("Generic Defendants'7)

Ingelheim Corporation
Memoranda m

and

defendant

Boehringer

(UBIC") have also filed separate Supplemental

support of their positions seeking dismissal.

At the conclusion of the hearing, the Court took the matter under
advisement to further consider the parties' respective legal positions
and written submissions, the relevant legal authority and counsel's oral
argument.

Being now fully informed, the Court rules as stated herein.
LEGAL ANALYSIS

The defendants' Motions seek dismissal of the State's Second Amended
Complaint under Utah Rules of Civil Procedure 9(b) and 12(b)(6).

The

defendants argue that the State has essentially ignored the Court's prior
Memorandum Decision, dated February 13, 2009, and that its Second Amended
Complaint contains the same type of pleading deficiencies addressed by
the Court in that Decision
According to the defendants, the State's Second Amended Complaint
once again fails to plead with particularity its claims for common law
fraudulent misrepresentation and for relief under the Utah False Claims
Act.

In addition, the defendants assert that dismissal is warranted

under Rule 12 (b) (6) because the Second Amended Complaint does not plead
uhe necessary elements of the State's claims, including actual fraudulent
misrepresentations and the submission of false claims under the False
Claims Act.

The defendants point, for example, to the State's failure
A nnoo
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to plead its reliance on the false pricing allegedly supplied to industry
reporting services in setting reimbursement rates.
The Pfizer defendants make a separate argument for dismissal under
Rule 12(b)(6) based on the statute of limitations

Prior to April 30,

2007, the statute of limitations under the Utah False Claims Act was one
year.

The Act was amended, effective April 30, 2007, to increase the

statutory limitations period to six years after the violation, or three
years after discovery, not to exceed ten years aftjer the violation.

In

the prior Decision, the Court ruled that uthe amendment extending the
statute of limitations period was intended to be retroactive."

The

Pfizer defendants now argue that the logical progression to the Court's
ruling is that the amended statute of limitations applies only to claims
that were not already barred under the prior version of the statute.
Since the initial limitations period was one year, the Pfizer defendants
reason that ..•. all of the State's claims for cont
duct alleged to have
occurred on or before April 30, 2006, are time-barred.
BIC's supplemental brief argues that the State has again lumped it
with several independent subsidiaries who are not even named or served
defendants in this case.

BIC points out that despite the Court's

directive to "identify only those drugs for which BIC, and not its
corporate subsidiaries, is legally responsible," the Second Amended
Complaint

continues

to refer to the

"Boehringer Defendants"

collective group.

A0100
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With respect to the Generic Defendants, they again detail the unique
reimbursement method that applies to their specific drugs.

The prior

Memorandum Decision ordered the State to identify how the allegedly false
publication of AWP's for generic drugs altered this method, which drugs
were reimbursed using a different method and why the State deviated from
the general method of reimbursement.

The Generic Defendants argue that

the State has failed to provide any of this information, particularly
with respect to how the typical method of reimbursement was altered or
influenced by the allegedly inflated AWP's provided by the Generic
Defendants .
In Opposition, the State maintains that its Second Amended Complaint
"vastly exceeds" the notice pleading requirements. The State again takes
the position that "[t]he Defendants know exactly what is at issue." This
precise argument was previously rejected by the Court and its Memorandum
Decision specifically indicated that each of the defendants was entitled
to know whet they allegedly did wrong.
The State next asserts that it has now listed the specific drugs at
issue in Exhibit A to its Second Amended Complaint.

However, this list

also contains drugs that the defendants did not manufacture and products
that are referenced only by their chemical compounds.

Exhibit A also

identifies non-prescription drugs and broad categories of drugs such as
*antibiotic" and "antacid."

It also references medical conditions such

as "arthritis" and "prenatal." The Court agrees with the defendants that
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this list is not helpful and falls far short of the applicable pleading
requirements.

Indeed, the State was required to (identify the specific

drug at issue for each defendant, the actual prices! that should have been
published and the identity of the purchaser. Exhibit A does not provide
this information.
With respect to group pleading, the State asserts tnat "tne second
Amended Complaint makes clear that each Defendant stands on the same
footing in that each Defendant in this case falsely reported and/or
suppressed the true prices of its drugs over the relevant time period in
essentially the same manner."

The State re-argues that there is nothing

wrong with attributing conduct to

w

all defendants" in this type of

context since they had a uniform practice in reporting allegedly false
prices.

Again, the Court previously rejected this argument and ruled

that "broadly-worded, blanket allegations of fraud

.against the

defendants as a collective will not suffice under (Rule 9 (b)
The State again asserts that the Court should apply a relaxed
standard and as to the Utah False Claims Act, the State re-argues its
prior position that Rule 9(b) has no application to this Act.

The Court

previously rejected this argument and concluded that Rule 9(b) applies
to the State's claims.

Further, the two supplemental cases that the

State relies on, United States v. McKesson Corp., 2009 WL 3176168 (N.D.
Miss.), and United States ex rel. Grubbs v. Kannecrinti, 565 F.3d 180 (5th
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Cir. 2009) , confirm that claims under the False Claims Act must meet the
heightened pleading standard of Rule 9(b).
Overall, the State maintains that the level of pleading required by
the Court in its Memorandum Decision is tantamount to the presentation
of evidence.

During oral argument, the State's counsel indicated that

Grubbs was the State's best case in support of its position that a
plaintiff alleging the submission of false claims need not detail its
allegations at the pleading stage and may instead provide the surrounding
information later, at the uproof stage."
After considering the parties7 respective legal arguments, the Court
determines that the defendants' Motions to Dismiss are well-taken and
that

the State's

Second Amended

Complaint must be dismissed

with

prejudice under both Rule 9(b) and Rule 12(b)(6).
First, the Court rules that the State's Second Amended Complaint
fails to satisfy the particularity requirements of Rule 9 (b) .
Court's

prior Memorandum

shortcomings

of

the

Decision

State's

identified

Amended

in great

Complaint

and

detail

The
the

specifically

articulated what was required in order for the State to meet its burden.
The Court rules that the State did not comply with the Court's directions
and failed to add the considerable detail required in order to meet this
burden.
Once again, the State has failed to identify each defendant's
allegedly fraudulent misrepresentations and False Claims Act violations
Anini
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with particularity; thereby affording the defendants no particularized
notice of the allegations against them individually.
Amended

Complaint

merely

offers

broad

conjecture

Indeed, the Second
with

respect to

statements and/or claims that were allegedly false |or fraudulent and that
were made by the defendants as a group.

The State has failed to

sufficiently identify the individual defendant's misrepresentations, the
State's reliance and the consequences thereof.
Moreover, the submission of Exhibit A, which the State relies on to
demonstrate its good faith effort to comply with th e Memorandum Decision,
is far too general to satisfy Rule 9(b)

The fa|llure to identify the

allegedly false publication of each specific drug'd pricing, to whom that
publication was made and when, renders the Second Amended Complaint
fatally deficient and unspecific.
the State merely

identifies

As the Pfizer defendants point out,

the same fifteen lyear period

publications of all prices for all drugs by all defendants.

for all
The Court

is of the opinion that to find that plaintiff's Second Amended Complaint
satisfies Rule 9(b) would render the particularity requirements of Rule
9(b) meaningless.
With respect to the State's False Claims 4 c t claims, the Court
remains convinced that these claims are subject to the particularity
requirements of Rule 9(b)

The State's own supplemental cases, Grubbs

and McKesson, confirm this point

Further, the State's interpretation

of these cases as purportedly providing a relaxed standard at the
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pleading stage, with proof to follow, is inapposite of the holdings of
those cases.

Indeed, those cases uniformly held that "to plead with

particularity the circumstances constituting fraud for a False Claims Act
. . . claim, a relator's complaint, if it cannot allege the details of
an actually submitted false claim, may nevertheless survive by alleging
particular
reliable

details

indicia

of

a scheme

that

lead

to

to

submit

a strong

false

claims

inference

that

paired

with

claims

were

actually submitted." McKesson, 2009 WL 3176168 at *6; Grubbs, 565 F.3d
at 190 (Emphasis added).
In McKesson, the court determined that the government had alleged
sufficient detail concerning such a scheme.
provided

significant

detail and

submitting false records

specific

Indeed, the government had
examples

of the

defendants

In evaluating the government's claims under

Rule 12 (b) (6) , the court found these allegations to be sufficient
detailing a conspiracy m
In Gr\it>bs, Dr

m

furtherance of a scheme.

Grubbs, a psychiatrist, alleged that his employer and

other doctors billed Medicare and Medicaid for services not performed.
The action was brought under the False Claims Act. As with McKesson, the
distinguishing fact is that the Grubbs case had "simple, concise and
particular allegations" of fraad, including the particular workings of
the scheme.

The allegations

attempts to assist Dr

included dates and

Grubbs m

times of meetings,

falsifying medical records, specific

A0105
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allegations

of a scheme

That

level of detail and

are lacking

in this case,

rendering Grubbs and McKesson relevant only to the point that Rule 9(b)
applies to a complaint filed under the False Clairrjs Act.
Based on the foregoing, the Court rules thatl the State has failed
to satisfy the requirements of Rule 9(b) with respect to its claim under
the False Claims Act. The defendants make the valid point that the State
has again failed to allege specific facts indicating that the defendants
communicated directly with the State, let alone submitted a claim to the
State.

Yet, the actual submission of a false c laim is an essential

element to any complaint seeking relief under Utaji' s False Claims Act.
See Utah Code Ann. § 26-20-7
Further, while the Second Amended Complaint "\jaguely alludes to the
defendants directing others to submit false claimp, the State does not
identify these other individuals and their role in the submission of the
allegedly false claims.

Equally significant is thle lack of allegations

concerning the benefit which the defendants derived directly from the
State. The State merely concludes that a benefit must have been derived
and ''ultimately ended up in the pockets of the defendants."
To summarize, the Court determines that the Second Amended Complaint
phrases its allegations in broad, vague language that cannot withstand
the strictures of Rule 9(b). Therefore, the defendants' Motions premised
on Rule 9(b) are granted.

A0106

STATE V

APOTEX CORP.

MEMORANDUM DECISION

PAGE 10

As additional grounds for dismissal, the Court grants the Pfizer
defendants' Motion

on

statute of limitations

grounds.

specifically adopts the Pfizer defendants' reasoning m

The Court

ruling that the

State's claims for conduct alleged to have occurred on or before April
30, 2006, are indeed time-barred as a matter of law
The Court also rules that the State's Second Amended Complaint is
subject to dismissal under Rule 12(b)(6).

In this regard, the Court's

previous analysis concerning the shortcomings of the Second Amended
Complaint with respect to Rule 9(b) pleading standards apply equally to
its analysis under Rule 12(b)(6).
Specifically,

not

only

has

the

State

failed

to

plead

with

particularity, but has also failed to allege fundamental elements of
common lav; fraudulent misrepresentation and for relief under the Utah
False Claims Act

Most notable is the State's failure to plead that the

pricing information supplied by the individual defendants, as opposed to
the defendants m

general, directly affected its reimbursement rates

While the Second Amended Complaint generally states that Utah Medicaid
relied on certain pricing information, there are no specific allegations
explaining the relationship between the individual defendant's alleged
false repeating of AWPs and the reimbursement formulas relevant to the
drugs manufactured by that specific defendant

1

Indeed, the State has

1

This is particularly true with respect to the Generic Defendants, where the State has
essentially admitted that inflated AWPs are primarily relevant with respect to reimbursement of
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simply not pled how the individual defendant's actiions led the State to
set its reimbursement rates or how it acted in reasonable reliance on the
pricing information.

The State has also failed to allege that it was

induced to act by the defendants' alleged misrepresentations.
While the State generally alleges that the AWPs were inflated, its
inability to plead reasonable reliance may be explained by its public
acknowledgment in 1999 that it understood that actual acquisition costs
for generic drugs was 60.1% below AWP and that AWP does not in fact
reflect market prices.2

Since the State knew that published AWPs did not

represent actual market averages, it cannot fulfill! two required elements
of its False Claims Act claim, namely that these defendants knowingly
made a false claim and that the State was deceived! by published AWP's in
setting its Medicaid reimbursement formula.
Likewise, as the Court discussed above, thfe State has failed to
include specific allegations pertaining to how any defendant submitted
or caused to be submitted a false claim, a key element of an action under

brand name drugs.
2

See State of Utah Dep't of Health, Div. Of Health Fin., Medicaid Pharmacy Acquisition Cost of Generic Prescription Drug Products (Feb. 1999b (Attached as Exhibit 2 to the
Generic Defendants' Reply Memorandum). Under Green River Canal Co. v. Thavne, 84 P.3d
1134, 1145 n. 8 (Utah 2003), the Court may take judicial notice of this document. Further, under
Alvarez v. Galetka. 933 P.2d 987, 990 n. 6 (Utah 1997), "items attached to pleading, items of
public record, and items in trial record will not covert 12(b)(6) mqtion to rule 56 motion for
summary judgment." (Emphasis added).
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Further, to establish a claim under the False

Claims Act, as well as common law fraudulent misrepresentation, the State
must allege each individual defendant's intent to deceive, which it has
failed to do.
Based on the foregoing and on the additional grounds set forth in
the defendants' moving papers, which are incorporated herein by this
reference, the Court grants their Motions to Dismiss.

Counsel for the

various groups of defendants are to prepare Orders consistent wiuh this
Memorandum Decision and Rule 7(f), Utah R. Civ. P., but also containing
details specific to their respective individual positions, for the
Court's review and signature.

The Court would prefer that counsel meet

and confer in an effort to submit Orders approved as to form by counsel
for plaintiff.
Dated this

If those efforts fail, then Rule 7(f) will control.
<^-^ day of February, 2010.

/s/
TYRONE E. MEDLEY
DISTRICT COURT JUDGE
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PRESCRIBED DRUGS
Prescribed drugs will be reimbursed based on an established pnbduct cost plus a dispensing
fee. The payment for individual prescriptions cannot exceed the amount billed. The amount
billed must be the usual and customary charge to the private pay patient. The following
methodology is used to establish Medicaid payments:
Except for special category fees, reimbursement will be the I lower of:
1.

The Utah maximum allowable cost (MAC) plus a reasohable dispensing fee or the
provider's usual and customary charge (billed charge) o the general public;
The Utah estimated acquisition cost (EAC) plus a reasonable dispensing fee or the
provider's usual and customary charge (billed charge) |to the general public.

Federal "Upper Limit"
The federal upper limit is the maximum allowable ingredient cosk reimbursement established
by the Department of Health and Human Services, Health Care Financing Administration, for
selected multiple-source drugs. The aggregate cost of product payment for the drugs on the
federal upper limit list will not exceed the aggregate established by Health Care Financing
Administration.
Average Wholesale Price
The Average Wholesale Price (AWP) is determined for each dnig by the Utah contract with
American Druggist, Blue Book First Data Bank. They provide a monthly update of drug
prices for the Reference File. First Data Bank used AWP from Wholesalers in many states
for determining AWP in specific regions.
Utah MAC
Utah MAC is the Maximum Allowable Cost reimbursement established by the Utah
Department of Health, Division of Health Care Financing, for se ected multiple-source
(generic) drugs not appearing on the federal upper limit list. Th^se drugs are listed in the
Pharmacy Provider Manual.

T.N.#

89-02

Approval Date

3-14-89

Supersedes T.N. #

87-37

Effective Date

1-1-89
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PRESCRIBED DRUGS (Continued)
Utah EAC
The Utah Estimated Acquisition Cost (EAC) is currently AWP minus 17 percent. This estimate
has been established using information provided by a survey conducted by the Utah
Department of Health. Effective July 1, 2009, the AWP will be AWP minus 15 percent.
Dispensing Fee
In setting the basic dispensing fee, the state will give consideration to costs shown on periodic
operation surveys, in-house studies of dispensing costs, national and regional data, and
economic trends and conditions. The Utah base dispensing fee is $3.90.
Special Category Fees
1.

Payment for insulin, birth control pills, and non-legend (OTC) drugs will be the lowest of:
a.
b.
c.
d.
e.

2.

Billed charge;
EAC + special category fee C;
Utah MAC + special category fee C; or
AWP + special category fee not to exceed the maximum on the Federal upper limits
list.
Special Category fee C = $1.00

Payment for non-legend OTC antacid liquids will be the lowest of:
a.
b.
c.
d.

Billed charge:
EAC + special category fee F;
Utah MAC + special category fee F; or
AWP J- special category fee not to exceed the maximum on the Federal upper limit
list.

Category fee F is calculated as follows: drug quantity + package size x $0.50
3.

Differential fee payment for select drugs reconstituted for Home I.V. infusion as typically
prepared by a specialty pharmacy. Specialty pharmacies have low volume but high
overhead expenses. The Department of Justice (DOJ) in year 2000 re-priced the AWP
for 437 NDC specific products. The re-priced products necessitated four new dispensing
fees. The four fees are defined as category J, category K, category L, and category M.

T.N. #

09-00l~

Approval Date

10-1-09

Supersedes T.N. #

03-005

Effective Date

3-1-09
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42CFR
440.120

S.

PRESCRIBED DRUGS (Continued)
Special Category Fees (Continued)
Table 1 shows unit values assigned for each category to estabnsn tne Tee. An asiensK (*)
equals one unit value. Items with two or more asterisks have a pigher value.
Table 1
Home Infusion Drug Categories

Catec pry 1 '

Category 'M'

Category J plus

Catego y K plus

Category L plus

**** clinical monitoring
*** quality assurance
***
labor factor

"Replacement into
individual doses
such as a syringe
"recalcula :ions from
vial to sf ringe to
be>g
*larg<3 bulk
inventc ry costs
"peer review

"Double gloves
""Gown
|
"Vertical Hood
I
"labor factor V
"OSHA
documentation
"Special handling
"special storage
"clean room
"hazardous waste

dispensing fee J

dispensing fee K

dispens ng fee L

dispensing fee M

$8 90

$18 90

$22 90

$33 90

Category 'B' or 'C

Category 'J'

Traditional
technician input
Point-of-Sale
Pharmacist input
Fixed overhead
costs

Category B or C
plus

dispensing fee
BorC
B=$3 90, C=$1 00

*Labor II factor
*clmical monitoring
"prefilled
synnges/PB
horizontal hood
technical input

Category 'K'

The special category fee is a negotiated fee initially developed in cooperation with the Utah
Pharmaceutical Association and other key pharmacists to apply to specific drugs historically
advertised and dispensed to the general public at minimal prices. Tpis fee may be periodically
changed to reflect changing market forces.

T.N.#

09-001

Approval Date

10-1-09

Supersedes T.N. #

01-004

Effective Date

3-1-09
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PRESCRIBED DRUGS (Continued)
Rural Pharmacies
In recognition of lower volume and higher acquisition costs, rural pharmacies are paid a $ 50
dispensing fee differential The differential is paid in addition to the dispensing fee paid to
urban pharmacies Rural is defined as those pharmacies located outside of Weber, Davis,
Utah and Salt Lake counties

TN #

93-002

Approval Date

5-21-93

Supersedes T N #

90-28

Effective Date

1-1-93
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Kenneth D. Lougee (Bar No. 10682)
David C. Biggs (Bar No. 0321)
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Robert E. Steed (Bar No. 6036)
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5272 College Drive, Suite 200
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Telephone: (801) 281-1258
Fax:(801)281-1250
Attorneys for Plaintiff

m THE THIRD JUDICIAL DISTRICT COTIRT OF
SALT LAKE COUNTY

STATE OF UTAH
THE STATE OF UTAH .
„, . .„
Plaintiff,
vs.
APOTEX CORPORATION; BAXTER
INTERNATIONAL, INC.: BOEHRINGER

SECOND AMENDED COMPLAINT
AND JURY DEMAND
'
Civil ^To. 080907678
Judge T

B' r 0 I i e E - Medley
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INGELHEIM CORPORATION;
MALLINCKRODT, INC.; CSL BEHRING;
FOREST LABORATORIES, INC.;
MORTON GROVE PHARMACEUTICALS,
INC.; MUTUAL PHARMACEUTICAL
COMPANY, INC.; NOVARTIS
PHARMACEUTICAL CORPORATION;
PFIZER, INC.; QUALITEST
PHARMACEUTICALS, INC.; SCHERINGPLOUGH CORPORATION; SCHWARZ
PHARMA US HOLDINGS, INC.; TARO
PHARMACEUTICALS, U.S.A., INC.;
UPSHER-SMITH, INC.; and WYETH, INC.
Defendants.

Plaintiff, the State of Utah ("State"), by and through its Attorney General Mark L.
Shurtleff, files this Complaint against the above-named Defendants and alleges, on information
and belief, the following:
INTRODUCTION
1,

The Defendants have engaged in false, misleading, willful, unfair, and deceptive

acts and practices in the pricing and marketing of their prescription drug products. The
Defendants' fraudulent pricing and marketing of their prescription drugs have impacted elderly,
disabled, and poor Utah citizens covered by the State's Medicaid program ("Utah Medicaid") by
causing Utah Medicaid to pay grossly excessive prices for the Defendants' prescription drugs.
Utah Medicaid is administered by the Division of Health Care Financing within the single state
agency, the Utah Department of Health.
2.

Fair and honest drug pricing is a matter of great importance to the State and its

citizens. Expenditures by the State for prescription drug reimbursement have increased
dramatically in the past several years as a result, in part, of Defendants' fraudulent pricing

A0118
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scheme. Each year Utah spends hundreds of millions of dollars on prescription drugs under the
Utah Medicaid program. In fiscal year 2005 alone, Utah Medicaid spent $207,6 million on
prescription drugs. Since 1990, Utah Medicaid prescription drug expenditures have increased
exponentially. This increase in prescription drug costs in recent years has contributed to a health
care funding crisis within the State that requires action to ensure fair dpaling between the
Defendants and the State,
3.

The State is accountable to its citizens and taxpayers ad to how it spends limited

State resources, and it is obligated to pursue any entity whose unlawful conduct has led to the
overspending of State funds. Consequently, the State, by and through) Attorney General
Shurtleff. brings this action to recover amounts overpaid for prescription drugs by Utah
Medicaid, as a result of the fraudulent and willful conduct of Defendants. 1 he State further
seeks to prohibit and permanently enjoin Defendants from continuing|to perpetrate their drugpricing scheme, to require Defendants to publicly disclose true drug pfcices, and to require
Defendants to account for and disgorge all profits obtained by Defendants as a result of their
improper and unlawful actions.
4.

This lawsuit seeks legal redress for the fraudulent and Willful pricing conduct of

Defendants, who have profited from their wrongful acts and practicesi at the expense of the State.
JURISDICTION AND VENUE
5.

Jurisdiction over the subject matter of this cause of actjion is based upon the False

Claims Act, Title 26, Chapter 20 of the Utah Health Code, which provides remedies to redress
Defendants5 actions under Utah Code Annotated § 26-20-1 et seq.
6.

Personal jurisdiction over these Defendants is proper Under the Utah Long Arm

Statute as codified in §§ 78-27-22 and 78-27-24 of the Utah Code Annotated.
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7.

Venue is proper in the Third Judicial District and Salt Lake County pursuant to

Utah Code Annotated § 78-13-7 in that many of the unlawful acts committed by Defendant were
committed in Salt Lake County, including the making of false statements and misrepresentations
of material fact to the State of Utah, its departments, agencies, instrumentalities and contractors,
including the Utah Medicaid Program, and relied upon by Utah Medicaid to reimburse providers
for the prescription drug needs of the Utah Medicaid recipients,
PARTIES
8.

Plaintiff is the State of Utah. The State brings this action in its capacity as

sovereign and on behalf of the Utah Medicaid Program. The Attorney General of the State of
Utah, Mark L. Shurtleff, as chief law officer of the State of Utah is statutorily authorized to
prosecute and maintain this action.
DEFENDANTS
Defendant Apotex
9.

Defendant Apotex Corp. ("Apotex") is a Florida corporation with its principal

place of business located at 2400 North Commerce Parkway, Suite 400, Weston, FL 33326.
Apotex is engaged in the business of manufacturing, distributing, marketing, and/or selling
prescription drags that are reimbursed by Utah Medicaid.
10.

The Apotex drugs at issue in this case are identified in Exhibit A, attached.

11

Defendant Apotex was involved in the sale, manufacture and pricing information

for all drags as set forth in Exhibit A.
12,

Defendant Apotex made false publications for each drug identified in Exhibit A as

follows: Apotex set, controlled and reported prices for said drugs to ihird-party compendia,
including Firsi Databank. First Databank, in turn, published prices for Apotex to the State of
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Utah. These publications became relevant each and every time Utah reimbursed a provider for
an Apotex drug between 1991 and 2006. The State actually relied upqn this false pricing
information each and every time it reimbursed a provider.
13.

The State does not know the actual price that should halve been published. The

published price should have been reflective of actual market prices, wjiich the Defendant keeps
confidential.
The Baxter Defendants
14.

Defendant Baxter International, Inc. ("Baxter International") is a Delaware

corporation with its principal place of business located at One Baxter parkway. Deerfield, IL
60015-4633.
15.

Defendant Baxter Healthcare Corporation ("Baxter Heklthcare"), a wholly-owned

subsidiary of Baxter International, Inc., is a Delaware corporation [with its principal place of
business located at One Baxter Parkway, Deerfield, IL 60015.
16.

Baxter International and Baxter Healthcare (collective^, the "Baxter Defendants")

are diversified healthcare companies that individually, and/or in combination with one another,
engage in the business of manufacturing, distributing, marketing, | and/or selling prescription
drugs that are reimbursed by Utah Medicaid.
17.

The Baxter Defendants drugs at issue in this case are identified in Exhibit A,

attached.
18.

The Baxter Defendants were involved in the sale, manufacture and pricing

information for all drugs as set forth in Exhibit A.
19.

The Baxter Defendants made false publications for ealch drug identified in Exhibit

A as follows: Baxter Defendants set, controlled and reported prices for said drugs to third-party
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compendia, including First Databank First Databank, in turn, published prices for Baxter to the
State of Utah These publications became relevant each and every time Utah reimbuised a
provider for a Baxter Defendant drug between 1991 and 2006 The State actually relied upon
this false pncing information each and every time it reimbursed a provide:
20

The State does not know the actual price that should have been published The

published price should have been reflective of actual maiket prices, which the Defendants keep
confidential
The Boehringer Defendants
21

Defendant Boehringer Ingelheim Corporation ("BIC) is a Kevada corpoiation

with its principal place of business located at 900 Ridgebury Road, Ridgefield, CT 06877
Boehringer includes a number of subsidiary companies that manufacture, distribute, market,
and/or sell preset lption drugs
22

Defendant Boehrmgei Ingelheim Pharmaceuticals, Inc (^BIPI") is a Delaware

corporation with its principal place of busmess located at 900 Ridgebury Road, Ridgefield, CT
06877
23

Defendant Roxane Laboratories, Inc (' BIRT) is a Delaware corpoiation with its

principal place of business located at 1809 Wilson Road, Columbus. OH 43228-9579
24

BIC, BIPI and BIRI (collectively "the Boehringer Defendants"; are diversified

healthcare companies that individually, and/oi m combination vsith one another, engage in the
busmess of manufacturing, distributing, marketing, and/or selling prescription drugs that aie
reimbursed by Utah Medicaid
25

The Boehringer Defendants drugs at issue in this case are identified in Exhibit A,

attached
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26.

The Boehringer Defendants were involved in the sale, ipianutacture ana pricing

information for all drugs as set forth in Exhibit A.
27.

The Boehringer Defendants made false publications fot each drug identified in

Exhibit A as follows: The Boehringer Defendants set controlled and (reported prices for said
drugs to third-party compendia, including First Databank. First Databank, in turn, published
prices for the Boehringer Defendants to the State of Utah. These publications became relevant
each and every time Utah reimbursed a provider for a Boehringer Defendant drug between 1991
and 2006. The State actually relied upon this false pricing informatioh each and every time it
reimbursed a provider.

28.

The State does not know the actual price that should haVe been published. The

published price should have been reflective of actual market prices, vltfiich the Defendants keep
confidential.
Defendant CSL Behring
29.

Defendant CSL Behring (nCSL") is a Pennsylvania corporation with its principal

place of business located at 1020 First Avenue, King of Prussia, PA 19406. CSL is engaged in
the business of manufacturing, distributing, marketing, and/or sellinb prescription drugs that are
reimbursed by Utah Medicaid.
30.

The CSL drugs at issue in this case are identified in Exhibit A, attached.

31.

Defendant CSL was involved in the sale, manufacture and pricing information for

all drugs as set forth in Exhibit A.
32.

Defendant CSL made false publications for each drug| identified in Exhibit A as

follows: CSL set, controlled and reported prices for said drugs to thitd-party compendia,
including First Databank. First Databank, in turn, published prices f6r CSL to the State of Utah.

7
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These publications became relevant each and every time Utah reimbursed a provider for a CSL
drug between 1991 and 2006. The State actually relied upon this false pricing information each
and every time it reimbursed a provider.
33.

The State does not know the actual price that should have been published. The

published price should have been reflective of actual market prices, which the Defendant keeps
confidential,
The Forest Defendants
34.

Defendant Forest Laboratories, Inc. ("Forest") is a Delaware corporation with its

principal place of business located at 909 Third Avenue, New York, NY 10022.
35.

Defendant

Forest Pharmaceuticals, Inc. ("Forest Pharm"), wholly-owned

subsidiary of Forest, is a Delaware corporation with its principal place of business located at
13600 Shoreline Drive, St. Louis, MO 63045.
36.

Forest and Forest Pharm (collectively, the "Forest Defendants") are diversified

healthcare companies that individually, and/or in combination with one another, engage in the
business of manufacturing, marketing, distributing, and/or selling prescription drugs that are
reimbursed by Utah Medicaid.
37.

The Forest Defendants drugs at issue in this case are identified in Exhibit A,

attached.
38.

The Forest Defendants were involved in the sale, manufacture and pricing

information for all drugs identified in Exhibit A.
39.

The Forest Defendants made false publications for each drug identified in Exhibit

A as follows: Forest Defendants set, controlled and reported prices for said drugs to third-party
compendia, including First Databank. First Databank, in turn, published prices for the Forest

8
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Defendants to the State of Utah. These publications became relevant each and every time Utah
reimbursed a provider for a Forest Defendants drug between 1991 and 2006. The State actually
relied upon this false pricing information each and every time it reimbursed a provider.
40.

The State does not know the actual price that should nave been published. The

published price should have been reflective of actual market prices, which the Defendant keeps
confidential.
Defendant Mallinckrodt
41.

Defendant Mallinckrodt, Inc. ("Mallinckrodt") is a Missouri corporation with its

principal place of business located at 675 McDonnell Blvd., Hazelwood, MO 63042.
Mallinckrodt is engaged in the business of manufacturing, distributin , marketing, and/or selling
prescription drugs that are reimbursed by Utah Medicaid.
42.

The Mallinckrodt drugs at issue in this case are identified in Exhibit A, attached

43.

Defendant Mallinckrodt was involved in the sale, manufacture and pricing

information for all drugs as set forth in Exhibit A.
44.

Defendant Mallinckrodt made false publications for eabh drag identified in

Exhibit A as follows: Mallinckrodt set, controlled and reported prices for said drugs to third'
party7 compendia, including First Databank. First Databank, in turn, published prices for
Mallinckrodt to the State of Utah. These publications became relevant each and every time Utah
reimbursed a provider for a Mallinclcrodt drug between 1991 and 200p. The State actually relied
upon this false pricing information each and every time it reimbursed a provider.
45.

The State does not know the actual price that should) have been published. The

published price should have been reflective of actual market prices, which the Defendant keeps
confidential.
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Defendant Morton Grove
46.

Defendant Morton Grove Pharmaceuticals, Inc. ("Morton") is an Illinois

corporation with its principal place of business located at 6451 W Main Street, Morton Grove, IL
60053. Morton is engaged in the business of manufacturing, distributing, marketing, and/or
selling prescription drugs that are reimbursed by Utah Medicaid.
47.

The Morton drugs at issue in this case are identified in Exhibit A, attached.

48.

Defendant Morton was involved in the sale, manufacture and pricing information

for all drugs as set forth in Exhibit A.
49.

Defendant Morton made false publications for each drug identified in Exhibit A

as follows: Morton set, controlled and reported prices for said drugs to third-party compendia,
including First Databank. First Databank, in turn, published prices for Morton to the State of
Utah. These publications became relevant each and every time Utah reimbursed a provider for a
Morton drug between 1991 and 2006. The State actually relied upon this false pricing
information each and every time it reimbursed a provider.
50.

The State does not know the actual price that should have been published. The

published price should have been reflective of actual market prices, which the Defendant keeps
confidential.
Defendant Mutual
51.

Defendant Mutual Pharmaceutical Company ("Mutual") is a Pennsylvania

corporation with its principal place of business located at 1100 Orthodox Street, Philadelphia,
PA 19124. Mutual is engaged in the business of manufacturing, distributing, marketing, and/or
selling prescription drugs that are reimbursed by Utah Medicaid.
52.

The Mutual drugs at issue in this case are identified in Exhibit A, attached.
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53.

Defendant Mutual was involved in the sale, manufacture and pricing information

for all drugs identified in Exhibit A.
54.

Defendant Mutual made false publications for each driig identified in Exhibit A as

follows: Mutual set, controlled and reported prices for said drugs to third-party compendia,
including First Databank First Databank, in turn, published prices for Mutual to the State of
Utah. These publications became relevant each and every time Utah reimbursed a provider for a
Mutual drug between 1991 and 2006. The State actually relied upon this false nricing
information each and every time it reimbursed a provider.
5 5.

The State does not know the actual price that should hive been published. The

published price should have been reflective of actual market prices. vi\hich the Defendant keeps
confidential.
Defendant Novartis
56.

Defendant Novartis Pharmaceuticals Corporation ("No\f artis") is a Delaware

corporation with its principal place of business located at One Health Plaza, East Hanover, NJ
07936-1080.
57.

Novartis engages in the business of manufacturing, distributing, marketing, and/or

selling prescription drugs that are reimbursed by Utah Medicaid.
58.

Novartis drugs at issue in this case are identified in ExhJibit A, attached.

59.

Novartis was involved in the sale, manufacture and priqing information for ail

drugs identified in Exhibit A.
60.

Novartis made false publications for each drug identified in Exhibit A as follows.

Novartis set, controlled and reported prices for said drugs to third-party compendia, including
First Databank. First Databank, in turn, published prices for Novartis to the State of Utah.
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These publications became relevant each and every time Utah reimbursed a provider for Novartis
drugs between 1991 and 2006, The State actually relied upon this false pricing information each
and every time it reimbursed a provider.
61.

The State does not know the actual price that should have been published. The

published price should have been reflective of actual market prices, which the Defendant keeps
confidential.
The Pfizer Defendants
62.

Defendant Pfizer. Inc. ("Pfizer") is a Delaware corporation with its principal place

of business located at 235 East 42nd Street New York? NY 10017. With the merger of Pfizer
and Pharmacia Corporation in 2003, Pfizer became the largest drug company in the world today.
63.

Defendant Pharmacia Corporation ("Pharmacia") is a Delaware corporation with

its principal place of business located at 235 East 42na Street, New York, NY 10017-5755.
64.

Defendant Pharmacia & Upjohn Company Corporation ("P & U"), a subsidiary of

Pharmacia Corporation, is a Delaware corporation with its principal place of business located at
235 E. 42nd Street, New York, NY 10017-5703.
65.

Pfizer, Pharmacia and P & U (collectively, the "Pfizer Defendants") are diversified

healthcare companies that individually, and/or in combination with one another, engage in the
business of manufacturing, distributing, marketing, and/or selling prescription drugs that are
reimbursed by Utah Medicaid.
66.

The Pfizer Defendants drugs at issue in this case are identified in Exhibit A,

attached.
67.

The Pfizer Defendants were involved in the sale, manufacture and pricing

information for all drugs as set forth in Exhibit A.
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68,

The Pfizer Defendants made false publications for each drug identified in Exhibit

A as follows: Pfizer Defendants set, controlled and reported prices for said drugs to third-party
compendia, including First Databank. First Databank, in turn, published prices for the Pfizer
Defendants to the State of Utah. These publications became relevant each and every time Utah
reimbursed a provider for the Pfizer Defendants drug between 1991 and 2006, The State actually
relied upon this false pricing information each and every time it reimbursed a provider.
69.

The State does not know the actual price that should have been published. The

published price should have been reflective of actual market prices, w|lliich the Defendant keeps
confidential.
Defendant Qualitest Pharmaceuticals, Inc
70.

Defendant Qualitest Pharmaceuticals, Inc. ("Qualitest") is an Alabama corporation

with its principal place of business located at 130 Vintage DR NE, Hunts ville, AL 35811.
Qualitest is engaged in the business of manufacturing, distributing, marketing, and/or selling
prescription drugs that are reimbursed by Utah Medicaid.
71.

The Qualitest drugs at issue in this case are identified in exhibit A, attached.

72.

Defendant Qualitest was involved in the sale, manufacture and pricing information

for all drugs as set forth in Exhibit A.
73.

Defendant Qualitest made false publications for eacn drug laentitiea in Exhibit A

as follows: Qualitest set, controlled and reported prices for said drugs to third-party compendia,
including First Databank. First Databank, in turn, published prices for Qualitest to the State of
Utah. These publications became relevant each and every time Utah reimbursed a provider for a
Qualitest drug between 1991 and 2006. The State actually relied upq>n this false pricing
information each and every time it reimbursed a provider.
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74.

The State does not know the actual price that should have been published. The

published price should have been reflective of actual market prices, which the Defendant keeps
confidential.
The Schering Defendants
75.

Defendant Schering-Plough Corporation ("Schering-Plough") is a New Jersey

corporation with its principal place of business located at 2000 Galloping Hill Road, Kenilworth,
NJ 07033,
76.

Defendant Warrick Pharmaceuticals Corporation ("Warrick"), a w?holly-owned

subsidiary of Schering-Plough, is a Delaware corporation with its principal place of business
located at 12125 Moya Blvd., Reno, NV 89506-2600,
77.

Schering-Plough and Warrick (collectively, the "Schering Defendants") are

diversified healthcare companies that individually, and/or in combination with one another,
engage in the business of manufacturing, distributing, marketing, and/or selling prescription
drugs that are reimbursed by Utah Medicaid.
78.

The Schering Defendants drugs at issue in this case are identified in Exhibit A}

attached,
79.

The Schering Defendants were involved in the sale, manufacture and pricing

information for all drugs as set forth in Exhibit A.
80.

The Schering Defendants made false publications for each drug identified in

Exliibit A as follows: Schering Defendants set. controlled and reported prices for said drugs to
third-party compendia, including First Databank. First Databank, in turn, published prices for
the Schering Defendants to the State of Utah. These publications became relevant each and
every time Utah reimbursed a provider for the Schering Defendants drug between 1991 and
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2006 The State actually relied upon this false pricing information eac^h and every time it
reimbursed a provider.
81.

The State does not know the actual price that should hav|e been published. The

published price should have been reflective of actual market prices, which the Defendant keeps
confidential.
Defendant Schwarz
82.

Defendant Schwarz Pharma USA Holdings, Inc. ("Schvjarz") is a Delaware

corporation with its principal place of business located at 103 Foulk Rd Suite 202, Wilmington,
DE 19803. Schwarz is a wholly-owned U.S. subsidiary of Schwarz Fharma AG, a German
corporation with its principal place of business located at Alfred-Nobtl-StraBe, 10 Monheim,
Geimany. Schwarz is engaged in the business of manufacturing, distributing, marketing, and/or
selling prescription drugs that are reimbursed by Utah Medicaid,
83.

The Schwarz drugs at issue in this case are identified iji Exhibit A, attached.

84.

Defendant Schwarz was involved in the sale, manufacture and pricing information

for all drugs as set forth in Exhibit A.
8 5.

Defendant Schwarz made false publications for each drug identified in Exhibit A

as follows: Schwarz set, controlled and reported prices for said drugs to third-party compendia,
including First Databank. First Databank, in turn, published prices for Schwarz to the State of
Utah. These publications became relevant each and every time Utah reimbursed a provider for a
Schwarz drug between 1991 and 2006. The State actually relied upop this false pricing
information each and every time it reimbursed a provider.
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86.

The State does not know the actual price that should have been published. The

published price should have been reflective of actual market prices, which the Defendant keeps
confidential.
Defendant Taro
87.

Defendant Taro Pharmaceuticals U.S.A., Inc. ('Taro"), a New York corporation

with its principal place of business located at 3 Skyline Drive, Hawthorne, NY 10532. Taro is
engaged in the business of manufacturing, distributing, marketing, and/or selling prescription
drugs that are reimbursed by Utah Medicaid.
88.

The Taro drugs at issue in this case are identified in Exhibit A, attached.

89.

Defendant Taro was involved in the sale, manufacture and pricing information for

all drugs as set forth in Exhibit A.
90.

Defendant Taro made false publications for each drug identified in Exhibit A as

follows: Taro set, controlled and reported prices for said drugs to third-party compendia,
including First Databank. First Databank, in turn, published prices for Taro to the State of Utah.
These publications became relevant each and every time Utah reimbursed a provider for a Taro
drug between 1991 and 2006. The State actually relied upon this false pricing information each
and every time it reimbursed a provider.
91.

The State does not know the actual price that should have been published. The

published price should have been reflective of actual market prices, which the Defendant keeps
confidential.
Defendant Upsher-Smith
92.

Defendant Upsher-Smith, Inc. ("Upsher-Smith") is a Minnesota coiporation with

its principal place of business located at 13700 1st Ave, N, Minneapolis, MN 55441. Upsher-
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Smith is engaged in the business of manufacturing, distributing, marketing, and/or selling
prescription drugs that are reimbursed by Utah Medicaid.
93.

The Upsher-Smith drugs at issue in this case are identified in Exhibit A, attached.

94.

Defendant Upsher-Smith was involved in the sale, manufacture and pricing

information for all drugs as set forth in Exhibit A.
95.

Defendant Upsher-Smith made false publications for eich drug identified in

Exhibit A as follows: Upsher-Smith set, controlled and reported prices for said drugs to thirdparty compendia, including First Databank. First Databank, in turn, published prices for UpsherSmith to the State of Utah. These publications became relevant each and every time Utah
reimbursed a provider for an Upsher-Smith drug between 1991 and 2006. The State actually
relied upon this false pricing information each and every time it reimbursed a provider.
96.

The State does not know the actual price that should have been published. The

published price should have been reflective of actual market prices, wpich the Defendant keeps
confidential.

The Wyeth Defendants
97.

Defendant Wyeth, Inc. ("Wyeth"), formerly Americanl!Home Products Corp., is a

Delaware corporation with its principal place of business located at Five Giralda Farms,
Madison, NJ 07940.
98.

Defendant Wyeth Pharmaceuticals, Inc. ("Wyeth Pharm"), a division of Wyeth, is

a Delaware corporation with its principal place of business located at 500 Areola Road,
Collegeville, PA 19426.
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99.

Wyeth and Wyeth Pharm (collectively, the "Wyeth Defendants") are diversified

healthcare companies that individually, and/or in combination with one another, engage in the
business of manufacturing, distributing, marketing, and/or selling prescription drugs that are
reimbursed by Utah Medicaid.
100.

The Wyeth Defendants drugs at issue in this case are identified in Exhibit A,

attached.
101.

The Wyeth Defendants were involved in the sale, manufacture and pricing

information for all drugs as set forth in Exhibit A.
102.

The Wyeth Defendants made false publications for each drug identified in Exhibit

A as follows, Wyeth Defendants set, controlled and reported prices for said dmgs to third-party
compendia, including First Databank. First Databank, in turn, published prices for the Wyeth
Defendants to the State of Utah. These publications became relevant each and every time Utah
reimbursed a provider for a Wyeth Defendants drug between 1991 and 2006. The State actually
relied upon this false pricing information each and every time it reimbursed a provider.
103.

The State does not know the actual price that should have been published. The

published price should have been reflective of actual market prices, which the Defendant keeps
confidential.
NATURE OF THE CASE
104.

This is a civil action for damages and civil penalties pursuant to the Utah False

Claims Act, Utah Code Annotated §26-20-1, et seq., and Utah Common Law No Federal
Claims are asserted and are hereby expressly disavowed.
FACTUAL BACKGROUND
The Utah Medicaid Program
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105.

The Utah Medicaid program is a state-administered program with federal

matching funds, which pays for medical care, including prescription drug benefits, for Utah's
low-income and disabled citizens. The Utah Medicaid program currently covers approximately
300,000 individuals. The prescription drug benefit cost has increased dramatically in recent
years from S47.5 million in 1996 to $207.6 million in 2005, an increase of 437% in nine years or
a compounded annual rate of 17.8%.
106.

Utah Medicaid reimburses medical providers, including physicians and

pharmacists, for drugs prescribed for, and dispensed to, Utah Medicaid recipients pursuant to
statutory and administrative formulas.
107.

Reimbursement for pharmacy-dispensed prescription drugs under the Utah

Medicaid program is based on information supplied by Defendants to industry reporting services.
This information includes the following price indices; (i) Average Wholesale Price ("AWP"),
which is commonly understood as the average price paid by retailers, such as hospitals, doctors
and pharmacies to wholesalers, for prescription drugs and (ii) Wholesale Acquisition Cost
("WAC"), which is commonly understood as the price paid by wholesalers to the manufacturers
for prescription drugs. At all times relevant to this action, Defendants were aware of Utah
Medicaid's drug reimbursement formulas and procedures for pharmacy-dispensed drugs.
108.

Under the federal Medicaid requirements, the State must submit plans for Utah's

Medicaid programs to the federal government for approval. Those plans must
[p]rovide such methods and procedures relating to the utilization of, and the
payment for, care and services available under the plan
as may be necessary
to safeguard against unnecessary utilization of such care and Services and to
assure that payments are consistent with efficiency, economy, and quality of care
and are sufficient to enlist enough providers so that care and sendees are available
under the plan at least to the extent that such care and service? are available to the
general population in the geographic area.
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42 U S C § 1396a(a)(30)(A)(emphasis added) The federal Medicaid regulations limit Utah
reimbursements foi prescription drugs The regulations distinguish between ''brand name drugs "
which are still under patent protection, and "multiple souice" (also called "generic*5) drugs,
winch enter the marketplace after the patent on the biand-name drug expires
109

Brand-name drugs Utah Medicaid leimbuisements to provideis for brand-name

drugs "must not exceed, in the aggregate, payment levels that the agency has determined by
applying the lowei of the (1) [estimated acquisition costs plus reasonable dispendmg fees
established by the agency or (2) [providers' usual and customary charges to the general public '
42 C F R § 447 331(b) ] "Estimated acquisition cost" means the agenc) *s "best estimate of the
price generally and currently paid by pioviders for a drug marketed or sold by a particular
manufactuiei oi labeler in the package size of drug most frequently purchased by providers " 42
C F R § 447 302 "Reasonable dispensing fee" means the fee that is "mcuired at the point of sale
oi service and pays for costs in excess of the ingredient cost of a covered outpatient drug each
time a covered outpatient diug is dispensed " Id
110

Although the Defendants may attempt to obfuscate this regulation, it could not be

clearer It forbids Utah Medicaid from deliberately setting the "estimated acquisition costs5 of
drugs at levels which give providers as a group a systematic "spread5 over what it costs them to
acquire drugs Setting "estimated acquisition cost at such levels would cause Utah s Medicaid
total leimbursements for brand-name drugs to exceed the sum of "estimated acquisition cosf
plus the reasonable dispensing fees as determined by the agency Regaidless of hovs much
piessure an agency feels to initiate its "estimated acquisition cost" to piovide piofit 10 pro\iders
1

The provider's "reasonable and customary" charge is normaJ) the list puce tha* providers like pharmacies
charge purchasers who aie not entitled to the discounts that aie customarily demandec and recen ea b) third party
payers such as private insuiers, Medicare, or Medicaid See V S i Bruno s Jnc 54 F Supp 2d 1252 1256-58 (MI
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such inflation cannot be reconciled with these regulations. "Congress inacted Title XIX of the
Social Security Act [which includes Medicaid] to care for the poor ancfl aged, not to subsidize or
otherwise to benefit health care providers.55
111.

Generic drugs. For many "generic" or multiple soured drugs, the federal Center

for Medicare and Medicaid Services (CMS) has set what is called a "Federal Upper Limit"
(FUL) - a maximum amount that states may not exceed in reimbursing providers of the drugs
subject to the FUL. Where CMS has set a FUL for a particular drug, federal regulations have
provided, during most times relevant to this suit, that Utah Medicaid cannot pay more in the
aggregate for these drugs than that FUL plus a reasonable dispensing fee. See 42 C.F.R. §
447.331, 332 (1999), now modified and renumbered as 42 C.F.R. § 447.512(a).
112.

Unlike the concept of "estimated acquisition cost" as defined by the federal

regulations, the concept of the FUL is not designed to forbid a profit to providers. To the
contrarys the FUL, which applies to generic drugs, may provide for some degree of profit to the
provider as an incentive to induce the provider to dispense a cheaper generic drug rather than the
more expensive brand-name version. But the FUL is a ceiling, not a flc|oor, on what a state can
pay. As discussed below, Utah is unwilling to pay the FUL for a drug if
: the provider's
"estimated acquisition cost" is lower.
113.

As contemplated by the federal scheme, the State of Uxah has set reimbursement

levels for prescription drugs under the Medicaid program, through regulations issued by the Utah
Department of Health, Division of Health Care Financing ("DHCF"). No Utah statute or
regulation tells the DHCF to set reimbursement rates at levels that would provide a systematic

Ala. 1999). It is relatively uncommon for a provider's "usual and customary" chargp to be lower than the sum of
"estimated acquisition cost" and the dispensing fee.v
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"profit" for pharmacists or other providers, and as shown, above, federal regulations prohibit a
systematic profit from being built into "estimated acquisition cost."
114.

Between 1991 and 2006, DHCPs regulation provided that the State would

reimburse for any drug by paying the drug's "estimated acquisition cost" plus the dispensing fee,
unless the drug in question had a FUL that was lower than the estimated acquisition cost, in
which case the DHCF would pay the FUL plus the dispensing fee. In 1989, Utah created a
"Maximum Allowable Cost" (MAC) program for certain drugs. Since then, the regulation has
provided that the State will pay the lowest of estimated acquisition cost the FUL (if one exists
for a drug), or the MAC (if one exists for a drug), plus, in any of the three cases, the reasonable
dispensing fee. In any event, the price cannot exceed the usual and customary charge (billed
charged) to the general public. Utah's MAC program had very limited use until November of
2008, at which time it was expanded due to budget constraints.
115.

The Defendants5 inflated AWPs were the only variable in the formulas used by

the State to reimburse brand name drugs. Thus, had the Defendants' AWPs been lower, the
amounts the State would have paid for brand name drugs would have been correspondingly
lower as a matter of arithmetic.
116.

Defendants' AWPs were an essential variable in deciding what the lowest price

was in the formula for reimbursing generic drugs - i.e., the State would pay the lowest of the
acquisition cost as estimated through AWT, the Federal Upper Limit if it existed for the drug in
question, or the State's Maximum Allowable Cost if it existed for the drug. MAC prices or
reimbursement rates are a schedule of pricing for generically equivalent drugs based upon the
listed AWPs of competing generic drug manufacturers. Generic drug makers are able to push
market share for their generic drugs by intentionally increasing the published AWT for a generic
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drug with the intention to create a profit margin for others in the distribution chain. That profit
margin is taken advantage of either directly (through reimbursement based upon AWP) or
indirectly on the AWP based upon the establishment of a MAC tied to the AWP.
117.

The State would have reimbursed on the basis of "estimated acquisition cost" if

that cost had been the lowest of these three measures. But because the estimated acquisition cost
was inflated by Defendants5 inflated AWPs, the State lost the chance :o make that comparison
and save itself money.
The Defendants' Reporting of Inflated Pricing Information
118.

Defendants knowingly, willfully, wantonly, and/or intentionally provided, or

caused to be provided, false and inflated AWP, WAC, and/or other pricing information for their
drugs to various nationally known drug industry reporting services, including First DataBank
(a/k/a Blue Book), Medical Economics, Inc. (a/k/a Red Book), and Mpdispan (collectively
referred to herein as "various nationally known drug industry reporting services" or "reporting
services'5)- These reporting services published the pricing information to various reimbursers,
such as Utah Medicaid, who have contracted to receive the information (either in electronic or
hard copy form) as a basis to provide reimbursement to the medical o^ pharmacy providers who
provide the drugs to patients.
119.

Utah Medicaid purchased and utilized the Defendants5 (published AWT, WAC,

and other pricing information from First DataBank (Blue Book), and Medical Economics, Inc.
(Red Book). The information from Blue Book was and is used by Utah Medicaid with respect to
reimbursement for pharmacy-dispensed drugs. At all relevant times to this action, Utah
Medicaid relied upon the AWT, WAC, and/or other pricing information provided by Defendants
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to the industry reporting services in determining the amount Utah Medicaid reimburses
providers.
120.

Defendants knew the false and deceptive inflation of AWP, WAC, and/or other

pricing information for their drugs would cause Utah Medicaid to pay excessive amounts for
these drugs. Defendants' inflated AWPs and WACs greatly exceeded the actual prices at which
drugs were sold to retailers (physicians, hospitals, and pharmacies) and wholesalers.
Defendants' reported AWPs and WACs were false and misleading and bore no relation to any
price, much less a wholesale or retail price.
121.

Defendants knowingly, willfully, wantonly, and/or intentionally concealed the

true prices for their respective drugs, by trick or artifice, from Utah Medicaid. At all times
relevant, each Defendant knew its own true prices which were not reported to the industry
reporting services for use by state Medicaid agencies. Each Defendant also knew whether the
price reported to the reporting services accurately and truthfully represented the actual prices as
reflected by market experience and conditions. At all times pertinent, the Defendants'
concealment of the true prices hindered Utah Medicaid from obtaining or knowing the true
prices. Furthermore, the Defendants concealed the true prices knowing that Utah Medicaid
relied upon the false reported prices.
122.

Unless governmental or industry surveys, lawsuits, or criminal or regulatory

investigations publicly reveal the true AWT or WAC for a particular drug at issue, Utah
Medicaid is not privy to the actual market prices which it can then compare against the reported
prices. Defendants have concealed true market pricing information from Utah Medicaid for the
purpose of avoiding detection of the fraudulent scheme described herein.
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123,

Defendants used undisclosed discounts, rebates and other inducements, which had

the effect of lowering the actual wholesale or retail prices paid by wholesalers and retailers as
compared to the reported prices. In addition, Defendants employed secret agreements to conceal
the lowest prices paid for their pharmaceutical products. As a result of these concealed
inducements, Defendants have prevented third parties, including Utah| Medicaid, from
determining the true prices paid by wholesalers and retailers.
FIRST CLAIM FOR RELIEF
(Restitution, Costs and Civil Penalties under the Utah Flalse Claims Act)
124.

Plaintiff incorporates paragraphs 1 through 129 as if fully set forth herein, and

further alleges as follows:
125.

Defendants violated the False Claims Act as codified iji the Utah Health Code at

Title 26, Chapter 20 of the Utah Code Annotated. Defendants issued false and inflated AWP,
WAC, and/or other pricing information for publication by the industry reporting services, in
violation of Utah Code Annotated §§ 26-20-3, 26-20-4 and 26-20-7. Because of Defendants5
fraudulent conduct and misrepresentations, Utah Medicaid relied on tne false information in
reimbursing providers for Medicaid drugs. Defendants "knowingly" acted in deliberate
ignorance or reckless disregard of the truth, and in so doing, caused the State to pay false claims
due to the grossly reimbursements for Defendants' prescription drugs
126.

Defendants' "false representation" regarding the price of their drugs was a

"material fact for use in determining rights to a medical benefit," and|-a violation of Utah Code
Annotated §26-20-3(2).
127.

According to U.C.A, 26-20-4, it is illegal to pay a kickback to induce the

"purchasings leasing, or ordering of any goods or services for which payment is or may be made

A0141
25

in whole or in part pursuant to a medical benefit program " Utah Code Annotated § 26-204(2)(a)(emphasis added). The discounts, rebates and other price concessions paid by Defendants
to providers are clearly considered "kickbacks", which is defined by U.C.A. 26-20-4(1) as
"rebates, compensation, or any other form of remuneration."
128.

The claims at issue were made for the medical benefit of Utah Medicaid

recipients. By injecting false prices into Utah's reimbursement process, the Defendants directed
others to submit claims which led to false reimbursements. Each and every Defendant derived
benefits directly from the State, in that the State's Medicaid expenditures ultimately ended up in
the pockets of the Defendants.2
129.

The false prices reported by Defendants5 "caused to be made or presented to an

employee or officer of the State a claim for a medical benefit" in violation of U.C.A. § 26-207(1). Specifically, the Defendants knew their false prices would result in the presentation of
claims that are, "wholly or partially false, fictitious, or fraudulent", in violation of U.C.A. § 2620-7(1 )(a)> and would "represent charges at a higher rate than those charged by the provider to
the general public," in violation of U.C.A. § 26-20-7(l)(d).
130.

Defendants also "retained unauthorized payment as a result of acts5* described in

U.C.A. § 26-20-7.
131.

Under Utah Code Annotated § 26-20-9.5, Defendant is liable for the following

damages:
a. Full and complete restitution to the State of all damages that the State sustained;
b. the costs of enforcement, including but not limited to the cost of investigators and
attorneys;
2

Industry Facts-at-a-Glance, National Association of Chain Drug Stores (NACDS),
http7/wvvr\v.nacds.org/wi-nspage.cfmf>parml=5Q7 (accessed March 26, 2009).
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c, a civil penalty equal to three times the restitution amouht: and
d. a civil penalty of $5,000 to $ 10,000 for each false clainfc filed.

132.

These costs and penalties are in addition to and not a substitute tor other damages

caused by Defendants5 actions.

SECOND CLAIM FOR RELIEF
(Fraudulent Misrepresentation)

133.

Plaintiff incorporates paragraphs 1 through 138 as if fijlly set forth herein, and

further alleges as follows:
134.

Defendants committed fraud against the State and its single state agency

administering Utah Medicaid, the Utah Department of Health. Defendants reported or caused to
be reported false AWP, WAC and/or other pricing information for their respective products on a
periodic and continuing basis for publication and dissemination to third party payers, including
Utah Medicaid and other state Medicaid programs. Defendants knew that the AWP, WAC and/or
other pricing information that they provided and caused to be reported was false and material to
the determination of Utah Medicaid reimbursement rates.
135.

Defendants misrepresented the pricing information wr.]th the intent of inducing

Utah Medicaid to rely on the false information in setting prescription drug reimbursement rates,
136.

Utah Medicaid reasonably relied on the false pricing data in setting prescription

drug reimbursement rates and making payment based on said rates, Defendants'
misrepresentations are continuing, as they regularly and periodically continue to issue false and
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inflated AWP. WAC and/or pricing information for publication by the industry reporting
services.
137.

As a result of Defendants' fraudulent conduct, the State has been damaged by-

paying grossly excessive amounts for Defendants' prescription drugs.
138.

By engaging in the acts and practices described above, the Defendants have

engaged and continue to engage in repeated fraudulent acts and practices in violation of Utah
common law7.
139.

Defendants' conduct was and is knowing, intentional, gross, oppressive,

malicious, wanton, and/or committed with the intention to cause injury. These actions subject
Defendants to an award of punitive damages sufficient to punish the Defendants and deter others
from similar fraudulent conduct.
JURY DEMAND
The State respectfully requests a trial by jury pursuant to Rule 38, Utah R. Civ. Proc.
PRAYER FOR RELIEF
Wherefore, Plaintiff, the State of Utah, prays for relief as follows:
1.

For costs of enforcement pursuant to § 26-20-9.5(2)(b), Utah Code Ann.;

2.

For an award of full and complete restitution to the State in such amount as is
proved at trial;

3.

For punitive damages for the wanton and reckless conduct as outlined herein and
as an example for the benefit of ail other drug manufacturers that wrongly
misrepresent the prices of their products to the detriment of Utah Medicaid;

4.

For civil penalties pursuant to § 26-20-9.5(2)(c). Utah Code Ann., equal to:
a.

Three times the restitution amount; and
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b.

$5,000 to $ 10,000 for each false claim filed with Utah Medicaid.

5.

For an award of costs and prejudgment interest; and

6.

For such other and further relief as may be justified kid which Plaintiff may be

entitled to by law including, but not limited to, all court costs, witness fees and deposition fees.

DATED: April.

fi'

_, 2009.

MARK L. SHURTLEFrj
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EXHIBIT A
Through the following list, the State of Utah intends to capture not only the drug names
listed, but also all variations of the drug names which incorporate prefixes, suffixes, modifiers,
supplements, application nomenclatures and/or drug delivery methods, to the extent not already
specified.

ACYCLOVIR
ALENDRONATE

]

CAT/JLODIPINE

H3ALSALAZID
BENAZEPRIL
feETAXOLOL
BUPROPION
BUTORPHANOL
pAPTOPRIL
fcARBAMAZEPINE
ICARBIDOPA
CARVEDILOL
pEFAZOLIN
pEFEPIME
CEFOXITIN
[CEFTRIAXON
hCEFUROXIME
CETIRIZ1NE
CHLQRHEXIDINE

CICLOPIROX
IclEcTSTAZOL
teiMETIDlNE
pPROFLOXA
CiTALOPRAM
[CIARITHROM
CLONAZEPAM
[CLOPIDPGREL
CROMOLYN
CYCLOSPORINS
pESMQPRESS
I DICLOFENAC
[DlLTlAZEM
[DIVALPROEX
DOXAZOSIN
RENALAPRIL
HEPLERENONE
CfobOLAC
FLUCONAZOLE
FLUNISOLIDE
[FLUOXETINE
TOPHENAZINE
pUJTICASON
fcEUVOXAMINE
GABAPENT1N
GEMFIBROZIL
GLIPIZIDE
HALOPERIDOL

1

EXHIBIT A

IPRATROPIUM
KETOCONAZOLE
KETOTIFEN
LACTULOSE
LEFLINOMID
LISINOPRIL
LITHIUM CA
LORATADINE
LOVASTATIN
MEGESTROL
MELOXICAM
METFORMIN
MIDAZOLAM
jMIDODRINE
jMIRTAZAPINE
1 MORPHINE
NIZATIDINE
OFLOXACIN
OMEPRAZOLE
ONDANSETRON"
OXAPROZ1N
OXCARBAZEPINE
OXYBUTYNIN
PAROXETINE
PENTOXIFYLLINE"
PRAVASTATIN
QUINAPRIL
RANITIDINE
SELEGILINE
SERTRALINE
SOTALOL
TERAZOSIN
TICLOPIDIN
TIMOLOL
TIZANIDINE
TOBRAMYCIN
TORSEMIDE
TRAMADOL
TRAZODONE
TRIAMETERENE"
TRIANTERENE
ZINISAMIDE
ZOLPIDEM F

ACETIC ACID
:ALDOCLOR
jALDOMET
IALDORIL
iAMERINET
[AMIKACIN
AMINOACETI

EXHIBIT A

AMINOPHYLL
AMPICILLIN
|AQUA-MEPHY~
ARALAST
ATIVAN
ATROPINE
AZ1THR0MYC~
BEBULIN
BENEMID
BLOCADREN
BUMINATE
CANCIDAS
CEFAZOLIN
CEFOXITIN
CEFTRlAXOlsT"
CEFUROXIME~
CERNEVIT
CHIBROXiN
CHLORPROMA
CLINDAMYC1
CLINORIL
COGENTIN
COL-BENEMI
CORTONE
COSMEGEN
COSOPT
~
COZAAR
CRIX1VAN

JCUPRIMINE
CYANOCOBAI"
CYCLOPHOSP"
DARANIDE
DECADRON
DECASPRAY~~
DEMSER
DEXAMETHAS
DEXTROSE
DIAZEPAM
pIGOXIN
pIPHENHYDR

JDIUPRES

~~

DIURIL
pOLOBID
DOXYCYCLlFT
DURAMORPTT
EDECRIN
ELAVIL
ELSPAR
EMEND
IEPINEPHRIN
[ERYTHROMYC
FAMOTIDINE
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EXHIBIT A

FEIBAVHI
FENTANYL C
,FLEXERIL
FLOROPRYL
FOSAMAX
FUROSEMIDE
GAMMAGARD
GENTAMICIN
GLYCOPYRRO
HEMOFIL
HEPARIN
HEP-LOCK
HEPTAVAX-B
HUMORSOL
HYDELlRA
HYDROCORTI
HYDRODIURI
HYDROMORPH
HYDROPRESHYDROXYZIN
HYZAAR
INDOCIN
INFUMORPH
INTRAUPID
INVANZ
INVERSINE
ISENTRESS
JANUMET
JANUVIA
KETOROLAC
LACRISERT
LACTATED
LIDOCAINE
LORAZEPAM
LOSEC
MAXALT
MEFOXIN
MEPERIDINE
MEPHYTON
METHYLDOPA
METOCLOPRA
METRONIDAZ
MEVACOR
M1DAMOR
MIDAZOLAM
MILRIONONE
MINTEZOL
M-M-RIIV
MODURETIC
MONISTATD
MORPHINE
IMUSTARGEN

1
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EXHIBIT A

1MY0CHRYSIN
NALLPEN
NEODECADRO
NEOSTIGMIN
NOROXIN
NUTREN
ONDANSETRO
OXYTOCIN 1
PENICILLIN
PEPCID
PERIACTIN
PHENERGAN
PHENOBARBl
PHENYTOIN
PLENDIL
PNEUMOVAX
POTASSIUM
PRILOSEC
PRIMAXIN
PRINIVIL
PRINZIDE
PROCHLORPE
PROMETHAZi
PROPECIA
PROSCAR
RECOMBINAT
RECOMBIVAX
REGLAN 5MG
REPLETE
RINGER'S L
ROBINUL
SINEMET
SINGULAIR
SODIUM CHl
STERILE WATER"
STROMECTOL
SULFAMETHO
SYPRINE
THIAMINE
TIMOLIDE
TIMOPTIC
TONOCARD
TRANSDERM
TRAVASOL
TRAVASORB
TRIAVIL
TRUSOPT
URECHOLINE
VANCOCIN
VANCOMYCIN
VAQTA
VASERETIC
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VASOTEC
VIOXX
VIVACTIL
iWATER
jZOCOR
ZOSTAVAX

[BSgsttM^SfME^S.^Ii^^Sll^ii^i^i^l W&Q
ACARBOSE
ACETAMINOPHEN
ACETAZOLAM
ACETYLCYST
ACYCLOVIR
ADRIAMYCIN
AGGRENOX
ALBUTEROL
ALPRAZOLAM
ALIMINUM
ALLPENT
AMIKACIN S
AMINOPHYLL
AMITRIPTYL
APTIVUS
ATROVENT
AZATHIOPRI
BALSALAZID
BUMETANIDE
BUTORPHANO
C AFC IT
CALC CARB
CALCIUM GLUCONATE
CALCITRIOL
CALCIUM CARBONATE
CATAPRES
CERUBIDINE
CHLORAL HY
CHLORPHENI
ICHLORPROMA
jCILOSTAZOL
CIMETIDINE
ICIPROFLOXA
ICISPLATIN
CITALOPRAM
CLADRIBINE
CLARITHROM
CLINDAMYCI
ICLOTRIMAZO
ICOCAINE HC
CODEINE 15
CODEINE PH
CODEINE SU
COMBIPRES
[COMBIVENT

EXHIBIT A

CROMOLN
CROMOLYN
CYCLOPHOSP
CYCLOSPORI
CYTARABINE
DEXAMETHASONE
DIHYDROTACHSTEROL
DIAZEPAM
DICLOFENAC
DIFLUNISAL
DIGOX1N
DIHYDROERGOTAMINE
DIPHENHYDR
DIPHENOXYL
DOCUSATE
iDOLOPHINE
DOXORUBICI
JDOXYCYCLIN
DULCOLAX
pURACLON
ENALAPRILA
FAMOTIDINE
FELCAINIDE
FERROUSSU
FLECAINIDE
FLOMAX
FLUCONAZOL
FLUPHENAZI
FLUT1CASON
FOLIC ACID
FUROSEMIDE
GLUCAGEN
GUAIFENESI
HALOPERIDO
HYDROCHLOR
HYDROMORPH
HYDROXYURE
IMIPRAMINE
INDOMETHAC
IODINATED
IPRATROPIU
ISOETHARIN
KAOLIN-PEC
KETAMINEH
KETOROLAC
LABETALOL
LACTULOSE
LACTULOSE
LEUCOVORIN
LEVOCARNIT
ILEVQRPHANO
LEVOTHYROX

EXHIBIT A
LITHIUM CARBONATE
!LITHIUM CITRATE
; LOPERAMIDE
,LORAZEPAM
'MARINOL
MEFLOQUINE
MEGESTROL
MELOXICAM
MEPERID50
MEPERIDINE
MERCAPTOPU
MESNAINJE
METAPROTER
METHADONE
METHOTREX
METHYLDOPA
METHYLPRED
METOCLOP
METOCLOPRA
METOPROLOL
MEXILETINE
MEXITIL
MICARDIS
MIDAZOLAM
MILK OF MA
MIRAPEX
MIRTAZAPIN
MITOMYCIN
MOBIC
MORPHINE SULFATE
MORPHINE
NAPROXSUSPEN
NAPROXEN
NEFAZODONE
NEOMYCIN
OCTREOTIDE
ONDANSETRO
ORAMORPH
OXCARBAZEP
OXYCODONE
PACLITAXEL
PAMIDRONAT
PAPAVERINE
PERSANTINE
PHENOBARBI
PHENTOLAMI
PILOCARPIN
PIROXICAM
POLYMYXIN
(POTASSIUM CHLORIDE
(PREDNISONE
[PRQCHLORPE
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EXHIBIT A

PROPANTHEL
PROPOXYPHE
PROPRAN
PROPRANOLO
PSEUDOTAB
PSEUDOEPHE
jQUINlDINE
RANITIDINE
RESPBID
RIFAMPIN
ROPINIROLE
ROXAN
ROXANOL
ROXICET
ROXICODONE
ROXILOX
ROXIPRIN
SALIVA SUB
SERENTIL
SERTRALINE
SODIUM POLY SULFONATE
SODIUM CHLORIDE
SODIUM POLYSTYRENE SULFONATE
SPIRIVA
STERILE AC
SULFAMETHOXAZOLE
TAMOXIFEN
THEOPHYLLI
THIORIDAZI
THIOTH1XEN
TORECAN
TORSEMIDE
TRIAZOLAM
VINBLASTIN
VIRAMUNE
ZALEPLON
ZIDOVUDINE
ZOLPIDEM T

mE&mmmmmmmm
ACTHAR H P
ALBUMINAR
AQUASOL A
ARM-A-VIAL
IBIOCLATE
ICARIMUNE
DIALUME
GAMMAR
HELIXATE
HUMATE-P
M V I PED
MONOCLATE
IMONONINE

^s^k»^-^rf^|

EXHIBIT A

RHOPHYLAC
STIMATE

AEROCHAMBE
jAMBENYL
APAP/HYDRO
ARMOUR THY
BANCAP
BENZONATAf
BETACHRON
BUCET
BUTALBITAL
BYSTOLIC
CAMPRAL
CARBAMAZEP
CEBOCAP
CELEXA
CITALOPRAM
COMBUNOX
DILTIAZEM
ELIXOPHYLL
ENDAL
ESGIC
FEOSTAT
FLUMADINE
HYDROCODON
INDOCHRON
INDOMETHAC
ISOSORBIDE
KAYCIEL
LEVOTHROID
LEXAPRO
LORCET
MONUROL
NAMENDA
NITROGARD
PARAL
{PEDAMETH
IPROPRANOLO
PYOCIDIN
RIMANTAD1N
SUS-PHRINE
TESSALON P
THEOCHRON
THEOPHYLLi
THYROLAR
TIAZAC
TRIAD
UAD OTIC EAR SU
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VERTAB
ZONE-A

mm^mmi
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ACETAMINOPHEN
AMPHETAMINE
ANAFRANIL
IANAGRELIDE
IANEXSIA
ATENOLOL
AZATHIOPRI
BENZONATAT
BUTALBITAL
COCAINE HYDROCHLORIDE
CODEINE PH
DEXTROAMPH
DIPHENOXYL
FLUOXETINE
HYDOCODONE
HYDROMORPH
IMIPRAMINE
MAGNACET
MELOXICAM
MEPERIDINE
METFORMIN
METHADONE
METHADOSE
METHYLINE
METHYLPHEN
MORPHINE
M-OXY
NALTREXONE
OXYCODONE
PAMELOR50
PEMADD
PEMOLINE
PENTAZOCIN
PROMETHAZI
IPROPADE
PROPOXYPHE
RESTORIL
RIBAVIRIN
SIMVASTATI
TEMAZEPAM
TOFRANIL
TRAMADOL
TUSSIZONE
WARFARIN

mmmmssmsmmBRSKm
mmmom
ACETAMINOPHEN
ACETIC ACID
ACIDULATED
[AMANTADINE

EXHIBIT A

BROMAXEFED
BROMODIPHE
CARBAMAZEP
•CARBAXEFED
iCARBINOXAM
CHLORAL HYRATE
CIMEDTIDIN
CIMETIDINE
CLEMASTINE
CLINDAMYCI
CLOBETASOL
C-PHED
CYCLOSPOR1
DEC-CHLORPHEN
DECOHISTIN
DEXAMETHAS
DIPHEN
DOCUSATES
DOXEPINHC
ERYTHROMYCIN
FERROUS SULF
FLUOXETINE
FUROSEMIDE
GENERLAC
GUAIFENESI
HYDROCODONE
HYDROXYZINE
HYOSCYAMINE
LACTULOSE
LIDOCAINE
LINDANE
LITHIUM CARBONATE
MEGESTROL
METAPROTERENOL
METOCLOPRAMIDE
MORPHINE
MULT1-VITAM
MYPHETANE
MYTUSSIN
NYSTATIN
OXYBUTYNIN
PAREGORIC
PHENCLOR
PHENOBARBI
PHENYTOIN
POTASSIUM
PREDNISOLONE
PROMETHAZINE
PYRILAFEN
SELENIUMS
TANNIHIST
[TETRA TANN

1
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THEOPHYLLINE
TR1AMCINOL
iTRIPLETAN
TRIPLE VITA ~
TRIPROLIDINET

VALPROIC A

ACETAZOLAM
ALBUTEROL
ALLOPURINOL
AMANTADINE
AMITRIPTYL
AMPHETAMIN
jASPIRIN
ATENOLOL
BENZTROPIN
BETHANECHO
BISOPROLOL
CARBAMAZEP
CARISOPRODOL
CHLORDIAZE
CHLORTHALID
CHLORZOXAZONE
CLONIDINE
CYCLOBENZAPRINE
DIPHENHYDRAMINE
DOXEPIN
pOXYCYCLlN
ERGOLOID
FELODIPINE
FLUOXETINE
FOLIC ACID
GABAPENTIN
GUAIFENESIN
HYDRALAZINE
HYDROCODONE
HYDROXYZINE
HYOSCYAMINE
IBUPROFEN
IMIPRAMINE
INDOMETHAC
KETOCONAZOLE
LABETALOL
LORAZEPAM
LOVASTATIN
MECLIZINE
MELOXICAM
METFORMIN
METOPROLOL
METRONIDAZOLE
MINOXIDIL

EXHIBIT A

MULTIHIST
NYSTATIN
ORDWNE
PANCREUPASE
PIROXICAM
PREDNISONE
PRIMIDONE
PROPAFENON
PROPOXYPHENE
QUINIDINE
SALSALATE
SPIRONOLAC
SULFASALAZ
SULFISOXAZ
SULINDAC
THEOPHYLLINE
THIORIDAZINE
TOLAZAMIDE
TOLMETIN
TRAMADOL
TRAZODONE
TRIMETHOBENZAMIDE
VERAPAMIL
ZOLPIDEM
IZONISAMIDE

1

1

HiPi
\mammsmmmmmmmmmmm
ACTIGALL
ANAFRANIL
ANTURANE
APRESOLINE
AREDIA
ASBRON G
ASCRIPT1N
ATROPISOL
AZMACORT
BELLERGAL
BETIMOL
(BRETHAIRE
IBRETHANCER
BRETHINE
BUTAZOLIDI
CAFERGOT
CATAFLAM
CERUBIDINE
CIBACALCIN
CIBALITH-S
CLEMASTINE
CLOZARIL
COMBIPATCH
COMTAN
CONSTANT-T
jCYTADREN

EXHIBIT A
CYTARABINE
D.H.E45
iDENAVIR
DESENEXAF~
DESFERAL
DEXACIDIN ~
plAPIDNAS~
DIOVAN
~
DOXORUBICT
pULCOLAX ~
DYNACIRC ~
EFIDAC
EFLONE
~
ELIDEL
~
ENABLEX
~
ESERINESU~
ES1DR1X
~
JESIMIL
IESTRADERM
EXELON
~
lEXFORGE FC
EX J APE
~
EX-LAX MIL ~
FAMVIR
FEMARA
~
FIORICET ~
FIORINAL
~
FIORTAL
~
FLUOR-OP ~
FOCALIN
~
FORADILAE"
GENTACIDINT
GENTEAL ~
GLEEVEC ~
GLUCOSE ~
HABITROL ~
HOMATROPTN
HYDERGINE~
HYPOTEARS
INFLAMASE~
ISMEL1N
~
KLORVESS ~
LAMISIL
~
LAMPRENE~
LESCOL
~
LIORESAL ~
L1THOBID ~
LIVOSTIN ~
LOPRESSOR"
LOTENSIN ~
LOTREL
~
LUDIOMIL

A0164

EXHIBIT A

MAALOX
MELLARIL
iMESANTOIN
iMETAPREL
METHERGINE
METOPIRONE
METOPROLOL
MIACALCIN
MIGRANAL
MYFORTIC
NEO-CALGLU
NEORALSOL
NICOTINE
NUPERCAINA
OCUPRESS
OSCO NTS 1
PAMELOR
PAREPECTOL
PARLODEL
PERDIEM FIBER
PILOCAR
PROLEUKIN
RECLAST
REGITINE
RESCULA
RESTORIL
RIMACTANE
RITALIN
SANDIMMUNE
SANDOGLOBULIN
SANDOSTATIN
SANSERT
SER-AP-ES
SERPASIL
SLO-BID10
SLO-PHYLLI
SLOWFE
SLOW-K
STALEVO
STARL1X60
SULF-10
SYNTOCINON
TASIGNA HG
TAVIST
ITEARISOL
(TEGRETOL
TEKTURNA H
TEN-K
TETRACAINE
TEXTURNA
THIORIDAZINE
[TOBI

A0165

EXHIBIT A

TOFRANIL
TOMYCINE
TRANSDERM
TRIAMINIC
TRIAMTEREN
TRILEPTAL
VASOCIDIN
VASOCINE
VASOCON
VASOSULF
VISKEN
VISUDYNE
VIVELLE
VOLTAREN
ZADITOR
ZELNORM
ZOMETA
ACCUPRIL
ACCURETIC
ACETAMINOPHEN
ACTH
ACTIVELLA
ADRENALIN
ADRIAMYCIN
ADRUCIL
ALDACTA2ID
ALDACTONE
ALPRAZOLAM
AMBIEN
AMINOPHYLL
AMiTRIPTYL
AMLODIPINE
AMOXICILLINE
AMPHOCIN
AMPICILLINE
ANSAID
ANTIMINTH
ANTIVERT
ANUSOL
APLISOL
APLITEST
AROMASIN
ARTHROTEC
ASPIRIN
ATARAX
AXERT
AXOTAL
AZITHROMYC
AZULFIDINE
BACITRACIN
BANTHINE

EXHIBIT A

BENADRYL
BENYLIN
BEXTRA
BLEOMYCIN
:BREVICON
BRONDECON
CABERGOLIN
CADUET
CALAN
CAMPTOSAR
CARDURA
CAVERJECT
CEFOBID PI
CELEBREX
CELONTIN
CENTRAX
CEREBYX
CHANTIX
CHERACOL
CHILDREN'S
CHLOROMYCE
CHLORPROMA
CHOLEDYL
CHOLYBAR
CLEOCIN
CLEOCIN
CLINDAMYCI
CLONIDINE
COGNEX
COLESTID
COLESTIPOL
COLY-MYCIN
CORTAID
CORTEF
CORTISONE
COVERA
CYCLOBENZA
CYTOSAR
CYTOTEC
DAYPRO
DELTASONE
DEMULEN
DEPO PROVE
DEPO-ESTRA
DEPO-MEDRO
DEPO-PROVE
DEPO-SUBQ
DEPO-TESTA
DETROL
DIABINESE
DIAZEPAM
jDIDREX

1
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EXHIBIT A
DIFLUCAN
DILANTIN
DIPENTUM
DIPHENOXYL
DIULO
; DORYX
IDOSTINEX ~
pOXIDAN
~
DOXYCYCLIN"
DRAMAMINE~
EASPR1N
~
ELASE
~
EMCYT
~
EMETE-CON~
EMETROL
E-MYCIN
~
EPLERENONE"
ERAXIS
~
ERGOSTAT ~
ERYC
ERYTHROMY"C
ESTRING
~
ESTROSTEP~
ESTROVIS ~
EUTHROID ~
EXUBERA
~
FELDENE
~
FEMHRT
~
FEMINONE ~
FEMPATCH~
FERROUS SU~
FLAGYL
~
FLAVORED C~
FLUCONAZOT
FLUOGEN ~
FLURBIPROF
FRAGMIN
~
FURQSEMIDT
GABAPENTIN~
IGELUSIL
~
GENOTROPJN"
GEOCILLIN " ~
GEODON
~
GLIPIZIDE ~
GLUCOTROf"
GLYBURIDE~
GLYNASE ~
GLYSET50M~
HALCION
~
HALOPERIDO"
HALOTESTIN"
HEPARIN SO

A0168

EXHIBIT A

HUMATIN
HYDROCHLOR
;IBUPROFEN
INDOMETHAC
INSPRA
KAOLECTRO
KAOCHLOR
KAON
KAOPECTATE
KERLONE
KETALAR
K-LEASE
LACTULOSE
LEOSTRIN2
LEOSTRINF
LEVORA-28
LEVSINDRO
LINCOCIN
LIPITOR
LOESTRIN
LOMOTIL
LONITEN
LOPID
LUNELLE
LYRICA
MANDELAMIN
MAOLATE
W1AXAQUIN
MECLOMEN
MEDROL
MEDROXYPRO
METAMUCIL
METHYLDOPA
METHYLPRED
MICRONASE
MICRONIZED
MILONTIN
MINIPRESS
MiNIZIDE 1
MIRAPEX
MISOPROSTO
MODANE
MOTRIN
MYCOBUTIN
NARDIL
NATABECRX
NAVANE
NEO-CORTEF
NEOSAR
NEURONTIN
NICOTROL
INITRODISC

A0169

EXHIBIT A

NITROL
NITROSTAT
NQRETH1N
NORtNYL
NORLESTR1N
NORLUTATE
NORPACE
1NOR-Q-D
NQRVASC
OGEN
[OMNICEF
[OPHTHOCORT
ORINASE
OXAPROZIN
PANMYCIN
PARSIDQL
PED1ACARE
PENICILLIN
PERMAPEN
PF1ZERPEN
PHENOBARBI
P1RQX1CAM
PITOCIN
P1TRESS1N
POLYMYXIN
PONSTEL
~
PRO-BANTHl~
PROCANSR
PROCAINAMIDE"
PROCARDIA
PROLOID
PROSTIN
PROVERA
PYRlDiUM
QUINAPRIL
QUINIDINE
QUININE SU
RELPAX
RENESE
RESCR1PTQR~
REVATIO
REZUL1N
~"
R-GENE10
SERTRALINE
SINEQUAN
SINUBID
SLOW-MAG
SODIUM C H L ~
SOLU-CORTE~
SOLU-MEDR~
ISPIRONOLAC
STREPTOMYC

A0170

EXHIBIT A

SULFASALAZ
SULFASALZI
SURFAK
SUSTAIRE
ISUTENT
SYNAREL
SYTOBEX
TABRON

TAO
TEDRAL
TERRA-CORT
TERRAMYCIN
TETRACYCU
THEELIN
THEO
TIKOSYN CA
TOLINASE
TRIAZOLAM
TRI-NORINY
TRIVORA
TROVAN
TYMPAGESIC
UNASYN
UTICORT
VAGIFEM
VANTIN
VERAPAMIL
VFEND
VIAGRA
VIBRAMYCIN
VIBRA-TABS
VINCASAR
V1RA-A
V1RACEPT
VISTAR1L
XALATAN SS
XANAX
ZARONTIN
ZINECARD
ZINECARDS
ZITHROMAX
ZMAX
ZOLOFT
ZYRTEC
ZYVOX

ymmffiffimmmmmmwum
A/B OTIC
ACETAMINOPHEN
ACETAZOLAM
ACETIC ACID
ACIDIC VAG
[ALBUTEROL

t^SSIs

EXHIBIT A
ALL0PUR1N0
AMANTADINE
AMILOR1DE
AMiTRlPTYL
AMOXAP1NE
|AMQXIC1LLI
lAMPICILLIN
ANTACID
~
ANTIBIOTIC
APAP
ASP1R1N-LQ
ATENOLOL ~
ATROPINES BACLOFEN ~
BENZONATA~
BENZOYL P E ~
BENZTROPihT"
BETAMETHAST
BETHANECHO
BISACODYL
BROMANYL
BROMATAPP
BROMOPHE~
BR0MPHEN1R~
BROMUPHE~
BUFFERED A ~
BUTALB1TAL
CALCIUM AN
CARBAMAZEF"
CARBIDOPA/
CARDEC
~
CARISOPROP"
[CEFACLOR
I CEPHALEXIN
1CEPHRAD1NE
CERVICAL A
CHERATUSST"
CHLORALHY
CHLORAMPPTE"
CHLOROUS!""
CHLOROTHi~
ICHLORPHENT
CHLORPROMA
CHLORPROPA"
CIMETIDINE~
CLEMASTINE""
|CLINDAMYCT~
CLONAZEPAM"
CLON1D1NE ~
CLORAZEPAT
CLQTRIMAZCT
CLOXAClLLi

A0172

EXHIBIT A

CODAMINE
CODITUSS D
COLCHICINE
iCORTISONE
jCYCLOBENZA
CYPROHEPTA
DECONESTIN
DECONGEST
DESIPRAMIN
DESOXIMETA
DETUSSIN
DEXAIR
DEXAMETHAS
DEXCHLORPH
DIAZEPAM
DICLOXACIL
DICYCLOMIN
DIGOXIN
DILTIAZEM
DIMENHYDRI
D1PHENHYDR
DIPHENOXYL
DIPYRIDAMO
DISOPYRAMI
DISULFIRAM
DOC-Q-LACE
DOXEPIN HC
DOXYCYCLIN
DREXOPHED
DRITUSSDM
DRITUSS
EAR-GESIC
ENTERIC CO
ERGOLOIDM
ERYTHROMYC
ESTROPIPAT
FENOPROFEN
FERROUS SU
FLOURIDEC
FLUOCINOLO
FLUOCiNONI
FLUORIDE D
FLUPHENAZI
IFLURAZEPAM
IFLURBIPROF
FOAMING ANTACID
FOLIC ACID
FUROSEMIDE
GENTAFAIR
IGENTAMICIN
GLIPIZIDE
JGLYBURIDE

A0173

EXHIBIT A

GRANUL-DER
GUAIFEN PS
GUAIFENESI
GUAIFEN-PS
GUAIVENT
GUANFACINE
HALOPERIDO
IHC TUSSIVE
HDROCODQNE
HEMORRHOIDAL
HYDORCODONE
HYDRALAZINE
HYDROCHLOR
HYDROCODONE
HYDROCORTISONE
HYDROMORPH
HYDROXYZIN
HYOSCYAMIN
IBUPROFEN
1MIPRAMINE
INDOMETHAC
INSULIN SY
IOPHEN
ISOSORBIDE
KEFFERVES
K+POTASSIUM
K-EFFERVES
KETOPROFEN
LACTULOSE
LEUCOVORIN
LEVOTHYROX
LIDOCAINE
LINDANE
LITHIUM CA
LOPERAMIDE
LORAZEPAM
[LOXAPINES
IMAPROTILIN
MATERNITY
MECLIZINE
MECLOFENAM
MEDROXYPRO
MEGESTROL
[MEPERIDINE
MEPERITAB
MEPROBAMAT
METAPROTER
METHAZOLAM
METHOCARBA
METHOTREXA
METHYLDOPA
METHYLPHENIDATE

EXHIBIT A

METHYLPRED
METOCLOPRA
METRONIDAZ
MINOCYCLIN
MINOXIDIL
jMULTIVIT
MULTI-BRET
MYLACARE
NAPHAZOLIN
NAPROXEN
NATURALVE
NEO-DEX
NEOPTIC
NIACIN ID
NIFEDIPINE
NITROFURAN
NITROGLYCE
NOLPHENAMI
NYSTATIN
OCTICAINE
OCUTRICIN
ORGAN-I
OR-P HEN-AD
OR-PRIN
OTICAINE
OTIGESIC 0
OXAZEPAM
OXYBUTYNIN
OXYCODONE
PANASE
PAPAVERINE
PAREGORIC
PEMOLINE
PENICILLIN
PERPHENAZINE
PHENAZOPYRIDINE
PHENOBARBI
PHENTERMINE
PHENYLHlSTiNE
PILOCARPIN
PINDOLOL
PINK BISMUTH
PIROXICAM
POLYCS
POLY-D
POLY-DM
POTASSIUM
PRAZOSIN H
PREDNISOLONE
PREDNISONE
PRENATAL
[PRIMIDONE

A0175

EXHIBIT A
PROBENECID
PROCAINAMIDE
PROCTOSERT
PROMETHAZINE
PROPAFENON
PROPOXYPHENE
PROPRANOLO
PSEUDOEPHE
QNOL325
Q-BID
Q-DRYL
Q-FED
Q-MIBID
Q-NOL
:Q-PAP
jQ-PROFEN
Q-TUSSIN
QU1NDAL
QUINIDINE
QUININE
QUINTEX
R-TANNAMIN
SALSALATE
SELENIUMS
SENNA LAX
SILVER SUL
SODIUM FLUOPJDE
SODIUM SULF
SORBITOL
SOTALOL
SPIRONOLAC
SUCRALFATE
SULFACETAM
SULFAMETHO
SULFASALAZ
SULFATRIM
SULFAZINE
SULFISOXAZ
SULINDAC
SULPRED
SUR-QLAX
TEMAZEPAM
TETRACYCLI
THEOPHYLLINE
THERMAZENE
THEROBEC
THIORIDAZINE
THIOTHIXEN
JTHYROID
[TOBRAMYCIN
TOLBUTAMID
TOLMETIN S

A0176

EXHIBIT A

TRAZODONE
TRIACTIN

ITRIAMONOL
TRIAMTEREN
TRIAZOLAM
TR1COSAL
TRIHEXYPHE
TRIMETHOPRIM
TRIPLE ANTIBIOTIC OINTMENT
TRIPLE SUL
TRI-VITAMIN
TRIXAICIN
URINARY ANTISEPTIC
URSODIOL
VALPROIC A
VEGETABLE LAX
VERAPAMIL
VICA-FORTE
Vl-Q TUSS
YOHIMBINE
Z+PRENATAL

ZOCORT HC
ZOLENE HC
ZOTANE HC

AEROBID
AFRIN
[ALBUTEROL
AMOXICILLIN
ASMANEX
AUGMENTED BETAMETHASONE
AVELOX IV
AVELOXTAB
BETAMETHAS
BILTRICIDE
CEDAX
CELESTONE
CHLOR-TRIM
CIMETIDINE
CIPRO
CLARINEX
CLARITIN
CLOTRIMAZO
DERMOLATE
pIPROLENE
[DIPROSONE
IDRIXORAL
ELOCON
EMKO
ESTINYL
ETRAFON

EXHIBIT A

EULEXIN
FEMCARE
FORADIL
FULVICIN P
GARAMYCIN
GLYBURIDE
GRISEOFULV
GYNE-LOTR1
IMDUR
IINSPIREASE
JINSPIREASE

ilNTRON
ilSOSORBIDE
K-DUR
LABETALOL ~
LEVITRA
~
LOTRIM1N
~
LOTR1SONE ~
METICORTEN"
METIMYD
~
MEXILET1NE ~
MIRADON
~
MOL-IRON
~
MOMETASONE
NAQUA
~
NASONEX
~
NASONEX NA~
NITRO-DUR ~
NONOXYNOlT"
NORMODYNET

NORMOZIDE~
NOXAFILPO~
OPTIMINE
ORETON MET"
OTOBIOTIC ~"
OXAPROZIN~~
PAXIPAM
~
PEG-INTROhF
PERMITIL
~
PERPHENAZT
POLARAMlNEr
POTASSIUM""
PROVENTIL ~
REBETOL
REBETRON 1
RELA
~
RIBAVIRIN
~
SEBIZON
~
[SODIUM SUL~
ISOLGANAL
SUCRALFAJT
TEMODAR

A0178

EXHIBIT A

THEO-DUR
THEOPHYLLI
TINACTIN
TRILAFON
TRINALIN
UNI-DUR
VALISONE
VANCENASE
VANCERIL

id
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CALCIFEROL
CODICLEAR
CODIMAL
CO-GESIC
COLYTE
CORT1FOAM
DEPONIT
DILATRATE
EDEX
EPiFOAM
FEDAHIST
GLYCOLAX
GUAIMAX-D
HYDROCODONE
HYOSCYAMINE
ISOSORBIDE
KUTAPRESSI
KUTRASE
KU-ZYME
LACTRASE
LEVATOL
LEVBID
LEVSIN
LEVSINEX
MILKINOL
MOEXIPRIL
MONOKET
NASCOBAL
NEUPRO
NIFEDIPINE
NIFEREX
NIRAVAMTA
NITROCINE
NULEV
(OMEPRAZOLE
IPARCOPA
PEDIAPAP
PEG 3350
PROCTOCREA
PROCTOFOAM
PSEUDOEPHEDRIN
REGLAN

EXHIBIT A

ROBAXIN
THEOCLEAR
TRILYTE
UNIRETIC
UNIVASC
jURSO
VERAPAMIL
VERELAN

^^^^^^si^^^PP^
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ACETAZOLAMIDE
ACETIC ACID
ALCLOMETASONE
AMCINONIDE
AMIODARONE
AMMONIUM
ANTIPYRINE
BETAMETHASONE
CARBASUSP
CARBAMAZEP
CICLOPIROX
CIPROFLOXACIN
CLINDAMYCIN
CLOBETASOL
CLOMIPRAMINE
CLOREZAPATE
CLOTRIM
CLOTRIMAZOLE
DESONIDE
DESOXIMETASONE
DIFLORASON
IECONAZOLE
ELIXSURE
ENALAPRIL
ETODOLAC
ETOLODAC
FLUCONAZOLE
FLUOCINOLONE
FLUOCINONIDE
FLUOROURAC
FLUTICASON
GENTAMICIN
HALOBETASOL
HYDROCORTISONE
KETOCONAZOLE
LIDOCAINE
LORATADINE
MICONAZOLE
MOMETASONE
MUPIROCIN
NYSTATIN
ORALONE
OVIDE

EXHIBIT A
PHENYTOIN
RX EAR PRO
RX-OTIC
TERCONAZOLE
TOPICORT
TRIAMCINOL
TRIPLE ANTIBIOTIC

ALTINAC
ASPIRIN
BISACODYL
CLEN1A
DIVALPROEX
DIVIGEL
~~
DOCUSATE
~
FERATAB
FERROUS SULF
FEVERALL
FOLGARD
FOLIC ACID
FORTICAL
GEMCOR
KLOR-CON
MIDODR1NE
QMS
PACERONE
~
PENTOXIL
POTASSIUM
PREVALITE
RMS-SUPPOS~
SALSITAB
SORBITOL
SSKI
~
VANDAZOLE
ZINC SULFATE

ACEL-IMUNE
IACETAMINOPHEN
ACHROMYCIN
ACYCLOVIR
.ADVIL
jALAVERT
ALBUTEROL
ALESSE
ALLOPURINO
ALPRAZOLAM
ALUDROX

EXHIBIT A

AMICAR
AMIKACIN S
AMILORIDE
JAMINOPHYLL
[AMITRIPTYL
AMOXICILLIN
AMPHOJEL
AMPIC1LLIN
AN AC IN
ANA-GUARD
ANA-KIT
ANTABUSE
ANT1VENIN
ARISTOCORT
ARTANE
ARTHRITIS
ASEND1N
ATENOLOL
ATIVAN
ATROMID
ATROPINE
AURALGAN
AXID
AYGESTIN
BASALJEL
BENEFIX
BENZTROPIN
BICILLIN
BISOPROLOL
BUTORPHANO
CALTRATE-6
ICAPTOPRIL
ICARAFATE
CARBAMAZEP
CARDIZEM
CEFACLOR
ICEFAZOLIN
I CENTRUM JR
CEPHALEXIN
CEPHRADINE
CERUBIDINE
CHILDREN'S ADVIL
CHLORDIAZEPOXIDE
CHLORPHENIR
CHLORPROMAZ
CHLORPROPAM
CHLORTHALID
CIMETIDINE
CLINDAMYCIN
CLONIDINE
ICLORAZEPATE
CLOXACILLIN

CODEINE PH
CORDARONE
COUMADIN
CVC HEPARI
CYANOCOBAL
CYCLOCORT
CYCLOPHOSPH
iCYCRIN
JDECLOMYCIN
DEPONIT
DEXAMETHAS
DEXTROSE
DIAMOX
DIAZEPAM
DICLOXACIL
[DICYCLOMTN
DIGOXIN
DILTIAZEM
DIMETANE
DIMETAPP
DIPHENHYDR
DjPHENOXYL
DIPHTHERIA ~
DIPYRIDAMOLE
DOCUSATE
DOLENE
DONNAGEL-P
DONNAZYME
pOXEPIN HC
DdXYCYCLIN
DTPC&A
DTPDMC&C
DURACT
DURAMORPH
EFFEXOR
[ENTOZYME
EPINEPHRIN
EQUAGESIC
EQUANIL"""'"
ERYTHROMYC
ESTRADIOL
[ESTROGENIC
ETODOLAC
FACTREL
FAMOTIDINE
[FptJPROFEN
FENTANYL
IFERRO-SEQU
FERROUS
IFIBERCON
IFILIBON
FLUIMMUNE

EXHIBIT A

FLURAZEPAM
FOLVITE
FUROSEMIDE
GEMFIBROZ1
GENTAMICIN
GRISACTIN
GRISEOFULVIN
GUAIFENESIN
IGUANFACINE
jHALOPERIDO
jHCTZ/RESER
jHEPARIN
1 HEP-LOCK
H1B-IMUNE
HYDRALAZIN
HYDROCHLOR
HYDROCODONE
HYDROCORTIZONE
HYDROMORPH
HYDROXYZIN
IBUPROFEN
IMIPRAMINE
INDERAL
INDERIDE
INDOMETHAC
INFLUENZA
INFUMORPH
ISMO
ISORDIL
ISOSORBIDE
KERODEX
KETOPROFEN
LEDERCILLIN
LEUCOVORIN
LEVO-T
LEVOTHYROX
LIDOCAINE
LO/OVRAL
LODINE
LORAZEPAM
LOXITANE
ILYBREL
MATERNA
MAXZIDE
MECLIZINE
MECLOFENAMATE
MEDROXYPRO
MEPERGAN
MEPERIDINE
METHAZOLAMIDE
METHENAMIN
METHOCARBA

A0184

EXHIBIT A
METHOTREXA
METHYCLOTH
;METHYLDOPA
METOCLOPRA
iMETRONIDAZ
M1CRO-K
~
MIDAZOLAM MINOCIN
~
M!NQCYCL1N~
MITROLAN ~
MORPHINE ~
MYAMBUTOL~
MYSOLINE ~
NAPRELAN ~
NAPROXEN
NENMEGA ~
NEPTAZANE~
NEUMEGA ~
NILSTAT
~
N1TROGLYCE"
NORDETTE-2~
NORPLANT ~
NOVANTRONE"
OCUCOAT ~
OMNIPEN
~
OPIUM
~
ORIMUNEDl""
ORUDIS
ORUVAIL
~
OVRAL-21
OVRETTE
~
OXAZEPAM PANTOPRAZO"
I PAPAVERINE"
IPATHOCIL ~
PENTOBARBT
PENTOXIFYL~
PEN-VEE K ~
PHENAPHEN"
PHENERGAN~
PHENQBARBT
PHENYTOIN~
PHOSPH I O ~
PHOSPHOLIN"
PIPRACIL
~
PIROXICAM""
PNU-IMUNE~
PONDIMIN ~
POSTURE
POTASSIUM"[PRAZOSIN H
IPREDNISONE

A0185

EXHIBIT A

PREMARIN
PREMPHASE
PREMPRO
PRENATAL PLUS
PRIMATENE
PRISTIQ EX
PROBENECID
PROCHLORPER
PROMETHAZINE
PROPOXYPHENE
PROPRANOLOL
PROPYLTHIOURACIL
PROSTEP
PROTONIX
PYRAZINAMIDE
QU1N1DEX
jQUINIDINE
IRAPAMUNE
REGLAN
RHEUMATREX
RIOPAN
ROBAXIN
ROBAXISAL
ROBICILLIN
ROBIMYCIN
ROB1NUL
ROBITET
ROBITUSSIN
SECTRAL
SELEGILINE
SEMICID
SERAX
SODIUM CHL
SONATA
SPARINE
SPIRONOLAC
STORZ-DEXA
STUART PRE
STUARTNATA
SULFAMETHO
SULFASALAZINE
SULINDAC
SUPRAX
SURMONTIL
SYNALGOS
TEMAZEPAM
TENEX
TETANUS PI
THEOPHYLLINE
THIAMINE H
THIORIDAZINE
THYROID

EXHIBIT A

TOBRAMYCIN
TODAY SPONGE
TOLAZAMIDE
TOLBUTAMIDE
TRAZODONE
TRI-IMMUNO
TR1PHASIL
TUBERCULIN
TUBEXINJ
TYGACIL IN
UNIPEN
VANCOLED
VANCOMYCIN
VERAPAMIL
VIOKASE
WYAMYCIN
WYCILLIN
WYDASE
WYGESIC
WYMOX
WYTENSIN
Z-BEC
ZEBETA
ZIAC
IZOSYN

"~1
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